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Abstract
Parkinson’s disease (PD) is an insidious neurodegenerative disorder characterized by a range of motor
symptoms which develop predominantly as a consequence of striatal dopamine depletion. The majority
of PD cases are idiopathic; however, discoveries of genetic mutations linked to familial forms of PD,
including mutations in the genes encoding DJ-1, parkin, and α-synuclein (α-syn), have provided insights
into sporadic PD pathogenesis.
Mutations in the gene encoding DJ-1 cause autosomal recessive early-onset PD (AREP). Though the
physiological role for DJ-1 is not fully elucidated, it is thought that DJ-1 mutations contribute to disease
as a consequence of a loss-of-function. Herein, we show that wild-type (WT) DJ-1 is a relatively stable and
soluble homodimer that has diffuse cellular distribution and that can protect mammalian cells against a
variety of noxious insults. Pathogenic mutant DJ-1 proteins, L10P, P158DEL, E163K, and L166P display
diverse altered biochemical properties. Thus, it is concluded that alterations to distinct DJ-1 residues may
specifically affect individual protein functions and may also implicate DJ-1 in a variety of biochemical
pathways.
When expressed in mice, human pathogenic mutant A53T α-syn can aggregate and result in fatal motor
impairments. It was hypothesized that DJ-1 may act to modulate this effect. Herein, DJ-1 null transgenic
animals are generated and assessed for viability against toxic A53T α-syn. However, in double transgenic
DJ-1 null mice expressing human pathogenic A53T α-syn, the consequences of DJ-1 deficiency are not
apparent and thus it is concluded that DJ-1 may not directly modulate α-syn nor mitigate the deleterious
effects of α-syn aggregation in vivo.
Parkin mutations cause AREP which is thought to develop secondary to a loss in parkin function. We
discover a novel endogenous parkin mutation in C3H mice, E398Q, which impairs the function of parkin in
a similar manner to that of pathogenic missense parkin mutations. It is therefore concluded that C3H
mice may serve as suitable models for future studies to assess the effects of parkin loss-of-function in
vivo.
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ABSTRACT
STUDIES OF DJ-1, PARKIN, AND ALPHA-SYNUCLEIN GIVE INSIGHTS INTO
PLAUSIBLE MECHANISMS FOR PARKINSON’S DISEASE PATHOGENESIS
Chenere P. Ramsey
Advisor: Benoit I. Giasson, Ph.D.
Parkinson’s disease (PD) is an insidious neurodegenerative disorder characterized
by a range of motor symptoms which develop predominantly as a consequence of striatal
dopamine depletion. The majority of PD cases are idiopathic; however, discoveries of
genetic mutations linked to familial forms of PD, including mutations in the genes
encoding DJ-1, parkin, and α-synuclein (α-syn), have provided insights into sporadic PD
pathogenesis.
Mutations in the gene encoding DJ-1 cause autosomal recessive early-onset PD
(AREP). Though the physiological role for DJ-1 is not fully elucidated, it is thought that
DJ-1 mutations contribute to disease as a consequence of a loss-of-function. Herein, we
show that wild-type (WT) DJ-1 is a relatively stable and soluble homodimer that has
diffuse cellular distribution and that can protect mammalian cells against a variety of
noxious insults. Pathogenic mutant DJ-1 proteins, L10P, P158DEL, E163K, and L166P
display diverse altered biochemical properties. Thus, it is concluded that alterations to
distinct DJ-1 residues may specifically affect individual protein functions and may also
implicate DJ-1 in a variety of biochemical pathways.
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When expressed in mice, human pathogenic mutant A53T α-syn can aggregate
and result in fatal motor impairments. It was hypothesized that DJ-1 may act to modulate
this effect. Herein, DJ-1 null transgenic animals are generated and assessed for viability
against toxic A53T α-syn. However, in double transgenic DJ-1 null mice expressing
human pathogenic A53T α-syn, the consequences of DJ-1 deficiency are not apparent and
thus it is concluded that DJ-1 may not directly modulate α-syn nor mitigate the
deleterious effects of α-syn aggregation in vivo.
Parkin mutations cause AREP which is thought to develop secondary to a loss in
parkin function. We discover a novel endogenous parkin mutation in C3H mice, E398Q
which impairs the function of parkin in a similar manner to that of pathogenic missense
parkin mutations. It is therefore concluded that C3H mice may serve as suitable models
for future studies to assess the effects of parkin loss-of-function in vivo.
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CHAPTER ONE
Introduction

2

1.1

“La maladie Parkinson”
Dr. James Parkinson (1755-1824) was a surgeon who lived and worked in the

southern part of London, England. Throughout his career, he wrote copiously on many
topics related to medicine and politics. He is most well-known for his work, An Essay on
the Shaking Palsy, which was written in 1817. In his essay, James Parkinson described a
motor condition which was coined some years later as “La maladie Parkinson” (39).
Parkinson’s account was based on conclusions drawn from only six patients (344). He
summarized the condition as, “Involuntary tremulous motion, with lessened muscular
power…with a propensity to bend the trunk forward, and to pass from a walking to a
running pace: the senses and intellect being uninjured”(344). According to Parkinson,
these symptoms, which progressively worsened over time, eventually debilitated the
affected individuals to the point of complete dependence on external care givers (344).
The classical symptoms described by Parkinson are common to the insidious disorder that
is known today as Parkinson’s disease (PD).
1.2

PD: a neurodegenerative movement disorder
PD is the leading cause of parkinsonism. Parkinsonism is the term used to

describe a group of symptoms that include tremor, slowness of movement (bradykinesia),
rigidity, and postural instability. PD is one of several neurological disorders that produce
similar symptoms (399;465). PD results from progressive degeneration of selective and
heterogeneous neuronal populations (Figure 1-1) (234). Among the neuronal populations
affected are the dopaminergic neurons (also known as the A9 group) of the substantia
nigra pars compacta (SNpc). Although PD is not limited to the SNpc, degeneration of
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Figure 1-1

A schematic showing the sites of neurodegeneration and neurochemical pathways that are involved in PD.
The sites of
neurodegeneration
are marked in dark
blue. The colored
arrows show the
neurochemical
pathways that are
affected by the
disease. Red arrows
depict DA pathways,
green arrows depict
norepinephrine
pathways, yellow
arrows depict
serotonin pathways,
and turquoise or
purple arrows depict
acetylcholine
pathways. The same
color scheme is also
used in the inset
which shows the
destinations of the
various
neurochemical
pathways from a
saggital section view.
Figure is from Lang
and Lozano, New Eng J
Med, 1998 (234).
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the nigra plays a major role in the pathobiology of the disease (112).
1.3

The direct/indirect pathways of motor control
Dopaminergic neurons of the SNpc release dopamine (DA) into the striatum via

the nigrostriatal pathway (Figure 1-2A and B). The striatum is largely composed of
medium spiny neurons (MSNs). Striatal MSNs generally express either D1 DA receptors
(striasome neurons) or D2 DA receptors (matriasome neurons) and can thereby be
regulated in parallel with respect to the type of receptor that they express. Striasome
MSNs are activated by DA while matriasome MSNs are inhibited by DA. Activation of
striasome neurons facilitates movement in a pathway known as the direct pathway
(Figure 1-2C)(92). Conversely, in the absence of DA, matriasome neurons are activated
and this acts to inhibit movement in a pathway known as the indirect pathway. These
processes require tight regulation and together, they play a role in fine-tuning motor
control (92;195).
1.4

Parkinsonism: the effects of depleted striatal DA content
In PD, as nigral neurons degenerate, striatal DA levels significantly depreciate

and this results in deactivation of the direct pathway while it simultaneously enhances the
indirect pathway. The deregulation of these two pathways leads to the onset of motor
impairments. PD is diagnosed if bradykinesia and at least one of the other cardinal
parkinsonism symptoms presents (377). It is thought that motor impairments first develop
when eighty percent of nigral neurons have already degenerated (234).
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Figure 1-2

Nigrostriatal signaling pathways involved in movement.
Part A shows a saggital illustration of the human brain. The grey area highlights the substantia nigra and the arrows depict
nigral dopaminergic projections into the striatum. Part B shows the nigrostriatal pathway illustrated in coronal sections.
Dopaminergic neurons in the substantia nigra pars compacta (“1”) release DA into the striatum which is composed of the
caudate nucleus (“13”) and putamen (“7”). Part C is a magnification of the box drawn in B. Part C shows the direct and
indirect pathways of DA neurotransmission. Inhibitory projections are depicted in red and excitatory projections are depicted
in blue. DA excites striatal MSNs which express D1 DA receptors and simultaneously inhibits striatal MSNs which express
D2 DA receptors. This affects subsequent basal ganglia signaling which is also illustrated in C.
Legend: 1-substantia nigra, 2-periaqueductal grey matter, 3-inferior colliculus, 4-cerebral aqueduct, 5-amygdala, 6-globus
pallidus (Gpe-globus pallidus externus, Gpi-globus pallidus internus), 7-putamen, 8-ventral posterior thalamic nucleus, 9ventral lateral thalamic nucleus, 10-corpus callosum, 11-fornix, 12-cerebral cortex, 13-caudate nucleus, 14-internal capsule,
15-cortical white matter, 16-mammillary body, 17-subthalamic nucleus
Figure 1-2 was generated using illustrations from Bear et al., An Illustrated Guide to Human Neuroanatomy, 2007 (30).
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1.5

PD prevalence, risks, and causes
The worldwide prevalence of PD is difficult to ascertain (58). In the United

States, PD is estimated to affect 1-2 percent of the population of age 65 years or older
(465). It is thought that 40,000 new cases of PD are diagnosed annually (465). Though
the disease has existed for hundreds of years, the cause for PD is still largely a mystery.
In fact, the only proven risk factor for idiopathic PD is old age (58;465). PD is rare in
individuals before the age of 50 but the risk increases greatly among the elderly(58).
A number of other risk factors for sporadic PD have also been proposed including
gender, ethnicity, family history, exposure to various chemicals or infectious agents, head
trauma, and even diet. However, many of these factors are controversial and have shown
to be inconsistent between studies. It is thought that PD is a multifactorial disease and
thus identifying a single cause has proven to be difficult (58;128).
1.6

PD treatments: L-DOPA is effective but also has limitations
There are no available methods to stop the progression of neurodegeneration in

PD; however, there are several pharmacologic treatments which act to temporarily abate
disease symptoms (Table 1-1). Each PD patient can respond differently to treatments
and thus, medication selection and dosage is made on an individual basis and may change
over the course of a patient’s disease progression (105). L-dihydroxyphenylalanine (LDOPA) is one of the most effective symptomatic medications for PD (25). In 1961, small
doses of L-DOPA (also known as levodopa) were first administered to PD patients as a
means to transiently reverse motor impairments (105). Levodopa acts to supplement DA
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that has been lost due to nigral degeneration. Unlike DA, levodopa can cross the blood
brain barrier. Subsequently, it can be converted into DA by aromatic L-amino acid
decarboxylase, an enzyme that is abundantly expressed in dopaminergic neurons (Figure
1-3). PD patients typically respond well to levodopa treatments initially. Responsiveness
to levodopa is often used as an indicator to distinguish PD from other types of
parkinsonism. However, while PD patients respond well to levodopa during early
treatments, for reasons that are poorly understood, the drug eventually loses its
effectiveness after roughly 5 years of use. It also has a number of negative side effects
(24;92;105).
Table 1-1 (25;105;235)
Treatment
monamine oxidase
(MAO)-B
inhibitors

Mode of Action
Decreases endogenous
dopamine (DA) catabolism

Examples
selegiline; rasagiline

DA receptor
agonists

Acts directly on DA receptors
to mimic DA activity

apomorphine,
bromocriptine,
pergolide, ropinirole,
pramipexole

DA precursors

Converted to DA in the CNS
as a form of DA replacement
(often administered in
combination with inhibitors
of peripheral degradation
enzymes)
Restrict the action of
acetylcholine, blocking nerve
impulses at the level of the
muscle

levodopa/carbidopa,
levodopa/benserazide,
levodopa/entacapone,
levodopa/tolcapone

dyskinesias,
nausea, wearingoff effect

benztropine, biperiden,
diphenhydramine,
ethopropazine,
orphenadrine,
procyclidine,
trihexyphenidyl

blocks NMDA receptor ( not
completely clear why this
reduces parkinsonism)

Amantadine

dry mouth,
confusion,
memory loss,
nausea, blurred
vision,
constipation,
urinary retention
Confusion,
insomnia,
hallucinations,
leg swelling

Anticholinergics

Antiglutamatergics

Side Effects
effects resulting
from interactions
with other
medications
nausea,
vomiting,
psychosis ,
dyskinesias
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Figure 1-3

1.7

Pathways of DA synthesis and catabolism.

Hypotheses for PD pathogenesis
With the increasing age of the population in advanced countries, the risk for PD

will continue to rise. It is therefore of great interest to improve treatments and to
determine better modes of disease prevention. Gaining insights into disease pathogenesis
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will be crucial in this effort. PD may develop as a consequence of dysfunctions in various
biochemical pathways (82;88;109;234;365). Hypotheses related to the effects of
proteasome, oxidative, and mitochondrial impairments on PD pathogenesis will be briefly
discussed below.
1.8

The ubiquitin-proteasome system
It is thought that PD may be caused by impairments in the ubiquitin-proteasome

system (UPS) (31;79;323). In order for protein substrates to be degraded in the UPS
pathway, a series of tightly controlled events must occur (73;159;160). First, ubiquitinactivating enzymes (E1 enzymes) modify ubiquitin protein molecules in a two-step
reaction which requires ATP. Once ubiquitin molecules have been activated by E1
enzymes, they are transferred to E2 ubiquitin-conjugating enzymes (E2 enzymes),
forming E2 enzyme-ubiquitin complexes. Next, E3 ubiquitin-protein ligases (E3 ligases)
act to facilitate covalent ligation of ubiquitin to protein substrates.
Different types of E3 ligases may facilitate protein-ubiquitin ligation by distinct
mechanisms (160). Many E3 ligases can bind to protein substrates and corresponding E2
enzymes simultaneously to form protein substrate-E3 ligase-E2 enzyme-ubiquitin
complexes. These complexes allow for the direct transfer of ubiquitin from E2 enzymes
onto specific lysine residues of respective protein substrates. Once a substrate protein is
ubiquitinated, E1, E2, and E3 enzymes can promote subsequent polyubiquitination of the
substrate by covalent linkage of ubiquitin molecules onto residue Lys 48 of the
previously conjugated ubiquitin molecule. The addition of a chain of at least four Lys-48-
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linked ubiquitin molecules onto a substrate protein marks the substrate for degradation by
the 26S proteasome (73;159;160).
The 26S proteasome is a complex consisting of a large protease (the 20S
proteasome) and several regulatory subunits (19S/PA 700, PA 200, PA28) (3;323;369). It
is arranged into a hollow symmetrical dumbbell-like structure with the catalytic 20S
subunit at the central core and regulatory subunits on either end (3;73;369). The 20S
catalytic core possesses chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide
hydrolase (PGPH)-like protease activities which act to break down substrate proteins into
small 2-25 amino acid peptide fragments. Such peptides can be further hydrolyzed into
individual amino acids which can be used to make new proteins (3;246;323).
It is important to note that when clearing proteins via the UPS pathway, each E2
enzyme only binds to a subset of E3 ligases and each E3 ligase only binds to a specific
number of protein substrates. While there is likely some redundancy in this system, the
failure of an E3 ligase to bind its substrates or to interact with corresponding E2 enzymes
could result in substrate accumulation and subsequent protein aggregation. It is
hypothesized that aggregated proteins can resist proteasomal degradation and that they
may even clog and inactivate 20S catalytic subunits (323 and references therein). When
misfolded proteins are not cleared, they can accumulate or aggregate, resulting in the
formation of proteinaceous inclusions.
1.9

Lewy bodies in PD and proteasome dysfunction
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In 1910, Fritz Heinrich Lewy, a German born neurologist and histopathology
specialist, presented a paper, To the Pathological Anatomy of the Paralysis Agitans, at the
Seventh Annual Meeting of the Society of German Neurologists. During his presentation,
Lewy described his discovery of intracellular “balls” that were detected in PD basal
ganglia tissues during post mortem analyses. These “balls” were noted to be
proteinaceous, eosinophilic and variable in size (382). In 1918, the term, “corpe de
Lewy” or “Lewy bodies”, was first used to describe these pathologies (166;382). Today it
is known that Lewy bodies (LBs) are the common neuropathological hallmark of PD
(396).
LBs are intraneuronal, cytoplamsic inclusions that typically only affect specific
neuronal populations in PD brains. The classical LB is spherical in shape with a dense
granular core and fibrillar halo (219;396)(Figure 1-4). The preponderance of LBs in PD
brains significantly links these pathologies to nerve cell degeneration. However, it is not
fully understood what molecular events lead to LB formation (112). It is known that LBs
are composed of deposits of aggregated proteins that are often ubiquitinated (356), and it
is possible that these proteins may accumulate and associate into LBs as a consequence of
proteasome impairments in PD. To support this idea, enzymatic analyses reveal that PD
substantia nigra tissues demonstrate reduced proteasome activities (287;290).
Additionally, decreased levels of regulatory subunits of the 26S proteasome have been
observed in PD (287;288). These findings may link proteasome impairments to PD
pathogenesis; however it is still unknown whether such changes may be causal of disease.

12

Figure 1-4

Lewy Body. The image shows multiple LBs in the same neuron
of the SNpc stained with hematoxylin-eosin. Scale bar is 25μm.
Figure modified from Kovari et al., Brain Res Bull 2009 (219).

1.10

Proteasome Inhibitors
Studies to understand the effects of proteasome dysfunction in rodent and cell

culture models of PD often utilize proteasome inhibitors such as carbobenzoyl-leu-leuleucinal (MG-132), lactacystin, and epoxomicin. MG-132 is a synthetic cell-permeable
peptide-aldehyde that can reversibly bind and inhibit chymotrypsin-like activities of the
20S proteasome (436;437). MG-132 is also known to inhibit calcium-modulated cysteine
proteases (calpains) to a lesser degree (437). Lactacystin is a naturally occurring
compound that was isolated from Actinomycetes in 1991 (326). It covalently binds to
20S proteasome subunits and acts to inhibit chymotrypsin-like and trypsin-like activities
in an irreversible manner while inhibiting PDPH-like activities in a reversible manner
(108). In aqueous solution, lactacystin is converted by hydrolysis into its active form,
clasto-lactacystin-β-lactone (Omuralide) (97). Omuralide specifically inhibits the
proteasome although it has also been shown to inhibit capthepsin A to a lesser degree
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(246). Since both MG-132 and omuralide can inhibit proteases in addition to the 20S
proteasome, when using these agents to study proteasome function, it is best to show
similar effects with other proteasome inhibitors (246). One such inhibitor, epoxomicin,
was originally isolated from an Actinomycetes strain in 1992 (149). Epoxomicin was
later discovered to be a provocative, irreversible and selective inhibitor of all 3 protease
activities of the 20S proteasome (293). Importantly, epoxomicin does not act to inhibit
other known cellular proteases, making it a suitable agent in proteasome studies (293).
1.11

Proteasome inhibitors are used to induce parkinsonism in rodent models.
There is evidence to suggest a strong link between the UPS and nigral neuronal

health. For instance, it has been shown that intranigral injections of lactacystin into rats
causes protein inclusion formation, nigral and extranigral lesions as well as parkinsonianlike behavioral impairments (289;451;300;318). Epoxomicin has similar effects on rats,
even when introduced systemically (292). Similarly, mice display nigral specific
degeneration following MG-132 exposure (415). MG-132 is also selectively toxic to
primary dopaminergic neurons in culture (415). It is not clear why proteasome inhibitors
are particularly toxic to nigral neurons. Determining the answer to this question will give
insights into the role of proteasome impairments in the etiology of PD.
1.12

Reactive oxygen species and oxidative stress
Oxidative stress is a term used herein to describe cellular damage which results

from reactive oxygen species (ROS). The term ROS can be used to describe any strong
electrophile which is composed in part by oxygen (15). In animal cells, while there are
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various sources of ROS, ROS can be generated by mitochondria during the process of
aerobic respiration (101;221;408). During respiration, in order to efficiently generate
energy in the form of ATP, electrochemical proton gradients must be established across
inner mitochondrial membranes (6). To generate these gradients, electrons are transferred
from an initial electron donor to electron acceptors in various mitochondrial enzyme
complexes which are together referred to as the electron transport chain (ETC). The
transfer of electrons along the ETC begins at mitochondrial complex I (or alternatively at
complex II) and proceeds in series until it terminates at mitochondrial complex IV.
Complex IV then catalyzes a series of reactions which transfers reactive ETC electrons to
O2 and this eventually results in the formation of water. Prior to reaching complex IV,
however, electrons can leak prematurely during each successive transfer along the ETC.
The monoelectronic transfer of one of these leaked electrons to an O2 molecule forms
superoxide (-.O2).
Superoxide can be generated by mitochondria as well as other enzymes and can
serve as a progenitor for other ROS (408;435). For example, mitochondrial superoxide
dismutase dismutates -.O2 to hydrogen peroxide (H2O2), which is another ROS. H2O2 can
readily diffuse across mitochondrial membranes and out into the cell where it can affect
various cellular processes (64;221). Alternatively, in the presence of iron (Fe 2+), H2O2
.

can be converted into highly reactive hydroxyl ( OH) radicals which are thought to be
.

very damaging (221;78). In addition to H2O2 and OH radicals, -.O2 is also a progenitor
for another extremely reactive species, peroxynitrite (ONOO-), which is formed by the
reaction of -.O2 with nitric oxide (NO-) (183;221). ONOO- can lead to the generation of
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.

additional reactive radicals including OH radicals, nitrogen dioxide (.NO2), and
carbonate (CO3.-) (417).
1.13

Oxidative stress and peroxiredoxins
If left unchecked, ROS can indiscriminately attack cellular proteins, lipids, and

nucleic acids resulting in variable degrees of oxidative damage (9;64;215;435). To
protect against this, healthy cells utilize a variety of regulatory enzymes that act to inhibit
undesirable redox reactions (9;408). However, such compensatory enzymes can become
overwhelmed when oxidants are overabundant, and the consequences of this can be fatal
(215;221). For example, the family of antioxidant peroxidase enzymes, peroxiredoxins
(Prxs), acts to decompose H2O2 and other intracellular peroxides by reducing them to less
reactive forms (147). In mammals, the Prx enzyme family is composed of six different
isoforms which confers tissue and subcellular expression specificities to each of its
members (193;222). It is known that Prxs utilize conserved cysteine residues that donate
electrons to peroxide substrates, resulting in the formation of Prx cysteine sulfenic acid
(147;472). Ideally, following oxidation to sulfenic acid forms, Prxs can be subsequently
reduced either by neighboring Prx molecules or by other electron donors (147;472).This
serves to recharge Prx enzymes for future reactions. However, when peroxide levels are
overwhelming, oxidation of Prxs to cyteine sulfinic or sulfonic acid forms can occur and
these modifications have been shown to disrupt future Prx enzyme activities (147;472).
1.14

Oxidative stress in PD
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In a study to assess for expression of Prx isoforms in neurodegenerative diseases,
a specific increase of PrxVI was detected in frontal cortex regions in PD brains as
compared to normal, Down’s syndrome, or Alzheimer’s disease brains (222).
Interestingly, this increase was not detected for other Prx isoforms, suggesting a specific
role for PrxVI in PD (222). Confirming this idea, Power et al. reported increased levels of
PrxVI in PD brain homogenates in comparison to homogenates from normal brains (360).
Histological analyses also revealed that PD brains exhibited increased PrxVI staining as
compared to controls (360). These findings could be correlated to an overabundance of
oxidation in PD.
Several common pathological markers for oxidative stress are known to be
associated with PD including DNA and protein oxidation, lipid peroxidation and
alterations in antioxidant levels (9;215;278). For instance, depleted levels of the
antioxidant glutathione (GSH) can often correlate with severe nigral degeneration in PD
(9;278). GSH is a tripeptide that is used as a souce of reducing equivalents in cells (278).
Interestingly, GSH serves to reactivate PrxVI following its conversion to cysteine
sulfenic acid forms (272). However, when GSH levels are depleted, it is possible that
PrxVI could become inactivated by excessive oxidation and it is not known whether this
could result in subsequent aggregation of the inactivated PrxVI enzyme. It is interesting
to note that PrxVI co-localized to nigral Lewy inclusions in PD brains (360). This is one
of many findings that may implicate a role for oxidative stress in LB formation.
1.15

Oxidation in dopaminergic neurons
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It is thought that dopaminergic neurons may be particularly vulnerable to
oxidative stress since oxidation is inherent in these cells even in healthy individuals. It is
known that DA can spontaneously oxidize to form electrophilic quinones, which can lead
to oxidative damage of proteins (140;267). DA itself can be metabolized by MAO to
form H2O2 (64). Additionally, the DA metabolite, 3,4-dihydroxyphenylacetic acid
(DOPAC) can also be converted to quinones which generate ROS (64).Thus, without
proper regulation, DA itself could promote oxidative stress which could result in
dopaminergic neuron toxicity. However, the heterogeneous pattern of dopaminergic
neurodegeneration in PD is confounding since dopaminergic neurons in extranigral brain
regions are less affected in disease (94;162).
1.16

Oxidative stress in PD models
Experimental paradigms designed to better understand the role for oxidative stress

on nigral neurodegeneration often utilize oxidizing agents such as paraquat, 6hydroxydopamine or H2O2. Reduction-oxidation cycling of paraquat leads to the
formation of -.O2 radicals (362;48;36). Paraquat can also oxidize Fe3+ to Fe2+ which can
.

then subsequently react with H2O2 to form OH radicals (362). Paraquat also acts to
increase nitric oxide levels, eventually leading to the formation of reactive ONOO(89;330). Traditionally, paraquat has been used as an herbicide since it efficiently
disrupts photosynthesis by scavenging electrons (414). Of interest to PD studies, paraquat
exposure in rodents results in nigrostriatal dopamine neuron degeneration and this can
result in parkinsonian motor impairments (49;231;286;331;430). However, it is not fully
understood why nigrostriatal neurons are particularly vulnerable to paraquat insult (36).
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The oxidizing agent, 6-hydroxydopamine (6-OHDA), can act to generate -.O2,
.

H2O2, or OH radicals (78). Due to its close structural similarity to the catecholamines
DA and norepinephrine, 6-OHDA is selectively taken up into catecholaminergic neurons
where it can exert its deleterious effects (397). For instance, when 6-OHDA is infused
into striatal or nigral tissues in various animal models, it results in dopaminergic
neurodegeneration and behavioral impairments that resemble those observed in PD. Thus
6-OHDA is a tool that is widely used to model PD; however, it is somewhat limited since
proteinaceous Lewy-like inclusions are not formed as a consequence of its use (397).
Yet an additional oxidizing agent, H2O2, can be used to induce oxidative stress in
vitro and in PD cell culture studies. For example, in a recent study by Zhou and Lim,
H2O2 treatment of mouse mesencephalic MN9D dopaminergic cells acted to inhibit
proteasome activity. It also sensitized these cells to MG-132 and resulted in cell toxicity
(495).
These findings suggest that oxidative stress may be a causal stimulus for
degeneration in PD. Thus, it will be beneficial to determine what specific factors can act
to mitigate oxidative insults that may occur with respect to the disease.

1.17

MPTP parkinsonism syndrome and mitochondrial dysfunction in PD
In a report in 1979, Davis et al. described a 23 year old male who presented with

acute parkinsonism following self-administration of home-made 4-propyloxy-4-phenylN-methylpiperidine (MPPP). MPPP is an opiate which has similar effects as the
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analgesic, Demerol (meperidine). While synthesizing MPPP, the patient also accidentally
generated a toxic byproduct, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
which contaminated his illegal drug preparations. Following self administration of this
preparation, the patient developed, “a state of muteness, severe rigidity, weakness,
tremor, flat facial expression, and altered sensorium” (87). In a later report, Langston et
al. described four heroin addicts who also developed severe parkinsonism subsequent to
only one week of illegal MPPP/MPTP contaminated drug use (237). Other similar reports
later followed (20;236;473). The agent responsible for the onset of disease symptoms was
concluded to be the MPTP contaminant (237).
Interestingly, the MPTP-induced parkinsonism syndrome was remarkably similar
to that of idiopathic PD. Further, post mortem histological analyses of four affected
patients revealed dramatic degeneration of nerve cells within SNpc as well as associated
gliosis and microglial activation (87;237;239). However, distinct from sporadic PD, no
MPTP-induced neuronal effects were detected in other brain regions such as locus
coeruleus, basal ganglia, hypothalamus, thalamus, cortex, cerebellum, or nucleus basalis
of Meynert. Further, traditional Lewy bodies were not apparent (239).
Following these reports, aggressive studies were conducted to understand the
mechanism by which MPTP induced cell toxicity. It was discovered that MPTP can
rapidly diffuse across lipid bilayer membranes into the brain where it can be metabolized
by the MAO type B (MAO-B) enzyme to form 1-methyl-4-phenylpyridnium (MPP+).
This reaction is thought to occur in glia since appreciable levels of MAO-B enzyme
localize particularly to glial cells and serotonergic neurons in the brain (466;467). The
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MPP+ metabolite is the chemically active form of MPTP, but since it is not as lipophilic
as the MPTP parent compound, to enter cells quickly, the MPP+ metabolite requires
active transport. Incidentally, MPP+ is a substrate for the dopamine transporter (DAT)
and can thereby selectively enter dopaminergic neurons. Once inside the cell, MPP+
accumulates in mitochondria where it can bind at two distinct sites in mitochondrial
complex I and thus disrupt complex I catalytic activity (363). Inhibition of complex I can
cause cellular dysfunction by the production of ROS (363;365;398). Discoveries of the
inhibition of mitochondrial complex I by MPTP/MPP+ and its specific effects on
dopaminergic neurons in humans provided the first line of evidence for the role of
mitochondrial impairments in PD pathogenesis.

1.18

Mitochondrial impairments in sporadic PD
Shortly thereafter, it was discovered that PD patients exhibited reduced activity in

mitochondrial complex I when compared to normal individuals (273;380) and that this
deficiency was specifically observed in the substantia nigra brain region (273;381). In
comparison to controls, some PD patients were also deficient in mitochondrial complex I
subunits in striatal tissues (302). It was also reported that PD patients demonstrated
reduced activities of mitochondrial complexes I, II, and IV in skeletal muscle (40),
although this finding has not been supported by other studies (10;273). Additionally,
reduced activity in mitochondrial complex I can be detected in platelets of PD patients
(145;223;223), although this idea may also be controversial (273). Taken together, these
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findings suggest that mitochondrial dysfunction is the link that connects MPTP-induced
parkinsonism to sporadic PD.

1.19

MPTP and parkinsonism animal models
Interestingly, the effects of MPTP on animal models also resemble features that

are common to idiopathic PD. When administered to nonhuman primates or mice,
MPTP/MPP+ selectively and irreversibly damages dopaminergic neurons of the SNpc and
markedly reduces striatal dopamine content (48;50;111;238). Additionally, protein
inclusion formation can result from chronic MPTP exposure in mouse models of PD,
though these inclusions are not necessarily reminiscent of LBs (111;192;295). Exposure
to MPTP can also lead to protein aggregation in primates (113;114;220).
In addition, MPTP can be a valuable tool for in vitro studies. For example,
Pavlovic et al. show that although mouse Neuro-2A (N2A) neuroblastoma cells do not
express the plasma membrane DAT, MPP+ is able to enter these cells by passive
diffusion, albeit relatively slowly (346). Following N2A cell entry, MPP+ can decrease
mitochondrial membrane potential, increase ROS, activate caspases, and induce apoptosis
(346). Thus MPTP is widely used in studies to model mitochondrial dysfunction.
1.20

Rotenone models of PD
Another commonly used mitochondrial inhibitor is rotenone. For centuries prior

to 1924, rotenone had been harvested from indigenous plants in South American
countries and was used by natives as a fish poison (225). Rotenone was later discovered

22

to act as a potent insecticide and became widely used in the United States for this purpose
(225). Investigations into the physiological mechanism of the rotenone toxin determined
that it can tightly bind to mitochondrial complex I and thereby block electron transfer
along the ETC (168;258;259;322). Rotenone is lipophilic and thus it can ubiquitously
and indiscriminately enter brain cells to exert its inhibitory effects on mitochondria (240).
Rotenone is actually proven to be a more potent complex I inhibitor than MPP+
(363) and thus it is often used to induce mitochondrial stress in various experimental
paradigms. Interestingly, while chronic systemic rotenone exposure in rats depletes
complex I enzyme levels throughout the entire brain, this can result in specific
degeneration in nigrostriatal tissues as well as intracellular inclusion formation and
associated parkinsonian behavioral traits (38;54;390). While rotenone may preferentially
affect nigral dopaminergic neurons for degeneration, other studies have shown that
neuronal loss can also be detected in rat locus coeruleus, cerebellum and mildly in frontal
cortex tissues (165). It is thought that the particular toxicity of rotenone on nigrostriatal
dopaminergic neurons may be due to the increased levels of oxidative stress that arise
secondary to mitochondrial complex I inhibition (429). Supporting this idea, a recent
study by Pan-Montojo et al. showed that chronic intragastric rotenone administration in
mice resulted in decreased motor activity and intracellular protein inclusion formation in
spinal cord, brainstem, and substantia nigra (336). It also resulted in nigral dopaminergic
neurodegeneration. This was likely due to secondary effects of rotenone exposure in
these animals since rotenone was not detected in systemic blood or in the central nervous
system (336). Other studies also confirm that rotenone has a toxic effect on mouse
nigrostriatal tissues following chronic oral administration (179;180). Together, these
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findings suggest that nigral dopaminergic neurons are vulnerable to mitochondrial
complex I inhibitors and this may further implicate a role for mitochondrial dysfunction
in PD pathogenesis. Nevertheless, more work must be done to determine what factors
may act to modulate this.
1.21

Genetic causes of PD
Discoveries of inherited forms of PD have increased awareness about

physiological mechanisms that may be implicated in the etiology of the disease. To date,
at least 14 chromosomal loci and 9 genes have been identified which cause monogenic
forms of PD (Table 1-2) (152;250). Although familial forms of the disease only comprise
~ 5% of all PD cases, studies of the gene products encoded by PD-linked genes have
given insights into the factors that may be relevant to understanding sporadic PD
(152;250). The roles of the PD-linked genes PARK1/4 (SNCA), PARK2 (parkin), and
PARK6 (DJ-1) will be the subject of the following sections.
Table 1-2
Locus

Chromosome

PARK1/PARK4
PARK2
PARK3
PARK5
PARK6
PARK7
PARK8
PARK9
PARK10
PARK11
PARK12
PARK13
PARK14
PARK15

4q21-q23
6q25.2-27
2p13
4p13
1p36.12
1p36
12q12
1p36
1p
2p37.1
Xq21-q25
2p13.1
22q13.1
22q11.2

Year of
discovery
1997 (357)
1997 (284)
1998 (125)
1998(249)
2001 (442)
2001(446)
2002 (118)
2005 (468)
2002 (161)
2008 (241)
2002 (337)
2005 (412)
2009 (332)
2009 (96)

Gene

Inheritance

SNCA/α-synuclein
parkin (208)
Unidentified
UCHL1
PINK1 (441)
DJ-1 (47)
LRRK2 (333;497)
ATP13A2 (364)
Unidentified
GIGYF2
Unidentified
Omi/HtrA
PLA2G6
FBXO7

Dominant
Recessive
Dominant
Dominant
Recessive
Recessive
Dominant
Recessive
Unknown
Unknown
X-linked
Dominant
Recessive
Recessive
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1.22

PARK1/4 (SNCA)/α-syn
In 1990, Golbe and colleagues released reports about an endemic of PD within a

large family from Contursi village in southern Italy (134). The affected individuals
developed early-onset disease at ~47 years of age and had relatively rapid courses of less
than 10 years from disease onset to death. At the time of the report, it was concluded that
a single gene was causal of this form of PD, though no putative gene candidates had yet
been identified (134). Years later, a genome wide scan in the affected Italian family
identified loci at chromosome 4q21-q23 that linked to the disease phenotype (357). SNCA
or alternatively PARK1/4 was among many genes that mapped to this particular
chromosomal region. Further sequence analysis of the SNCA gene in the Contursi kindred
revealed a single nucleotide (G209A) missense mutation which resulted in the A53T αsynuclein (α-syn) amino acid substitution (357). The pathogenic A53T α-syn mutation
showed an autosomal dominant pattern of inheritance and this finding provided the first
solid evidence for a monogenic cause of PD.
α-syn immediately became a hot topic of discussion in the field of PD research.
Human α-syn had been previously cloned in 1993 by Ueda and colleagues as an
“unrecognized component of amyloid in Alzheimer disease” (438). In the initial report by
Ueda and colleagues, α-syn was detected in diffuse, primitive and mature amyloid
plaques but was absent in neurofilbrillay tangles. Thus it was called non-Aβ component
of AD amyloid (NACP) (438). The identified NACP species was later coined “αsynuclein” by Jakes and colleagues (188) based on its close sequence homology to
previously described synuclein proteins (277).
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α-Syn is a small protein of 140 amino acid residues which is predominantly
expressed in the brain and which localizes to presynaptic nerve terminals (187;188;277).
It is largely a hydrophilic protein with the exception of a central hydrophobic core which
is designated as the “NAC” region (187). The amino terminus of α-syn contains repeat
motifs consisting of the residues, K-T-K-E-G-V (277), and the carboxyl terminus is
acidic due to prevalent Glu residues (187).
In the same year following the report of the Contursi kindred, it was discovered
that α-syn protein localized to LBs in idiopathic PD brains (405). Full-length, partially
truncated and insoluble forms of α-syn were detected in these pathologies and it was
eventually concluded that, “α-syn is the building block of LBs” (18;119;182;396). These
findings were the first to implicate a fundamental role for α-syn in the etiology of both
inherited and sporadic forms of PD.
To date, several mutations in the SNCA gene are known to cause autosomal
dominant PD. In addition to the initial report of the Italian Contursi kindred (357), the
A53T α-syn mutation has been identified in many PD patients of European descent
(17;276;338;406). In addition, a missense mutation resulting in the A30P amino acid
substitution in α-syn was shown to be causal of PD in a German family (224). In a
Spanish kindred, severe parkinsonism phenotypes are also associated with another α-syn
amino acid substitution, E46K (488). Furthermore, short chromosomal duplications and
triplications that include the SNCA gene are associated with clinical phenotypes that
resemble idiopathic PD (61;107;176;400). Taken together, these findings implicate α-syn
protein as an important player in parkinsonism-associated diseases.
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Although the physiological role for α-syn has yet to be identified, years of
extensive analyses point towards several putative functions. Some studies suggest that αsyn may normally behave in a protective capacity (76;368). For example, α-syn may act
to regulate synaptic vesicle integrity since it can co-localize with the vesicle membrane
protein, synaptophysin (187), and is also known to be in close proximity or in association
with synaptic vesicles (187;277). α-Syn also exhibits chaperone-like activity
(5;205;206;343;403) and may even act as an auxiliary molecular chaperone for synaptic
vesicle proteins (59). Additionally, α-syn may act to protect against dopamine induced
oxidative stress. For instance, α-syn may down-regulate dopamine synthesis by
modulating the tyrosine hydroxylase (TH) or aromatic L-amino acid decarboxylase
enzymes (7;348;351;427;70).
Though α-syn may exhibit protective features under certain experimental
conditions, it is thought that α-syn mutations contribute to PD by a gain-of-function. For
instance, studies suggest that α-syn may induce and/or enhance oxidative stress which
acts to promote cell toxicity (27;95;169;191;197;339;340;413). It is also known that αsyn can polymerize into filaments and aggregate into amyloidogenic inclusions, and that
this ability is enhanced by A53T and E46K mutations (464). Further, α-syn inclusion
formation may be lethal in vivo due to associated impairments of the proteasome
(34;410;425;432). Alternatively, α-syn may exert its detrimental effects by inducing
mitochondrial impairments (95;103;169;256;261;264;279;329;339;340;388;425;447;448;474).
An array of α-syn animal models has been developed for the purpose of
understanding the physiological role of α-syn in vivo. α-Syn null mice were generated in

27

order to determine the effect of α-syn loss-of-function (1). However, although subtle
alterations in DA neurotransmission were reported, α-syn null mice exhibited normal life
spans, did not display nigrostriatal deficits, and appeared to be normal as it related to
synaptic nerve terminal integrity (1). Alternatively, gain-of-function, transgenic mouse
models expressing human α-syn protein have yielded more provocative findings. In brain
tissues of transgenic mice expressing wild-type (WT) human α-syn protein, α-syn was
phosphorylated and exhibited reduced biochemical extractability (315). This was
interesting since both biochemical features are common to human LB diseases
(11;117;375;463). Transgenic mice expressing pathogenic mutant A30P human α-syn
developed phosphorylated, aggregated, proteinase K-resistant LB-like deposits of α-syn
in various regions of the central nervous system (CNS) (199;315) and this was associated
with the onset of fatal motor impairments in an age-dependent manner (315). Similarly,
when expressed in mice, pathogenic mutant A53T human α-syn aggregated into Lewylike inclusions that could be detected throughout the neuroaxis (131;247;444). This
resulted in marked axonal degeneration (131;279;444) and the induction of progressive,
severe motor abnormalities (131;444;247). These mouse studies suggest that the onset of
disease phenotypes directly correlate to the propensity for α-syn to aggregate in vivo;
however it remains to be determined what cellular mechanisms may act to modulate this,
especially as it relates to how other gene products may be implicated. Identifying such
factors would be insightful.
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1.23

PARK 2 (Parkin)
Evidence of autosomal recessive types of juvenile parkinsonism (AR-JP) were

first reported by Yamamura and colleagues in 1973 (481). AR-JP was described as an
insidious disease with juvenile to early-onset (before 40 years of age) (481;184;420) that
was clinically characterized by progressive typical parkinsonism, superb levodopa
responsiveness, and a slow and protracted disease course (481). Neuropathological
analyses of AR-JP cases showed highly selective degeneration of neurons in SNpc but
without evidence of LB formation. Additionally, degeneration could be detected to a
lesser degree in the locus coeruleus. Gliosis was also prominent in the affected brain
regions (420). In 1997, Matsumine and colleagues identified a gene for AR-JP which
mapped to chromosome 6q25.2-27 (284). This gene, which was designated as PARK2
(285), was later cloned by Kitada et al. and was discovered to encode a protein product
that was called “Parkin” (208).
The parkin protein is 465 amino acids in length (208). It is expressed in many
tissues with highest expression in skeletal muscle, heart, testis and brain (208). In
general, parkin can be detected throughout the brain (84;226) and can be localized to
neurons, astrocytes, and microglia (172;391;411). It is most abundant in cell soma
(84;411) but can also localize to processes and presynaptic terminals (84;172;411).
Based on sequence homology studies, it was determined that parkin shows
similarity to ubiquitin protein at the N-terminus (208). It was also originally thought that
parkin had one Really Interesting New Gene (RING) finger motif at the C-terminus
(208), but it was later determined that parkin actually contains two C-terminal RING
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finger domains separated by an In-Between-Ring (IBR) finger domain (308). Many
proteins with this RING1-IBR-RING2 signature are found in nature (445), and it was
known that some RING finger proteins could act as E3 ligases in the UPS (194).
Together, this knowledge provoked several studies which aimed to determine whether
parkin could act as an E3 ligase. Subsequently, it was determined that parkin could
interact with the E2 enzymes UbcH7, UbcH8, Ubc7, and Uev1/UbcH13
(100;178;283;325;392;490) and that this association could result in parkin
autoubiquitination (283;490) as well as polyubiquitylation of unidentified cellular protein
substrates (178;392). Thus, it was concluded that parkin can function as an E3 ligase;
however, the physiological relevance for this function has yet to be fully established.
The parkin gene consists of 12 exons and large intron regions spanning a total of
1.38 Mega bases in size, making it one of the largest known genes (16). Genes of large
size, such as parkin, may be particularly susceptible to mutations. To date, it is known
that a variety of parkin exonic deletion, duplication, triplication, splice site, missense, and
nonsense mutations result in juvenile to early-onset PD (26;155;270;282;359;416). In
fact, parkin mutations are the leading cause of recessive juvenile PD (478). Thus, there
has been much focus on understanding the role of parkin protein, especially as it relates
to how parkin mutations may be causal of PD.
It is thought that parkin mutations cause disease by a loss-of-function. Supporting
this idea, it has been reported that many pathogenic parkin missense mutants show
reduced or impaired E3 ligase activities when analyzed in vitro (72;283;392;407;490). It
is also known that several pathogenic parkin mutants have a tendency to form
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intracellular aggregates when expressed in cultured cells (81;143;148;407;460) and that
this may be due to improper folding of mutant protein (383). Based on these findings, one
would expect for parkin-associated PD patients to exhibit an overabundance of parkinpositive pathologies in their brains; however such an observation is very uncommon. In
fact, to the contrary, most parkin-associated PD patients seemingly resist inclusion
formation since neither LBs nor other pathological inclusions are typically detected
during postmortem analyses (4). However, it should be mentioned that α-syn and/or
parkin positive pathologies have been observed in the brains of a few patients with parkin
mutations (106;361;378;384).
The absence of Lewy inclusions in parkin-associated PD brains led some to
speculate that functional parkin protein must be required for LB formation (72;384). In
agreement with this notion, parkin has been shown in some studies to localize to LBs in
sporadic and inherited forms of PD (22;384;391) and may act to ubiquitinate Oglycosylated forms of α-syn as a substrate in vivo (393). Additionally, parkin may
ubiquitinate α-syn positive LB-like inclusions in cultured cells (72). Further, the α-syn
interacting protein, synphilin-1 (104;317;202), was identified as a putative parkin
substrate by Chung and colleagues in 2001 (72). This is interesting since synphilin-1 can
localize to LBs in sporadic PD brains (458;312;22) and can promote the formation of
cytosolic α-syn-positive inclusions in cultured cells (104;72). Though the physiological
role for synphilin-1 is not clear, it is known to be polyubiquitylated in the presence of
parkin and to co-immunoprecipitate with parkin in vivo (72). Additionally, although it is
thought that parkin may facilitate polyubiquitylation of synphilin via Lys-63-linked
chains and that this may regulate synphilin in a proteasome-independent manner, it is
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known that parkin can mediate proteasome degradation of synphilin under certain
experimental conditions (257).
It should also be mentioned that to date, a growing number of other putative
parkin substrates has been identified. Among them are included the synaptic vesicle
associated protein, CDCrel-1 (490); the parkin-associated endothelin receptor-like receptor,
Pael-R (177); cytoskeletal proteins α/β-Tubulin (370); the synaptic vesicle protein,
synaptotagmin XI (173); the aminoacyl-tRNA synthetase cofactor, p38/JTV-1 (83;217);
the cell division control-related protein, SEPT5_v2/CDCrel-2 (68); the cell cycle protein,
cyclin E (409); and the p38/JTV-interacting protein, far upstream element-binding
protein 1 (FBP1; 216). Determining the authenticity of these proposed substrates remains
to be confirmed in vivo since studies in parkin deficient animals and AR-JP brains have
been somewhat limited. More work must be done to determine the effects of parkin on
putative substrates especially as it relates to how these effects may contribute to PD
pathogenesis.
Studies suggest that parkin acts to protect against a multiplicity of toxic insults. It
is known that parkin actively decreases ROS formation (190) and can also mitigate the
effects of harmful protein aggregation (311;262). When overexpressed in cultured cells,
parkin can protect against noxious agents such as ONOO-, H2O2, MPP+, DA, 6-OHDA,
and MG-132 (174;175;440;190;71;151). It can also assuage the deleterious effects
following MPTP or 6-OHDA exposure in vivo (345;450). It is thought that parkin may
prevent cell death by activating protective signaling pathways (156;386) and also by
down-regulating classical apoptotic signaling molecules (85;151;190;56). Additionally,
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parkin may have a specific role at protecting cells by maintaining mitochondrial
homeostasis (373;314;126;230;229;75;342;485;358;93;341;268;141;35).
Parkin deficient animals are known to be particularly vulnerable to certain types
of stressors and this is likely due to a loss of protective parkin function. For example,
transgenic parkin null worms and mice exhibit selective vulnerability to rotenone
exposure (447;55). Parkin deficient Drosophila are highly sensitive to paraquat (353).
Systemic exposure of aged parkin deficient mice to the inflammatory stimulus,
lipopolysaccharide (LPS), can result in selective nigral dopaminergic neurodegeneration
(116). Taken together, this evidence supports the notion that loss of parkin function can
have detrimental consequences within certain confines. However, in the absence of
stressful stimuli, determining the in vivo effects of parkin loss-of-function has proven to
be difficult, especially in mouse models. Parkin deficient mice appear to be
phenotypically normal as it relates to lifespan, body weight, brain size, brain morphology,
and nigrostriatal neuronal integrity (135;186;211;350;379;496). Some labs report mild
motor or learning deficits in parkin null mice (135;186;350;454;496); however these
observations are not confirmed in other studies (379). Parkin deficient mice also show
slight alterations in nigrostriatal dopamine neurotransmission and/or turnover (186;496)
(135;379), although this finding is inconsistent with other reports (116;349;350).
Interestingly, von Coelln and colleagues observed a loss of locus coeruleus neurons in
parkin null mice (454), but this finding was not reported by other groups. Additionally,
some studies suggest that parkin deficient animals suffer from mitochondrial
impairments, oxidative stress, and glial dysfunction (335;372;401) while others show that
parkin null mice are resilient against stressors like MPTP and 6-OHDA (349;431), and
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the latter findings seem contradictory to the former. Thus, the reported inconsistencies
regarding the effects of parkin loss-of-function in mice make it very difficult to conclude
what physiological role parkin may play in PD pathogenesis.

1.24

PARK7(DJ-1)
In 2001, a report was published by van Duijn and colleagues about 4 individuals

in a Dutch family who presented with early-onset parkinsonism (446). The affected
individuals developed symptoms prior to 40 years of age, were responsive to levodopa
and dopamine agonist therapies, showed severe abnormalities consistent with
nigrostriatal dopaminergic system dysfunction, and had slow disease progression (446).
The affected patients did not harbor mutations in the other known PD-linked genes, and a
novel locus at chromosome 1p36 was identified and linked to the disease phenotype with
an autosomal recessive pattern of inheritance (446). The new locus was called PARK7
(446). In later studies, Bonifati et al. sequenced the candidate genes at the PARK7 locus
and identified an exonic deletion in the affected Dutch family which mapped to the DJ1gene (46). Interestingly, in the same report, Bonifati and colleagues also discovered a
homozygous missense mutation in the DJ-1 gene that was causal of early-onset PD in an
Italian family (46). Together, these discoveries sparked new interest in DJ-1 as a novel
PD-linked gene.
To date, a variety of pathogenic DJ-1 mutations have been reported (Table 1-3)
and are thought to cause disease by a loss of DJ-1 function (46). While most affected
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patients clinically exhibit the cardinal symptoms of PD, autopsy tissues are not yet
available to determine the neuropathological features associated with causative DJ-1
mutations (200). These mutations are rare (433;66;214), perhaps only contributing to 12% of all early-onset PD cases (154).
Table 1-3
Mutation

Inheritance

Average Age of

Ethnic group
affected

Year reported
(Reference)

disease onset
L166P

Homozygous

30

Italian

2003(45;47)

M26I

Homozygous

39

Ashkenazi Jesish

2003 (2)

E64D

Homozygous

34

Turkish

2004 (157)

E163K

Homozygous

31.6

Italian

2005 (14)

L10P

Homozygous

18.5

Chinese

2008 (144)

P158DEL

Homozygous

33.8

Dutch

2009 (270)

14 kb deletion

Homozygous

32.6

Dutch

2003 (47;446)

R98Q

Heterozygous

< 50

European descent

2003 (146;263)

A104T

Heterozygous

35

Latino

2003(146)

c.253-322 deletion

Heterozygous

45

Serbian

2004 (98)

A179T

Heterozygous

47

Dutch

2009 (270)

Exon1-5 duplication

Heterozygous

46

Dutch

2009 (270)

c.C56DEL

Compound
Heterozygous

24

Latino

2003 (146)

Compound
Heterozygous

36

Afro-Caribbean

2003(2)

c.G57A
c. intron6, G1C
D149A
G78G

The DJ-1 gene is comprised of 7 exons and 8 introns that span 16-24 kilobases,
and exons 2-6 encode DJ-1 protein (419). DJ-1 had originally been discovered in 1997 by

35

Nagakubo et al. in a yeast two-hybrid study to identify proteins that interacted with the
known cancer gene, c-myc (313). In this study, the nucleotide and amino acid sequences
determined for one of the isolated clones was designated as “DJ-1”. DJ-1 was later found
to be a false-positive clone that actually did not interact with c-myc directly.
Nevertheless, Nagakubo and colleagues knew that DJ-1 was a novel protein and reported
that it could function as an oncogene (313). Later studies to clarify the role for DJ-1
identified it as a protective protein component in rat sperm (457), a modulator for
androgen-receptor mediated transcription (421), as well as a regulatory component of
RNA-binding protein complexes (163).
It is known that DJ-1 is a 189 amino acid protein (313) that is ubiquitously
expressed in the brain and peripheral tissues (47;228;489). It can be detected in neurons
(309;476;218;371;316;324), astrocytes (21;218;324;316), reactive astrocytes (309;316),
and microglia (181). It exhibits a diffuse cellular localization pattern (313;163) and can
be redistributed to cell nuclei and mitochondria during stressful conditions
(489;53;253;196), though neither nuclear nor mitochondrial localization signals have yet
been identified for the protein.
Crystallization studies reveal that DJ-1 is composed of eight α-helices and 11 βstrands that are arranged into a helix-strand-helix sandwich (170). These structural
features are common to the ThiJ/PfpI superfamily of enzyme proteins (167;170;469).
Like other members of the ThiJ/PfpI superfamily, DJ-1 conserves a catalytic cysteine
residue, Cys-106 (469); however, DJ-1 lacks the other coordinating residues required to
form a catalytic active site, and this distinguishes DJ-1 from its structural homologues
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(167;170;469). Further, it is known that DJ-1 exists as an obligate homodimer (469)
(170) which may be able to associate into filaments (57).
Extensive analyses reveal that DJ-1 exhibits a diversity of protective functions.
For instance, DJ-1 acts as a molecular chaperone in vitro (389;494). It has also been
shown to protect against cell toxicity that is induced by proteasome inhibition and/or
toxic protein aggregation (260;479;487;493). DJ-1 may also act to maintain
mitochondrial homeostasis (43;196) since it can protect against mitochondrial toxins such
as MPTP/MPP+ and rotenone (204;8;418;53;253;43;345;310) and has specifically been
shown to bind and maintain the activity of mitochondrial complex I (153). Several studies
also support a role for DJ-1 in regulating the transcription of specific mRNA targets
(163;395;421;479;491;443) such as pro-survival genes (43). DJ-1 can also protect
against ischemia-induced insults (482) and inflammatory stimuli (456).
Following the discovery of oxidized forms of DJ-1 in human umbilical vein
endothelial cells, it was proposed that DJ-1 may play a role in maintaining cell redox
homeostasis (299). It is known that oxidative stress can upregulate the DJ-1 promoter
(203). This may explain why DJ-1 protein is often increased both in vitro and in vivo
following oxidative insult (251-253;294;418;185). DJ-1 protein levels are also elevated
and/or oxidized in various human diseases (21;29;65;251;374;428).
The oxidation state of DJ-1 is thought to be regulated by a major oxidation site at
amino acid residue Cys-106 (13;43;207;327;455;494). Oxidation of Cys-106 to cysteine
sulfinic acid is thought to facilitate the protective functions of DJ-1 protein (53);

37

however, further oxidation of DJ-1 to cysteine sulfonic acid functionally inactivates the
protein (301;494).
DJ-1 is known to protect against a variety of toxic oxidative agents such as DA
(252), 6-OHDA (181;418;253;27), H2O2 (204;418;479;253;482;27;196) and paraquat
(137). It is possible that DJ-1 may not directly quench ROS since it has been shown in
many studies to mediate cell viability by modulating other protein targets. For instance,
DJ-1 may exert its protection by upregulating chaperones such as Hsp70 (27;260;255)
(493) or by modulating signaling proteins such as extracellular related kinases 1 and 2
(ERK1 and 2) (252;142), apoptosis signal-regulating kinase 1 (ASK1) (198;455),
phosphatidylinositol 3-kinase (Akt) (8;129;484), homeodomain interacting protein kinase
(HIPK1) (385), or c-Jun N-terminal Kinase (JNK1) (303;498). Alternatively, DJ-1 may
ameliorate harmful oxidation by acting to upregulate other known antioxidant proteins
(13;77;271;492). On account of these factors, it is reasonable to understand why the loss
of DJ-1 function may have detrimental consequences in vivo.
Surprisingly, genetically altered DJ-1 null mice do not exhibit phenotypes that
model disease. Ablation of DJ-1 in mice does not result in nigrostriatal degeneration or
obvious neuropathology (13;60;63;136;211;274). However, subtle alterations have been
detected in some animals. For example, in a study by Andres-Mateos et al., DJ-1
deficient mice exhibited reduced brain mitochondrial peroxidase enzyme activities and
this resulted in increased mitochondrial H2O2 production (13). Chandran and colleagues
detected abnormal gait, decreased grip strength, and hypokinesia in DJ-1 null animals but
this was not due to any apparent nigrostriatal abnormalities (60). Some studies suggest
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that DJ-1 may regulate DA neurotransmission since the loss of DJ-1 in mice results in
subtle defects. For instance, age-dependent motor abnormalities, increased stimulated DA
release, and higher striatal DA levels resulted from the lack of DJ-1 in one mouse model
(63). Additionally, nigral neurons in DJ-1 deficient mice were less responsive to D2
autoreceptor stimulation (136). DJ-1 null mice also demonstrated increased levels of
striatal cell surface DAT protein (274).
Although DJ-1 deficient mice do not display overt parkinsonian phenotypes,
several studies suggest that they may be particularly vulnerable to stressful stimuli.
Paraquat induces behavioral and biochemical deficits in DJ-1 deficient animals that are
not observed in WT mice (483). Rotenone alters the firing pattern of nigral neurons in
mice lacking DJ-1 but does not affect WT mice to the same extent (354). DJ-1 null
animals are also hypersensitized to the MPTP neurotoxin (204), although this is thought
to be due to enhanced DAT-mediated uptake (274). Future studies to assess for the
effects of stress on DJ-1 deficient mice may give insights into the biochemical and
cellular functions of DJ-1 protein.
Alternatively, approaches to investigate the effects of pathogenic DJ-1 mutations
on protein function may also prove to be beneficial in understanding the role of DJ-1 in
the etiology of PD.
1.25

Hypotheses and Organizational Overview
The focus of this thesis was to analyze the biochemical and cellular properties of

mutant DJ-1, α-syn, and parkin proteins using cultured cell and mouse models.
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Little is known about the effects of recently reported pathogenic DJ-1 mutations,
E163K, L10P, or P158DEL, on protein function. Since it is thought that DJ-1 mutations
cause disease by a loss of function, it was hypothesized that mutants would exhibit
aberrant biochemical properties in comparison to WT DJ-1 protein and would also cause
other secondary effects related to such functional deficits. In chapter two, it is shown that
pathogenic E163K mutant DJ-1 is similar to WT DJ-1 protein when assessed for protein
stability, solubility, and dimerization. However, E163K mutant DJ-1 renders stably
expressing mouse Neuro-2A neuroblastoma cells to be selectively vulnerable to oxidative
insults. Additionally, following oxidative stress, E163K mutant DJ-1 shows aberrant
subcellular localization in comparison to WT protein. Interestingly, since both WT and
E163K mutant DJ-1 proteins are protective against proteasomal and mitochondrial
stressors, it suggests that the E163K DJ-1 mutation specifically abolishes the antioxidant
properties of the protein and may implicate a role for DJ-1 in multiple biochemical
pathways.
In chapter three, the pathogenic DJ-1 mutants, L10P, P158DEL and L166P, are
characterized biochemically in comparison to WT protein. It is discovered that all 3
pathogenic DJ-1 mutants exhibit reduced protein stabilities. Additionally, all mutants can
be partially stabilized in the presence of proteasome inhibitors, though the effects of this
on L10P are most provocative. Further analyses reveal that unlike L166P DJ-1, the L10P
and P158DEL DJ-1 mutants can form dimers. Interestingly however, all of the
pathogenic DJ-1 mutants show aberrant folding patterns in comparison to WT protein.
Further, under normal cellular conditions, P158DEL mutant DJ-1 demonstrates reduced
solubility in comparison to all other DJ-1 variants. Insoluble pools of L10P and L166P
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are also accumulated in response in proteasome inhibition. Immunocytochemistry
analyses reveal that L10P and P158DEL mutant proteins can associate into inclusions
under normal culturing conditions. Further, proteasome inhibition results in the formation
of atypical intracellular protein inclusions in cells expressing L10P, L166P, or P158DEL
DJ-1 while these inclusions are not detected in cells expressing WT DJ-1 under the same
conditions. Together, these findings suggest that the aberrant folding patterns adopted by
L10P, P158DEL and L166P DJ-1 protein mutants result in rapid degradation of the
respective protein variants and that this could thereby have deleterious effects on
downstream cellular targets.
It has been previously shown that transgenic mice expressing human pathogenic
mutant A53T α-syn (M83 mice) develop an age-dependent severe motor impairment
phenotype associated with the formation of cytoplasmic α-syn inclusions throughout the
neuroaxis (131). While reports by other labs suggest that DJ-1can chaperone misfolded
α-syn in vitro (389;494), it is not known whether DJ-1 regulates α-syn in vivo. Thus it is
of interest to better understand the physiological role of DJ-1 especially as it relates to its
effects on α-syn aggregation. Chapter four describes the generation of homozygous Ala53-Thr α-syn transgenic mice on a DJ-1 null background (M83-DJnull mice). If DJ-1
normally acts to modulate α-syn in vivo, it is hypothesized that M83-DJnull mice should
exhibit an exacerbated phenotype in comparison to M83 mice. M83-DJnull mice were
analyzed and compared to M83 mice as it relates to survival rate, distribution of α-syn
pathologies, nigrostriatal integrity, biochemical properties of the α-syn protein, and the
secondary effects of expressing mutant α-syn. These analyses revealed that there were no
significant differences between mouse genotypes, suggesting that DJ-1 may not directly
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modulate α-syn, nor protect against the harmful effects that result from α-syn aggregation
in vivo.
There are few studies to assess for the effects of pathogenic parkin mutations in
vivo. Analyses of genetically altered parkin deficient mice demonstrate that these animals
do not recapitulate the key features of PD. Studies using more suitable approaches to
model parkin deficiency in vivo would be very useful. In chapter five, we describe the
discovery of a novel homologous endogenous mutation in the C3H mouse strain which
results in the E398Q parkin amino acid substitution. Characterization of E398Q parkin in
cultured cells reveals that it may be functionally inactive in comparison to WT parkin
protein as the mutant shows aberrant biochemical properties. Mutant parkin also exhibits
reduced interactions with UbcH7 and UbcH8 E2 enzymes. Additionally, C3H mice
display age-dependent alterations in the steady-state levels of synphilin-1. Together, these
findings suggest that C3H (E398Q) parkin may be functionally inactive and that C3H
mice may serve as natural parkin loss-of-function models, similar to PD patients
harboring missense parkin mutations.
In chapter six, I conclude by discussing the implications of these findings in the
realm of the field. Additionally, I propose outstanding questions and future directions for
these studies.
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2.1

Abstract
Recent discoveries of genetic mutations linked to familial forms of PD, including

mutations in DJ-1, have provided insights into the pathogenesis of sporadic PD.
Recently, a novel homozygous missense mutation in the gene encoding human DJ-1
protein resulting in the E163K amino acid substitution has been reported. This mutation
is associated with early-onset and clinical presentations that include parkinsonism,
cognitive decline, and amyotrophic lateral sclerosis. The specific effect of this mutation
on the function of DJ-1 protein as it relates to disease pathogenesis is currently unknown.
Herein we show that the E163K pathogenic mutant retains similar properties to WT DJ-1
protein as it relates to protein stability, solubility, and dimerization. However, we show
that the E163K mutant loses the ability to protect against oxidative stress while
demonstrating a reduced redistribution towards mitochondria, but retains the ability to
mitigate toxicity due to mitochondrial stress and proteasomal impairment. These findings
suggest that DJ-1 influences several neuroprotective pathways and that the E163K
mutation impairs the mechanism that is more specific to oxidative stress.
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2.2

Introduction
Although the majority of PD cases are idiopathic, a growing number of mutations

have been found to be associated with familial forms of the disease (110;213;305). Mutations
in genes at multiple loci, designated PARK1 through PARK 13, result in parkinsonian
phenotypes with distinct features (32;80;213). Various mutations in PARK7 (DJ-1), including
truncation, missense, splice-site, and large deletions have been discovered (2;47). Mutations in
DJ-1 cause autosomal recessive PD with early to mid age of onset, and these may contribute to
1-2% of early onset PD cases (154;263).
DJ-1 encodes a 189 amino acid protein which is a member of the ThiJ/PfPI
superfamily based on its structure (170;248;313;469). It is expressed in both neurons and
astrocytes in the brain (19;21;218;325;387), but it is also expressed in many other organs
(121;170;248;324;324;469;489). A number of studies have shown that DJ-1 can have
protective functions against oxidative, proteasomal and mitochondrial stresses
(53;181;204;281;418;483;487;493).
Interestingly, a novel missense E163K DJ-1 mutation was reported for a family in
southern Italy which results in a severe phenotype as early as 24 years. Subjects
homozygous for this E163K mutation develop symptoms that include parkinsonism,
dementia, and amyotrophic lateral sclerosis (14). Characteristics include weakness and
muscle atrophy in the upper and lower extremities, speech deficits, cognitive impairment,
and parkinsonism. Because of the early onset and more extensive phenotype associated
with this mutation, its analysis and an understanding of how it can lead to disease may
provide new insights into the function of DJ-1. In this study, we explore the properties of
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human E163K mutant DJ-1 protein as it relates to its solubility, dimerization, stability,
subcellular localization, and effects on cell viability as compared to WT protein.
2.3

Results
Neuro-2A (N2A) mouse neuroblastoma cell lines (Figure 2-1a) and Chinese

Hamster Ovary (CHO) cell lines (data not shown) stably expressing WT and E163K DJ-1
were generated as described in “Material and Methods”. The studies on solubility,
dimerization, and protein stability were reproduced in both types of cells, but toxicity
studies were conducted exclusively on N2A cell lines (see below).
Figure 2-1

Assessment of the solubility, dimerization and stability of E163K human DJ-1 in N2A cells.
(A) Western blot analysis with DJ5 antibody, specific for human DJ-1, showing the expression of WT
human DJ-1 in two stable N2A cell lines (clones 11 and 12) and E163K human DJ-1 in three stable N2A
cell lines (clones 16, 47 and 52). An immunoblot with an anti-Actin antibody is shown as a loading control.
(B) Biochemical fractionation was performed on N2A cells and stable cell clones of N2A cells expressing
WT (clone 11) or E163K (clone 16) human DJ-1. Cellular proteins were extracted with buffers of
increasing solubilization strengths as described in “Experimental Procedures”. Each fraction was analyzed
by western blotting with the anti-human DJ-1 antibody, DJ5, and an anti-ERK 1/2, ERK1, antibody to
verify equal protein loading. (C) Size-exclusion chromatography was performed to analyze the native size
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of E163K human DJ-1 compared to WT human DJ-1 and endogenous murine DJ-1. Soluble extracts from
N2A cells and stable cell clones of N2A cells expressing WT (clone 11) or E163K (clone 16) human DJ-1
were loaded on a precalibrated Superose 6 column as described in “Experimental Procedures”. The total
cell lysates ("Start") and fractions were collected and analyzed by western blot analysis with DJ5 antibody
to detect human DJ-1 or 691 antibody to detect endogenous murine DJ-1. Fractions 20-30 are shown. The
elution profile of known molecular mass standards [BSA (66 kDa), ovalbumin (44 kDa), carbonic
anhydrase (29kDa) and cytochrome C (12kDa)] are indicated above. (D) Pulse-chase turnover assay of
E163K human DJ-1 compared to WT human DJ-1. N2A stable cell clones expressing WT (clone 11) or
E163K (clone 16) human DJ-1 were pulsed with 35S-methionine for 30 minutes and chased for 0, 3, 6, 12,
or 25 hours. Experiments were conducted in quadruplicates. The results are plotted as percentage of protein
over time standardized to the 0 hrs time point. The error bars show standard deviation.

The E163K mutation does not lead to changes in solubility.
Protein aggregation is known to be a key component in the disease pathogenesis
of many neurodegenerative disorders (245) and reduced solubility of DJ-1 has been
reported in some diseased brains (227;296;304;316;371). To assess whether the E163K
mutation may lead to changes in solubility, N2A cells stably expressing WT and E163K
DJ-1 were sequentially extracted with buffers of increasing solubilization strengths. The
WT and the E163K mutant form of human DJ-1 both were extracted most abundantly in
the soluble Triton X-100 fractions (TX1 and TX2) (Figure 2-1b) and to a lesser extent in
the RIPA fractions. Additionally, neither E163K mutant nor WT DJ-1 were detected in
the SDS fractions, and there were no differences between the distribution of WT and
E163K DJ-1 across any of the biochemical fractions.
Biochemical fractionation experiments also were performed in CHO cells stably
expressing the human WT or E163K mutant DJ-1 protein and no differences in protein
solubility between the WT and E163K variants were observed in these cells (data not
shown).
The E163K mutation does not alter the ability of DJ-1 to dimerize.
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DJ-1 has been previously shown to form a homodimer in vitro which may be
essential to its function (139;248;324). Some mutations like L166P have previously been
shown to affect protein folding such as to prevent dimer formation, resulting in rapid
degradation (28;42;139;158;171;298;324). Crystal structure analysis of DJ-1 protein
shows that the L166P mutation occurs in helix 7, which is one of the helices in the dimer
interface of DJ-1 (167;170;426;469). Since the E163K mutation also occurs in helix 7, it
is possible that a similar effect could occur. To assess whether E163K DJ-1 dimerizes
under native conditions, size exclusion chromatography was performed on soluble
extracts from N2A cells expressing endogenous DJ-1 alone or expressing WT or E163K
human DJ-1. The elution of purified proteins with known molecular masses was used to
standardize this assay. Both the WT DJ-1 and the E163K mutant DJ-1 exclusively eluted
in fractions 24 through 26 (Figure 2-1c), which corresponds to a molecular mass of ~42
kDa, the proposed molecular mass for the DJ-1 dimer. Endogenous DJ-1 protein
expressed in N2A cells also eluted in the same fractions.
Size exclusion chromatography was also performed in CHO cells stably
expressing either the WT or the E163K mutant form of DJ-1 protein in order to confirm
the protein dimerization results. In the CHO cells, both the WT and the E163K mutant
DJ-1 protein eluted in fractions 24 and 25 (data not shown), corresponding to the mass of
a dimer.
The DJ-1 E163K mutant shows comparable stability to WT.
It has been previously shown that some pathogenic mutants of DJ-1 like M26I are
structurally similar to WT DJ-1 in the ability to form a homodimer, but can demonstrate
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reduced stability compared to the WT protein (42;324;422;479). Therefore, the effect of
the E163K mutant on protein stability was assessed by pulse-chase experiments with 35 Smethionine and comparison to the WT protein. Both the E163K mutant and WT DJ-1
proteins showed similar turnover in N2A cells (Figure 2-1d), indicating that the E163K
mutation does not result in reduced stability. These experiments were also performed in
CHO cells (data not shown) and both protein variants also showed similar turnover rates
in this alternate cell type.
The E163K mutant DJ-1 does not show altered subcellular localization by western
blot.
DJ-1 is normally diffusely expressed in cells (21), but WT DJ-1 as well as
pathogenic mutants may localize to the mitochondria (489) and the latter localization may
increase in response to mitochondrial stress (37;42). However, the subcellular
localization of the E163K pathogenic mutant form of DJ-1 has not been previously
investigated. To determine a possible effect of this mutation on altering the localization
of DJ-1, subcellular fractionation was performed by differential centrifugation as
previously used by others (298). Untransfected N2A cells and N2A cells stably
expressing either human WT DJ-1 or human E163K DJ-1 were homogenized in triplicate
in subfractionation buffer. Cytosolic and mitochondrial fractions were collected. Cell
lysates were resolved by SDS-PAGE and analyzed by western blot analysis with DJ5
(human specific monoclonal DJ-1 antibody), 691 (polyclonal DJ-1 antibody that reacts
with mouse and human protein), Tim23 (translocases of the inner mitochondrial
membrane) as a mitochondrial marker, and ERK1/2 as a cytoplasmic marker.
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Endogenous DJ-1 protein in N2A cells and both human WT and E163K DJ-1 expressed
in these cells demonstrated similar predominant cytoplasmic distributions (Figure 2-2).
Figure 2-2

The E163K mutant does not show altered subcellular localization. N2A cells and stable cell clones of
N2A cells expressing WT (clone 11) or E163K (clone 16) human DJ-1 were subjected to subcellular
fractionation by differential centrifugation as described in “Experimental Procedures”. Cellular fractions
were analyzed by western blot with the monoclonal anti-human DJ-1 antibody, DJ5, the polyclonal antiDJ-1 antibody, 691, anti-Tim 23 antibody (used as a mitochondrial marker), and anti-ERK1/2 antibody
(used as a cytoplasmic marker). Experiments are shown in triplicates.

The E163K mutant protein fails to rescue under conditions of oxidative stress.
Many studies have reported that WT DJ-1 can serve in a protective capacity when
overexpressed in various cells lines (53;389;447;487;493). To investigate the ability of
human E163K DJ-1 to protect N2A mouse neuroblastoma cells from mitochondrial
stress, proteasomal stress, and oxidative stress, cells expressing WT or E163K human DJ1 were challenged with various specific stressors.
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Native N2A cells or N2A cells stably expressing WT DJ-1 or E163K mutant DJ-1
were treated with either fresh DMEM/FBS or DMEM/FBS containing MG-132 (a
proteasome inhibitor) or MPP dihydrochloride (a mitochondrial complex I inhibitor) at a
range of concentrations. N2A cells demonstrated reduced cell viability to MG-132
treatment at all concentrations used (10-30 uM). Additionally, N2A cells were vulnerable
to MPP dihydrochloride concentrations that exceeded 10 uM and WT DJ-1 protein was
able to protect against both of these stressors at all toxic concentrations tested (Figure 23A). Expression of E163K DJ-1 was also able to protect against MG-132 and MPP
dihydrochloride toxicity.
To further assess the specific effect of the E163K mutation, other specific
mitochondrial complex inhibitors were analyzed (Figure 2-3B). Antimycin, an inhibitor
of mitochondrial complex III, resulted in a ~40% decrease in viability in N2A cells at the
100 nM concentration and a ~60% decrease in viability at the 200 nM concentration
while expression of either WT or E163K DJ-1 had a protective effect at these
concentrations (Figure 2-3B). The irreversible inhibitor of mitochondrial complex II, 3nitropropionic acid (3-NP), did not have a significant effect on the viability of any of the
three cell lines at the 5 uM or 10 uM concentrations tested. However, N2A cells showed a
slight vulnerability to 15 uM 3-NP and expression of either the E163K mutant DJ-1 or
WT DJ-1 was protective.
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Figure 2-3

The E163K mutant fails to rescue under
conditions of oxidative stress.
(A) N2A cells and stable cell clones of N2A
cells expressing WT (clone 11) or E163K
(clone 16) human DJ-1 were treated with
various chemical stressors and the Trypan
Blue Exclusion Assay was used to assess
viability. Results were plotted as the
percentage of viable cells over time of
chemical treatment. The error bars show
standard deviation. In A, cells were treated for
20 hrs with either fresh DMEM/FBS or
DMEM/FBS containing 10-30 uM MG-132,
or 7.5-20 uM MPP dihydrochloride. In B,
cells were treated for 96 hours with either
fresh DMEM/FBS or DMEM/FBS containing
50-200 nM Antimycin or 5-15 uM 3nitropropionic acid. (C) Several N2A stable
clones expressing either WT human (clones
11 and 12) or E163K human mutant DJ-1
(clones 16, 47 and 52) were treated for 20
hours with either fresh DMEM/FBS or
DMEM/FBS containing 10-30uM H2O2.
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Native N2A cells or stable clones expressing WT or E163K DJ-1 protein were
challenged with H2O2 ranging from 10-30 uM in order to induce oxidative stress. We
found that challenging the cell line expressing E163K mutant DJ-1 (E163K clone #16)
that had been used in all of the aforementioned toxicity experiments not only
demonstrated a lack of protection against H2O2 oxidative stress, but furthermore showed
increased vulnerability to H2O2 exposure at all of the concentrations used (Figure 2-3C).
To determine whether enhanced sensitivity to oxidative stress was due to expression of
the E163K DJ-1 mutant, two additional N2A cell lines (clone #47 and clone #52) stably
expressing the human E163K mutant DJ-1 were tested for H2O2 toxicity (Figure 2-3C).
Both of these clones also revealed increased vulnerability to H2O2 oxidative stress when
compared to native N2A cells. In contrast, two N2A cell lines stably expressing human
WT DJ-1 (clones #11 and #12) demonstrated protection against H2O2 stress. These
results indicate that the E163K mutation selectively compromises the protective role for
DJ-1 on oxidative stress.
Human exogenous DJ-1 protein does not co-immunoprecipate with endogenous DJ1 in N2A cells.
One plausible explanation for the selective vulnerability of N2A cell lines
expressing E163K mutant DJ-1 to oxidative stress is that the mutant protein may behave
as a dominant negative by forming a heterodimer with endogenous murine DJ-1 protein,
inactivating the antioxidant capacity of the endogenous protein. Size exclusion
chromatography analysis demonstrated that endogenous and human DJ-1 formed dimers,
but these studies do not ascertain whether these proteins could form heterodimers (Figure
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2-1). Coimmunoprecipitation experiments were performed to test the interaction between
human WT and E163K DJ-1 with endogenous DJ-1. Since mouse and human DJ-1
migrate with the same mobility on SDS-PAGE, transfections with N-terminal flagged
human DJ-1 constructs were used for these studies. Cell extracts from N2A cells or
extracts from N2A cells transiently expressing either WT Flag-DJ-1 or E163K Flag-DJ-1
were immunoprecipitated with a mouse anti-flag monoclonal antibody.
Immunoprecipitates were resolved by SDS-PAGE and analyzed by western blot with the
polyclonal DJ-1 antibody, 691. Endogenous DJ-1 protein was not pulled downed by
immunoprecipitation with either WT-flag tagged or E163K-flag tagged DJ-1 (Figure 24), indicating that there is no detectable formation of heterodimers between the
endogenous DJ-1 and exogenous human DJ-1 protein.
Figure 2-4

Human exogenous DJ-1 protein does not co-immunoprecipate with N2A endogenous DJ-1. N2A cells
were mock transfected or transiently transfected with either flag-tagged human WT or E163K mutant DJ-1 constructs.
Soluble protein extracts were immunoprecipitated with anti-flag antibody. Fractions were resolved by SDS-PAGE and
immunoblotted with the polyclonal DJ-1 antibody, 691. The “Start” fraction represents the total soluble extracts before
IP and the “Unbound” fraction represents the protein remaining in the protein lysates after the IP.
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Immunofluorescence microscopy reveals an altered localization for E163K mutant
DJ-1 protein in response to oxidative stress.
To further understand the effect of the E163K mutation, quantitative
immunofluorescence studies were conducted comparing untreated cells and cells
challenged with oxidative stress. Under normal conditions, DJ-1 exhibited a diffuse
staining pattern throughout the cell and co-immunofluorescence experiments with the
mitochondrial marker, MitoTracker ® Red CMXRos, revealed some overlap with both
WT and E163K DJ-1 (Figure 2-5a). However, after treating with hydrogen peroxide,
cells expressing WT DJ-1 showed a 5-fold increase in staining overlap of the human DJ-1
protein with the mitochondrial marker as compared to untreated cells. In striking contrast,
under the same oxidative conditions, cells expressing the E163K mutant DJ-1 showed a
6-fold decrease in the overlap with mitochondrial marker (Figure 2-5b). To try to assess
whether these alterations in DJ-1 distributions were due to changes in the presence of DJ1 in the mitochondria, subcellular biochemical fractionation of cells treated with
oxidative stress was performed. However, no biochemical mitochondrial localization was
observed under harsh conditions of oxidative stress (Figure 2-5c). These results suggest
that under oxidative stress, WT human DJ-1 in N2A cells can relocate in close proximity
to the mitochondria, but does not enter these organelles, while E163K DJ-1 is impaired in
this property, which may play a role in its inability to protect against oxidative stress.
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Figure 2-5

Immunofluorescence microscopy reveals an altered mitochondrial localization for E163K mutant DJ-1 protein
in response to oxidative stress.
(A) N2A cells stably expressing WT (clone 11) or E163K (clone 52) human DJ-1 were treated either DMEM/FBS containing 20uM
H2O2 or with DMEM/FBS. Cells were stained with Mitotracker (red), DJ5 (green), and DAPI (blue) and visualized by confocal
microscopy. Representative images are shown. Bar = 13.5μm (B) The confocal microscopy images were quantified using MetaMorph
6.0. The graph represents the average of the relative pixel intensity for DJ-1 per mitochondrial area. The error bars show the standard
deviation between replicate images. (C) N2A cells and N2A cells stably expressing WT (clone 11) or E163K (clone 52) human DJ-1
were either untreated (lanes labeled with “U”) or treated with 350uM H2O2 (lanes labeled with “T”) for 1.5 hrs and then fractions
enriched for mitochondria were isolated by differential centrifugation as described in “Material and Methods”. Cellular fractions were
analyzed by western blot with the monoclonal anti- human DJ-1 antibody, DJ5, the polyclonal anti-DJ-1 antibody, 691, anti-Tim 23
antibody (used as a mitochondrial marker), and anti-ERK1/2 antibody. Experiments are shown in duplicates.
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2.4

Discussion
DJ-1 mutations are associated with early-onset parkinsonism. The E163K

mutation is also causal of early-onset disease, but clinical presentations are more
extensive and diverse than for other DJ-1 disease-causing mutations (14). In this study,
the properties and effects of this mutant were assessed in cultured cells. Under normal
conditions, the E163K mutant had properties similar to WT DJ-1 in terms of subcellular
localization, dimerization abilities, stability, and solubility. These findings are consistent
with recent findings by Lakshminarasimhan and colleagues that showed that in vitro
E163K DJ-1 was able to form stable dimers (233).
Many groups have shown that WT DJ-1 protein can act to mitigate the deleterious
effects of various insults including oxidative stress both in cell culture and in animal
models (181;242;281;297;418;487). While the E163K mutant retains the ability to protect
N2A cells against proteasome inhibition as well as mitochondrial stress through
mitochondrial complex I and III inhibition, this mutation compromises the ability of DJ-1
to protect against oxidative stress and even increases sensitivity to oxidative insult. A
number of studies demonstrated that the DJ-1 pathogenic mutant, L166P, insufficiently
protects against oxidative stress (139;181;198;281;418;493), but in contrast to the E163K
mutation the L166P mutation impairs the ability of DJ-1 to form stable dimers resulting
in a dramatic instability of the mutant protein and loss of expression that can explain the
loss of protective function (138;269;298;324). The M26I mutant also displays reduced
protection against oxidation stress (422) despite the ability to form stable dimers
(42;304;422), but this mutation appears to reduce protein stability, albeit much less than
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the L166P mutation (42;304;422;479). However, it is unclear if the reduced protection
against oxidative stress by the M26I mutation is simply associated with reduced half-life
or perhaps with an increased propensity for the M26I mutant protein to aggregate as
recently reported (171).
In contrast to these other mutations in DJ-1, the effect of the E163K mutation on
impairing DJ-1 function is specific to oxidative stress and it does not impair dimerization,
protein stability or increase aggregation. E163 is in close proximity of L166, and both
residues are located in α-helix G7 which is critical in forming stably folded protein
(139;170). The E163K mutation clearly does not cause the dramatic structural changes of
the L166P mutation which introduces a helix-breaking residue, but the fact that E163 is
highly conserved in DJ-1 across species underscores the importance of this residue (139).
The E163K mutation appears to result in subtle structural changes and recent biophysical
studies by Lakshminarasimhan et al. demonstrated that E163 can form a salt bridge with
R145 and that the disruption of this interaction by the E163K mutation results in
increased mobility of R145 (233).
Our findings that oxidative stress promoted the redistribution of DJ-1 towards
mitochondria but without evidence of mitochondrial import are consistent with the
studies of Canet-Aviles and colleagues that reported that oxidative stress can increase the
amount of DJ-1 on the cytoplasmic side of this organelle without resulting in import (53).
It is shown in the present studies that under conditions of oxidative stress, the E163K
mutant demonstrated a paucity of localization towards mitochondria. It is possible that
simply the change from a negatively to positively charged residue and/or the subtle
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structural effects discussed above may prevent the interaction of DJ-1 with other proteins
that may be involved in the redistribution of DJ-1 under conditions of oxidative stress.
Identifying such mechanisms may be important to further understand the function of DJ1. The toxicity studies demonstrate that DJ-1 influences several neuroprotective
pathways but that the E163K mutation specifically impairs the oxidative stress protective
mechanism. The findings that this mutation appears to exacerbate the response to
oxidation and diminish the redistribution of DJ-1 towards the mitochondria suggest that
both processes may be related, but further studies will be needed to substantiate a direct
association.
Our results reveal that the loss of DJ-1 protective function can occur without overt
biochemical changes on the protein and demonstrate that alterations to specific residues
in this protein can specifically affect individual functions indicating that DJ-1 is likely
involved in multiple cellular pathways. A more detailed understanding of the mechanism
by which DJ-1 can protect against stresses is still needed to better understand the
activities of this protein and its role in neurodegenerative diseases.
2.5

Experimental Procedures

Antibodies
DJ-5 is a mouse monoclonal antibody specific for human DJ-1 protein (296). 691 is a
rabbit polyclonal antibody raised against recombinant human DJ-1 protein but that reacts
with DJ-1 from various species (296).

60

Anti-Tim23 is a purified mouse monoclonal antibody to Tim23 (BD Transduction
Laboratories, San Jose, CA). Anti-extracellular signal related kinase-1 (ERK-1) (C-16) is
an affinity purified rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) that reacts with both ERK-1 and -2. Anti-Flag-tag mouse monoclonal antibody
(GenScript Corporation, Piscataway, NJ) is a purified antibody that reacts with proteins
with the amino acid sequence, DYKDDDDK . Anti-Actin is a purified mouse
monoclonal antibody (Millipore Corporation, Billerica, MA 01821) that reacts with all
six isoforms of vertebrate Actin.
Cloning of human DJ-1 constructs
Human full-length WT DJ-1 cDNA was cloned into the mammalian expression
vector pZeoSV2 (Invitrogen, Carlsbad, CA) at the Not I and Hind III restriction sites to
create the plasmid pZeoWThDJ. Using the pZeoWThDJ construct, the QuickChange®
Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used in order to generate
the E163K mutant form of human DJ-1 in the pZeoSV2 vector. The sequences of the
oligonucleotides used for mutagenesis were as follows: Forward- 5’-GGG CCT GGG
ACC AGC TTC AAG TTT GCG CTT GCA ATT GTT-3’ and Reverse- 5’- AAC AAT
TGC AAG CGC AAA CTT GAA GCT GGT CCC AGG CCC-3’. The sequence of the
plasmid with E163K mutant DJ-1 was verified by DNA sequencing as a service offered
by the DNA Sequencing Facility of the University of Pennsylvania, and the construct was
named pZeoEKhDJ.
Sequential restriction digestions with Not I and Apa I were performed on both
pZeoWThDJ and pZeoEKhDJ. The DNA fragments containing the full-length DJ-1
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sequences were ligated into the pcDNA3.1 (Invitrogen, Carlsbad, CA) mammalian
expression vector in order to generate the human WT and E163K mutant DJ-1 constructs
named pc3.1WThDJ1 and pc3.1EKhDJ1, respectively.
An N-terminal flag-tagged WT DJ-1 construct was generated by PCR, using the
pZeoWTDJ-1 construct as a template. The sequences for the oligonucleotides used were
as follows: Forward-5’- GAT CGC GGC CGC CAC CAT GGA TTA CAA GGA TGA
CGA CGA TAA GGC TTC CAA AAG AGC TCT GGT CAT CCT -3’ and Reverse-5’GAT CAA GCT TCT AGT CTT TAA GAA CAA GTG GAG CCT TC-3’. The tagged
insert was cloned into the pCR 2.1 TOPO vector (Invitrogen, Carlsbad, CA) and
subsequently cloned into the pcDNA3.1 (-) vector at the Hind III and Not I restriction
sites. The construct was named pc3.1WThDJ1-Nflag. The sequence of the plasmid was
verified by DNA sequencing as described above. The E163K N-terminal flag-tagged DJ1 construct was generated by performing site directed mutagenesis using the
pc3.1WThDJ1-Nflag construct as a template. The same oligonucleotides were used as
described above for mutagenesis. The plasmid was named pc3.1E163KhDJ1-NFlag.
Cell culture
N2A and CHO cells were cultured in Dulbecco-modified Eagle medium (DMEM)
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma, St.Louis,
MO), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA).
Cells were incubated at 37ºC and 95% air/5% CO2 atmosphere.
Generation of stable cell lines expressing WT and E163K DJ-1
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The pc3.1WThDJ and pc3.1EKhDJ constructs were used to transfect N2A cells
using FuGENE reagent following the manufacterer’s protocol. Stably expressing clones
were isolated and selected with G418 (Invitrogen, Carlsbad, CA) at 200-500 μg/mL and
screened by Western blotting for the expression of DJ-1 using the antibody DJ5 that is
specific for human DJ-1. Stably expressing clones expressing WT (clone #11 and clone
#12) or E163K (clone #16, #47 and #52) human DJ-1 were used in the studies (See
Figure 1A).
The pZeoWThDJ and pZeoEKhDJ constructs were used to transfect CHO cells
using FuGENE (Roche, Basel, Switzerland) transfection reagent according to the
manufacturer’s protocol. Stably expressing clones were isolated following selection with
Zeocin (Invitrogen, Carlsbad, CA) at 50 ug/mL.
Biochemical fractionation
Native N2A and CHO cells or stable clonal lines expressing WT or E163K human
DJ-1 were cultured in 10 cm dishes as described above. Cells were grown to confluency,
rinsed and scraped in PBS, and harvested by centrifugation at 13,000 x g. Cells were
vortexed vigorously in 2 pellet volumes of PBS/0.1% Triton, sedimented, and the
supernatant was collected as the TX1 fraction. This was repeated on the remaining pellet
and the supernatant was collected as the TX2 fraction. The pellet was resuspended in 2
volumes of RIPA buffer, vortexed vigorously, sedimented, and the supernatant was
collected as the RIPA fraction. The remaining pellet was solubilized in 2%SDS/17mM
Tris, pH 8.0 and kept as the SDS fraction.
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Gel filtration chromatography
Gel filtration chromatography was performed by calibrating a Superose 6 column
(Amersham Biosciences) attached to a fast performance liquid chromatography (FPLC)
system with standards of known molecular mass using 10 mM Tris, pH 7.5, 100 mM
NaCl as the mobile phase. Molecular mass standards [BSA (66 kDa), ovalbumin (44
kDa), carbonic anhydrase (29 kDa) and cytochrome C (12 kDa)] were resolved separately
to calibrate the column. The elution of the standards was monitored by protein
absorbance at 280 nm. N2A or CHO cells and stable cell lines thereof were cultured in
10 cm dishes and grown to confluency. Cells were rinsed and scraped in phosphate
buffered saline, pH 7.4. After recovery by centrifugation, cells were lysed in PBS/0.1%
Triton and the cell debris was sedimented at 13,000 x g for 5 min. The extracts were
filtered through a 0.45 µm filter and loaded onto the column. Fractions were analyzed by
immunoblotting with anti-DJ-1 antibodies, DJ5 (1:1000) and 691 (1:1000).
Pulse-chase protein turnover experiments
N2A or CHO cells stably expressing WT or E163K DJ-1 were cultured in 6-well
dishes. Cells were methionine-deprived for 15 minutes by incubation in methionine-free
DMEM (Invitrogen, Carlsbad, CA)/ 10% dialyzed FBS before adding 100 μCi [35S]methionine (Invitrogen, Carlsbad, CA) per ml of methionine free DMEM/10% dialyzed
FBS for 30 min. Chase experiments were conducted in quadruplicates with normal
DMEM/FBS for 0, 3, 6, 12, and 25 hours. Cells were then rinsed with PBS and harvested
in CSK buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100)
containing 1 % SDS and boiled at 100 ºC for 5 minutes. CSK buffer was added to the
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lysates in order to bring the final concentration of SDS to 0.25%. Lysates were frozen on
dry ice and kept frozen at -20 ºC until the last time point was harvested. The radiolabelled
protein extracts were pre-cleared with a rabbit serum pre-incubated with protein Aagarose (Santa Cruz Biotechnologies, Santa Cruz, CA) for 3 hours at 4ºC and
radiolabelled extracts were then immunoprecipitated overnight at 4ºC with anti-DJ-1
polyclonal antibody 691 pre-incubated with protein A-agarose (Santa Cruz
Biotechnologies, Santa Cruz, CA). The antibody-protein complexes were washed 3 times
with 10 volumes of CSK buffer, resuspended in 2 volumes of 2X SDS sample buffer and
boiled at 100 ºC for 5 minutes. The beads were removed by centrifugation and the
samples were loaded on 12 % polyacrylamide gels. Following electrophoresis, gels were
fixed with 50% methanol/5% glycerol, dried and exposed to a PhosphorImager plate and
the signal was quantified using ImageQuant software (Molecular Dynamics, Inc.,
Sunnyvale, CA).
Subcellular fractionation
The subcellular fractionation procedures used were similar to those previously
described (298) with some changes. Native N2A, or N2A cells stably expressing WT or
E163K DJ-1 were cultured in 10 cm plates. Cells were rinsed and scraped in phosphatebuffered saline, pH 7.4 (Invitrogen, Carlsbad, CA) and pelleted at 13,000 x g. Cells were
resuspended in 3 pellet volumes of subfractionation buffer (0.25 M sucrose, 10 mM
HEPES/NaOH, pH 7.5, 1 mM DTT, and protease inhibitors). Cells were homogenized
with 20 strokes of a Dounce homogenizer (Kontes Glass Co;Vineland, NJ). The nuclei
and unlysed cells were pelleted by sedimentation at 489 x g for 10 minutes at room
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temperature (RT). The supernatants were further cleared at 1585 x g for 10 minutes. The
supernatants (S1) were removed to fresh tubes and sedimented for 10 minutes at 1585 x g
at RT. The supernatants (S2) were removed to fresh tubes and pelleted for 17 minutes at
22000 x g at 4º C. The supernatants (S3) were removed as the crude cytoplasmic fraction
and incubated on ice. In the mean time, the pellet (mitochondrial enriched fraction) was
rinsed with 3 pellet volumes of subfractionation buffer and centrifuged again at 22000 x g
for 17 minutes at 4ºC. The supernatant from this rinse was discarded and the
mitochondrial pellet was solubilized in 3 pellet volumes of 2% SDS/17mM Tris and
boiled at 100 ºC for 5 minutes. The tube containing the crude cytoplasmic supernatant
(S3) was then sedimented at 103,000 x g for 25 minutes at 4 ºC in order to pellet small
organelles and cell debris, and the resulting supernatant (S4) was collected as the
cytosolic fraction. The protein concentrations were determined in each fraction using the
bicinchoninic acid protein (BCA) Assay (Pierce, Rockford, IL) with and bovine serum
albumin as a standard. Fractions were analyzed by immunobloting with antibodies DJ5
(1:1000), 691 (1:1000), Tim23 (0.5ug/mL), and ERK1 (0.2ug/mL).
For subcellular fractionation experiments that followed oxidative stress, N2A
cells or cells stably expressing human WT or E163K mutant DJ-1 were cultured in 10 cm
plates and were treated for 1.5 hours with DMEM/FBS or DMEM/FBS containing
350uM H2O2. Cells were treated with H2O2 in duplicate. Cells were rinsed and scraped in
PBS. Subcellular fractionation by differential centrifugation was performed as described
above.
Cell viability assay
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Native N2A or N2A cell lines expressing WT or E163K DJ-1 were cultured
separately into 48 well plates. Each cell type was treated for 20 hours in sextuplicates
with DMEM/FBS containing either 10, 20 or 30 uM H2O2, 7.5, 10, or 20 uM MPP
dihydrochloride (Sigma, St.Louis, MO ), 10, 20, or 30 uM MG-132 (Sigma, St.Louis,
MO), or fresh DMEM/FBS. In separate experiments, these cell lines were treated for 96
hours in sextuplicates with either 50, 100, or 200 nM Antimycin A (Sigma, St.Louis,
MO) or 5, 10, or 15 uM 3-nitropropionic acid (Sigma, St.Louis, MO). After treatment,
the media from each well was collected into separate 1.5 mL microfuge tubes. The cells
remaining in the wells were trypsinized, and harvested in corresponding microfuge tubes.
Cells were pelleted and resuspended in fresh DMEM/FBS, and then 3-fold volumes of
Trypan Blue solution (Sigma, St.Louis, MO ) was added. Live and dead cells were
counted manually using a hemacytometer and an Olympus CKX41 microscope. The
percentage of live cells relative to the total number in each well was calculated.
Co-immunoprecipitation and heterodimer studies
N2A cells were cultured in 10 cm plates. Cells were mock transfected or
transiently transfected with pc3.1E163KhDJ1-NFlag, or pc3.1WThDJ1-NFlag constructs
using Lipofectamine reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. After 24 hours, cells were rinsed and scraped in PBS and lysed into 500 uL of
1X CSK buffer by vortexing. Cell debris was sedimented at 13,000 x g for 5 minutes and
supernatants were removed to fresh tubes. 30 uL of each supernatant was saved as the
“Start” fraction. The remainders of the supernatants were incubated at 4 ºC with a mouse
anti-flag antibody preabsorbed to protein A/G PLUS Agarose beads (Santa Cruz
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Biotechonogy, Inc., Santa Cruz, CA). The beads were sedimented, repeatedly rinsed with
1X CSK buffer, resuspended in sample buffer, heated to 100 oC and saved as the “IP”
fractions. The supernatants remaining after the immunoprecipitation were saved as the
“Unbound” fractions. Sample buffer was added to the “Start” and “Unbound” fractions
and then they were heated to 100 oC for 5 minutes.
Immunofluorescence and confocal microscopy
Native N2A, or N2A cells stably expressing WT or E163K DJ-1 were treated with
DMEM/FBS or DMEM/FBS containing 20 uM H2O2 for 3 hours. The media was
removed and replaced with warmed DMEM/FBS containing 100 nM Mitotracker ® Red
CMXRos (Invitrogen, Carlsbad, CA). The cells were allowed to respire for 20 minutes
and then were fixed with neutral buffered formalin according to the manufacturer’s
protocol. The cells were rinsed with PBS for 5 minutes and then blocked for 30 minutes
at room temperature in PBS/2% FBS/0.1% Triton. Cells were then incubated at 4ºC with
DJ5 antibody diluted into PBS/2% FBS at a concentration of 1:500 overnight, washed 3
times with PBS at 10 minutes each, and then incubated at room temperature with a goat
anti-mouse secondary antibody conjugated to Alexa Fluor ® 488 (Invitrogen) diluted into
PBS/2% FBS at a concentration of 1:500 for 2 hours. Cells were rinsed for 10 minutes
with PBS, incubated at room temperature with DAPI (Pierce, Rockford, IL) diluted into
PBS at a concentration of 1ug/mL for 5 minutes, and then rinsed 3 times with PBS at 10
minutes each. Cells were coversliped with CytosealTM 60 mounting media (Richard-Allen
Scientific, Kalamazoo, MI). The images were visualized with a Zeiss LSM-510 Meta
confocal microscope. For each sample, five 143 x 143 μm images were taken from a
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single plane using the 63x /1.4 oil objective. The images were then quantified using
MetaMorph 6.0 software (Molecular Devices, Sunnyvale, CA). The relative integrated
staining for DJ-1 per mitochondrial area was calculated by measuring the integrated pixel
intensity for DJ5 signal that overlapped with pixels positive for Mitotracker Red
CMXRos divided by total mitochondrial area. Integrated pixel intensity is defined as
pixel intensity times the area of pixels positive for the signal. The average values for the
replicate images were calculated.
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3.1

ABSTRACT
A variety of mutations in the gene encoding DJ-1 protein are causal of autosomal

recessive early-onset parkinsonism. Recently, a novel pathogenic homozygous DJ-1
missense mutation resulting in the L10P amino acid substitution was reported. In a
separate study, a novel homozygous mutation resulting in the deletion of DJ-1 residue
P158 was also reported to be causative of disease. The specific effects of the novel L10P
and P158DEL mutations on protein function have not been studied. Herein, L10P and
P158DEL DJ-1 proteins were assessed for protein stability, dimerization, solubility, and
subcellular localization in comparison to WT and the L166P DJ-1 pathogenic variant. It
was discovered that in comparison to WT protein, L10P, L166P, and P158DEL DJ-1
variants exhibited dramatically reduced protein stabilities. Degradation of each of the
respective pathogenic mutants appeared to be mediated in-part by the proteasome.
Interestingly, unlike L166P DJ-1, the L10P and P158DEL DJ-1 variants retained the
ability to dimerize and thus it was concluded that the observed decreases in protein
stability were due to aberrations in protein folding. Supporting this idea, the L10P,
L166P, and P158DEL DJ-1 variants exhibited altered profiles on size-exclusion
chromatography and reduced solubilities in comparison to WT protein, and the latter
aberration could be exacerbated in the presence of MG-132. Taken together, these
findings suggest that DJ-1 mutations may cause disease by distinct mechanisms and
indicate that the pathogenicity of the L10P and P158DEL variants are related to
aberrations in protein stability and protein folding.
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3.2

INTRODUCTION
Several genes, designated PARK1-PARK13, that can cause Parkinson disease

(PD) have been indentified (124;250). A variety of mutations in PARK7/DJ-1,
including large genetic deletions, splice-site alteration and missense mutations, are also
known to be causal of autosomal recessive early-onset parkinsonism (200). Recently, two
novel recessive mutations in the PARK7/DJ-1 gene have been reported which result in
early-onset parkinsonian phenotypes in the affected patients (144;270). A homozygous
missense mutation resulting in the DJ-1 amino acid substitution L10P was identified in a
consanguineous Chinese family (144). The affected patients presented with disease
symptoms at 19 years of age which is the earliest age of onset reported for any PD case
specifically linked to DJ-1 mutations. Following this report, another DJ-1 mutation
carrier was identified in a genetic study conducted on early-onset PD patients from the
Netherlands (270). The affected individual harbored a small homozygous deletion in DJ1 exon 7 which resulted in the deletion of the highly conserved DJ-1 residue, P158DEL
(270).
Although the first causative PARK7/DJ-1 mutations were reported nearly a
decade ago (47) and DJ-1 has been implicated in many biological pathways (200 and the
references therein;109), the specific role of DJ-1 in disease pathogenesis is still unclear.
DJ-1 is a relatively small 189 amino acids protein that is evolutionarily conserved across
many species (23;47;313). It is ubiquitously expressed in most tissues and is present in
cell nuclei and cytoplasm (28;47;313). Crystallization studies reveal that DJ-1 is
composed of eight α-helices and eleven β-strands that are arranged into a helix-strand-
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helix sandwich (12;170). These structural features are common to members of the
ThiJ/Pfp superfamily of proteins (167;170;469). Further, it is known that DJ-1 tightly
associates into a homodimer and that the dimer interface is composed of α-helices 1, 7,
and 8 and β-strands 3 and 4 (12;170;167;469). DJ-1 dimer formation may be required
for the protein to function properly, though this hypothesis has never been proven. It is
well known that the pathogenic DJ-1 mutant L166P fails to dimerize and that this deficit
is likely caused by structural perturbations of the dimer interface
(12;42;139;139;269;298;324;469). Such conformational abnormalities target L166P DJ-1
protein for rapid degradation by the proteasome, and the associated reductions in mutant
protein abundance may be causative of disease phenotypes (139;263;298). Studies to
assess for the effects of pathogenic DJ-1 mutations on protein function will give insights
into the cellular mechanisms that may be implicated in the etiology of PD.
In the current study, the biochemical properties of the novel pathogenic DJ-1
mutants, L10P and P158DEL are explored. The novel mutants are assessed for protein
stability, dimerization, solubility, and subcellular localization in comparison to WT and
L166P DJ-1. These analyses reveal that L10P, L166P and P158DEL DJ-1 mutants are
dramatically destabilized in comparison to WT protein. Interestingly, since L10P and
P158DEL mutants retain the ability to dimerize, it suggests that enhanced turn-over of
mutant proteins may be related to aberrant protein folding and not necessarily to
dimerization. Taken together, the studies herein suggest that L10P, L166P, and
P158DEL DJ-1 mutations may be causative of disease by distinct mechanisms.
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3.3

RESULTS

Pathogenic DJ-1 mutants demonstrate reduced protein stabilities and are partially
regulated by the proteasome.
It has been previously shown that L166P mutant DJ-1 demonstrates dramatically
reduced protein stability in comparison to WT protein (42;138;139;269;298;307;324) and
that this aberration is due in part to rapid degradation of mutant protein by the
proteasome (138;139;298;307;324;422). To determine the effects of the recently reported
L10P and P158DEL DJ-1 mutations on protein stability, protein turn-over pulse-chase
experiments were performed with 35 S-methionine. The turn-over rates of WT, L10P,
L166P, and P158DEL DJ-1 protein were compared. Following these analyses it was
determined that the half-life of WT DJ-1 was ~8 hours (Figure 3-1A). As expected, the
half-life of L166P mutant DJ-1 was ~1 hour, which is consistent with previous reports
(307;324). L10P and P158DEL DJ-1 mutants exhibited half-lives of ~2.5 hours and ~4
hours respectively, demonstrating that both of these mutants also destabilize DJ-1.
To determine the effects of the proteasome complex on the turn-over rates of
WT, L10P, L166P, and P158DEL DJ-1 protein variants, protein pulse-chase experiments
were performed in the presence of 20μM MG-132. The ratio of DJ-1 protein remaining
with the addition of MG-132 to that without the addition of MG-132 after 6 hours of
chase was calculated and the results were compared for each DJ-1 variant. The turn-over
rate for WT DJ-1 was not significantly affected by proteasome inhibition (Figure 3-1B).
Conversely, treatment of cells with MG-132 partially stabilized all of the DJ-1 mutants
analyzed, though the effect was most striking for the L10P DJ-1 mutant. Interestingly,

75

proteasome inhibition slowed the decay of L10P, L166P, P158DEL DJ-1 mutant proteins,
but it did not completely block the degradation of these mutants. This observation has
been previously reported for the L166P DJ-1 mutant (139;298;324), suggesting that in
addition to proteasome-mediated degradation, turn-over of L10P, L166P, and P158DEL
DJ-1 mutant proteins can also be regulated by proteasome-independent mechanisms.
Figure 3-1

Pathogenic DJ-1 mutants
demonstrate dramatically reduced
protein stabilities that are partially
due to proteasome degradation.
CHO cells were transfected with fulllength WT, L10P, L166P, or P158DEL
human DJ-1 pZeoSV2 “(+)”
constructs. At 48 hours post
transfection, cells were labeled with
35
S-methionine for 30 mins and chased
for 0, 1, 3, 6, or 10 hours. A) The graph
represents the protein turnover results
for the respective DJ-1 variants. The
results are plotted as percentage of
protein remaining over time
standardized to the 0 hrs time point.
The error bars show standard deviation
(n=6). The inset shows representative
pulse-chase experiments. B) The ratio
of DJ-1 decay in the presence of 20 μM
MG-132 added at 0 hrs to that in the
absence of MG-132 at 6 hours of chase
was calculated for each sample. The
graph depicts the average of the ratios
between replicate samples for each DJ1 variant. The error bars indicate
standard deviation (n=3). The inset
image represents the DJ-1 signal
remaining after 6 hours of chase for
each of the DJ-1 variants in the
absence and presence of MG-132.
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The L10P and P158DEL DJ-1 mutations do not disrupt dimer formation but may
alter protein folding.
Previous studies reveal that in comparison to WT DJ-1 protein, L166P mutant DJ1 displays aberrant folding (12;139;324;469) that impairs the dimerization of this mutant
and that is associated with a dramatic instability of this mutant protein
(12;42;139;269;298;307;324). Thus, it is possible that L10P and P158DEL DJ-1 mutants
are destabilized due to disrupted dimerization and/or improper protein folding. To assess
the ability of L10P and P158DEL DJ-1 variants to form dimers, co-transfection and coimmunoprecipitation experiments were conducted. Experiments with WT and L166P DJ1 were also conducted for comparison. CHO cells were transiently co-transfected with
human HA-tagged full-length WT DJ-1 and human untagged full-length WT, L10P,
L166P, or P158DEL DJ-1. Cells extracts were immunoprecipitated with an anti-HA
antibody followed by immunoblot with antibody DJ5. These analyses revealed that the
untagged WT, L10P, and P158DEL DJ-1 variants were all co-immunoprecipitated with
HA-tagged WT DJ-1 protein (Figure 3-2A). However, L166P DJ-1 was not coimmunoprecipitated with HA-tagged WT DJ-1. This indicates that L10P and P158DEL
DJ-1 variants retain the ability to dimerize.
To further analyze the consequences of DJ-1 mutations on protein structure, size
exclusion chromatography experiments were conducted. Soluble lysates were
fractionated from CHO cells expressing WT, L10P, P158DEL, or L166P human DJ-1.
The assay was standardized by elution of purified proteins of known molecular masses.
Fractions were resolved by SDS-PAGE and analyzed by immunoblot with the anti-
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Figure 3-2

The L10P and P158DEL DJ-1 mutations do not disrupt dimer formation but appear to alter protein folding
patterns. A) CHO cells were co-transfected with HA-tagged full-length WT DJ-1 and pZeoSV2 (+) mock vector
(“mock”) or with untagged full-length WT, L10P, P158DEL, or L166P human DJ-1 pZeoSV2 (+) constructs. At 24
hours post transfection, cells were harvested and soluble protein lysates were extracted (“Start”). The cell lysates were
then immunoprecipitated using anti-HA polyclonal antibody (“IP”). Equal amounts of the start, IP, and unbound
supernatant (Unbound) fractions were resolved by SDS-PAGE and analyzed by western blot (“WB”) with the
monoclonal DJ-1 antibody, DJ5. B) CHO cells were transiently transfected with full-length WT, L10P, L166P, or
P158DEL human DJ-1 pZeoSV2 (+) constructs. Soluble extracts from CHO cells expressing the respective exogenous
human DJ-1 proteins were loaded on a precalibrated Superose 6 column as described in the “Materials and Methods”
section. The total cell lysates ("total") and fractions collected from the size-exclusion column were analyzed by western
blot analysis with DJ5 antibody to detect human DJ-1. Fractions 20-32 are shown. The elution profile of known
molecular mass standards [BSA (66 kDa), ovalbumin (44 kDa), carbonic anhydrase (29kDa) and cytochrome C
(12kDa)] are indicated above.

human specific DJ-1 antibody DJ5. The peak elution fraction for WT human DJ-1 was
fraction 26 (Figure 3-2B), consistent with dimer formation. It has been previously
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reported that L166P DJ-1 forms high molecular weight complexes which increase its
apparent molecular weight when analyzed by gel filtration analyses (269;324). In the
studies herein, L166P DJ-1 eluted in peak fraction 24, suggesting that it also forms highmolecular weight complexes in CHO cells. Interestingly, L166P DJ-1 that would elute in
fractions that would be consistent with monomeric forms of DJ-1 was not detected in
these analyses. Surprisingly, the peak elution for L10P DJ-1 was fraction 25, indicating
that the L10P mutant adopts an apparent larger conformation than WT DJ-1 protein.
Conversely, P158DEL DJ-1 primarily eluted into fractions 27 and 28, suggesting that it
adopts a smaller conformation than WT DJ-1 protein.
L10P, L166P and P158DEL DJ-1 mutants show reduced protein solubilities.
Protein misfolding and aggregation is a prominent feature of many
neurodegenerative disorders (402) and reduced solubility of DJ-1 is correlated with
human disease (227;296;304;316;371). L166P DJ-1 is known to be misfolded
(12;139;324) and this may result in reduced solubility of the mutant in comparison to WT
DJ-1 (394). Gel filtration analyses revealed that the L10P and P158DEL DJ-1 variants
may adopt abnormal folding patterns (Figure 3-2B); however, it is unknown whether
protein solubility is affected by these mutations. To assess for changes in solubility, CHO
cells expressing full-length WT, L10P, L166P, or P158DEL human DJ-1 were harvested
and cell lysates were extracted into buffers of increasing solubilization strengths. The
lysates were then analyzed by western blot with antibody DJ5. WT, L10P, L166P, and
P158DEL DJ-1 variants were all predominantly extracted in the soluble PBS/0.1% Triton
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(TX) (Figure 3-3A). However, a significant fraction of P158DEL DJ-1 protein was
extracted in the RIPA and SDS fractions.
Figure 3-3

L10P, L166P and P158DEL DJ-1 mutants show reduced protein solubilities. CHO cells were transfected with fulllength WT, L10P, L166P, or P158DEL human DJ-1 pZeoSV2 (+) constructs. At 24 hours post transfection, cells were cultured for an
additional 18 hours in fresh DMEM with or without the addition of either 20μM MG-132 or 1μM Epoxomicin. A) Cells were
harvested and sequentially extracted into PBS/0.1% Triton (TX) buffer, RIPA buffer, and 2% SDS/17mM Tris (SDS) buffer. Equal
amounts (10ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by western blot for DJ-1 distribution with the
DJ5 antibody. Blots were also probed with an actin antibody to assess equal protein loading. The mobility of molecular mass markers
is indicated on the left. B) Cells were harvested and extracted using the Qproteome Cell Compartment Kit (Qiagen), following the
manufacturer’s instructions. Equal amounts (10ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by
western blot with antibody DJ5 to assess the distribution of human DJ-1, GAPDH monoclonal antibody as a cytoplasmic marker,
histone H3 polyclonal antibody as a nuclear marker, and vimentin polyclonal antibody as a cytoskeletal marker. “CE2” represents the
cytoplasmic fractions, “CE3” represents the nuclear fractions and “CE4” represents the cytoskeletal/insoluble fractions. “1” lanes were
loaded with extracts from cells treated with fresh DMEM only. “2” lanes were loaded with extracts from cells treated with fresh
DMEM + epoxomicin. “3” lanes were loaded with extracts from cells treated with fresh DMEM +MG-132.
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Proteasome inhibitors have been shown to stabilize insoluble forms of L166P DJ1 protein when assessed in cell culture studies (307;325); however, it is not known
whether L10P and P158DEL DJ-1 protein mutants display similar biochemical
properties. To analyze the effects of proteasome inhibitors on DJ-1 solubility, CHO cells
expressing WT, L10P, L166P, or P158DEL human DJ-1 were treated for 18 hours with
20μM MG-132 or 1μM epoxomicin followed by harvesting and extraction into buffers of
increasing solubilization strengths. The extracts were then assessed by immunoblot with
antibody DJ5. Treatments with either MG-132 or epoxomicin resulted in only trace
amounts of WT DJ-1 detected in the RIPA or SDS-soluble fractions (Figure 3-3A). Both
MG-132 and epoxomicin dramatically promoted the accumulation of RIPA and SDSsoluble forms of L10P DJ-1, though the effects were more provocative with MG-132.
Similarly, MG-132 and epoxomicin resulted in the buildup of Triton-insoluble pools of
L166P DJ-1. Interestingly, however, neither MG-132 nor epoxomicin treatments affected
the amount of Triton-insoluble P158DEL DJ-1 protein.
To expand on these biochemical fractionation results and to assess for possible
changes in cellular localization, protein fractionation experiments were performed using
the Qproteome Cell Compartment Kit. CHO cells expressing WT, L10P, L166P, or
P158DEL human DJ-1 were compared when untreated or challenged with 20μM MG-132
or 1μM Epoxomicin for 18 hours. Cytoplasmic (CE2), nuclear (CE3), and
cytoskeletal/insoluble (CE4) protein fractions were generated. Cell extracts were
analyzed by western blot with the antibodies to human DJ-1 (DJ-5), GAPDH, histoneH3, and vimentin. These analyses revealed that under normal conditions, WT DJ-1
protein primarily localized to cytoplasmic biochemical fractions and to a much lesser
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extent into nuclear fractions (Figure 3-3B). WT DJ-1 protein was absent from
cytoskeletal/insoluble protein fractions. As expected, MG-132 and epoxomicin treatments
had little effect on WT DJ-1 protein. Under normal conditions, L10P DJ-1 was
predominantly detected in both cytoplasmic and cytoskeletal/insoluble protein fractions.
Following treatments with MG-132 or epoxomicin, L10P DJ-1 accumulated in the
nucleus and cytoskeletal/insoluble fractions, suggesting that inhibition of the proteasome
may act to stabilize insoluble forms of the L10P DJ-1. Under normal conditions, L166P
DJ-1 was predominantly observed in the cytoplasmic fraction; however, following
treatments with MG-132 or epoxomicin, L166P DJ-1 dramatically accumulated in
cytoplasmic and cytoskeletal/insoluble protein fractions, and to a much lesser extent in
nuclear fractions. In the absence of proteasome inhibitors, the P158DEL DJ-1 variant
was extracted in all three fractions and treatments with either MG-132 or epoxomicin had
no significant effect on the biochemical extractability of P158DEL DJ -1 protein as
detected by this method (Figure 3-3B). This finding further implies that this mutant
exhibits reduced solubility even in the absence of induced proteasome challenge.
L10P, L166P, and P158DEL DJ-1 form intracellular inclusions following
proteasome inhibition.
Olzmann et al. showed that MG-132 induced the recruitment of L166P DJ-1 into
aggresomes (325). To determine whether a similar effect would be observed for the L10P
and P158DEL DJ-1 mutants, co-immunofluorescence studies were conducted comparing
untreated and treated CHO cells expressing WT, L10P, L166P, or P158DEL human DJ-1
challenged for 12 hours with 20μM MG-132. Cells were co-labeled with DJ5 and
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vimentin antibodies to assess for DJ-1 staining and inclusion formation, respectively.
Under normal culturing conditions, WT and mutant DJ-1 proteins exhibited diffuse
staining (Figure 3-4A). However, nuclear and cytoplasmic DJ-1 positive inclusions were
detected in a small percentage of L10P and P158DEL DJ-1 expressing cells (Figure 34A and C and data not shown). MG-132 treatment induced the formation of
intranuclear and cytoplasmic DJ-1 positive protein inclusions in cells expressing L10P,
L166P, and P158DEL DJ-1 but had little effect on cells expressing WT DJ-1 (Figure 34B and C). Interestingly, co-immunofluorescence analyses with DJ5 and vimentin
antibodies did not reveal any accumulation or redistribution of vimentin surrounding
L10P or P158DEL DJ-1 protein inclusions, although vimentin was co-localized with
these inclusions on rare occasions, suggesting that the observed DJ-1 positive inclusions
are not classical aggresomes. MG-132 caused inclusion formation most provocatively in
cells expressing L10P DJ-1 since ~74±15% of these cells had inclusions. P158DEL DJ-1
formed inclusions in 59±19% of cells, while L166P DJ-1 formed inclusions in 45±7% of
cells.
3.4

DISCUSSSION
A short nucleotide deletion resulting in P158DEL DJ-1 and a missense mutation

resulting in the L10P DJ-1 amino acid substitution are novel recently reported
PARK7/DJ-1 mutations causative of autosomal recessive early-onset parkinsonism
(144;270). In the current study, the effects of these mutations on DJ-1 protein stability,
dimerization, solubility, and localization were assessed in cultured cells. Additionally, the
previously extensively characterized pathogenic L166P DJ-1 mutant was also analyzed in
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Figure 3-4A
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Figure 3-4B
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Figure 3-4C

L10P, L166P, and P158DEL DJ-1 form intracellular inclusions following proteasome inhibition. CHO cells were
transfected with full-length WT, L10P, L166P, or P158DEL human DJ-1 pZeoSV2 (+) constructs. At 48 hours post
transfection, cells were cultured for an additional 12 hours in fresh DMEM with or without the addition of 20μM MG132. Cells were stained with the mouse monoclonal anti-DJ-1 antibody DJ5 (green), a rabbit polyclonal anti-vimentin
(red) and Hoechst 33342 (blue) and visualized by microscopy. Representative images are shown for cells that were not
treated with MG-132 in A) and cells that were treated with MG-132 in B). Bar = 50μm (C) The proportion of cells
depicting DJ-1 inclusions was quantified as the percentage of the total cells expressing full-length WT, L10P, L166P,
or P158DEL human DJ-1 with or without MG-132 challenge. The graph represents the percentage of cells with
inclusions averaged between replicate images. The error bars show standard deviation.

parallel. In comparison to WT DJ-1 protein, the L10P, L166P, and P158DEL DJ-1
mutants all exhibited reduced protein stabilities when assessed by pulse-chase protein
turn-over analyses; however, the extent of the effects of the respective mutations on
protein stability was variable. The L10P and P158DEL mutants were relatively less
unstable than L166P. To begin to explain these findings, and because it was previously
reported that the instability L166P DJ-1was at least partially mediated by the proteasome
(138;139;298;307), pulse-chase analyses were conducted in the presence of the
reversible proteasome inhibitor, MG-132. As previously shown by others (138;139), MG132 only partially stabilized L166P DJ-1 protein in the studies herein. Similarly, MG-132
failed to completely block degradation of L10P and P158DEL DJ-1 mutants, though turnover was dramatically slowed for both variants. Noteworthily, in comparison to the other
mutants, MG-132 most effectively slowed the degradation of L10P DJ-1, suggesting that
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this mutation renders DJ-1 to be more susceptible to degradation by the proteasome.
Based on the findings herein, is it also likely that proteasome-independent mechanisms
can act to degrade L10P, L166P, and P158DEL DJ-1 mutant proteins. It is worth
mentioning that autophagy inhibitors did not impede the degradation of any of the DJ-1
protein variants analyzed in these studies (data not shown). This observation has also
been reported by other groups (42;324). Though a recent paper by Giaime and colleagues
supports a role for caspase-6 mediated cleavage of DJ-1, it is not clear what additional
proteases may act to regulate DJ-1 protein (129). The current findings suggest that
reduced DJ-1 protein stability resulting from the L10P and P158DEL mutations may at
least be partially responsible for DJ-1 loss-of-function.
It has been previously shown that the L166P mutation causes DJ-1 to unfold and
it is believed that this disconformity effectively disrupts dimer formation, which may be
associated with rapid degradation (12;139;298;307;324). Interestingly, it was determined
that unlike L166P DJ-1, L10P and P158DEL DJ-1 mutants were able to dimerize with
WT DJ-1 protein. A similar finding has been reported for another pathogenic DJ-1
mutant, M26I, which also exhibits decreased stability without associated dimerization
impairments (42). This indicates that the ability for DJ-1 to form dimers may not
necessarily correlate to protein stability. However, improper protein folding may be
causal of the decreased stability observed for some pathogenic DJ-1 mutants. Supporting
this idea, the studies herein revealed that L10P and P158DEL DJ-1 variants adopted
altered structural conformations in comparison to WT DJ-1 protein as determined by size
exclusion chromatography. Though it is believed that L166P DJ-1 cannot dimerize,
monomeric forms of L166P DJ-1 of the expected ~21 kDa size were not detected in the
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current study. This may be due to the unstable nature of monomeric L166P DJ-1.
Instead, the observed L166P DJ-1 eluted with an apparent molecule mass greater than
that of WT DJ-1. This finding is consistent with a previous report showing that L166P
DJ-1 forms higher-order protein complexes (269), and this suggests that L166P DJ-1 may
also form such complexes in CHO cells. The elution of WT DJ-1 was primarily
consistent with dimer formation, although the broad elution profile would also suggest
equilibrium with a monomeric pool. Surprisingly, the L10P DJ-1 mutant exhibited an
apparent elution profile that is consistent with a slightly larger conformation than WT
protein. The L10P mutation is located in the first β-strand of DJ-1, which is not directly
involved in the dimer interface (167;170;469). Therefore, this mutation is not predicted to
affect dimerization, but would have a significant effect on disrupting the first β-strand.
Conversely, P158DEL DJ-1 exhibited an elution profile that suggests that it is slightly
smaller than WT protein. Residue P158 is also outside of the DJ-1 dimer interface;
however it located right before the beginning of DJ-1 α-helix 7 which is required for
dimer formation (167;170;469). Additionally, P158 is a highly conserved residue in the
DJ-1 protein family (23). Thus, it is possible that deletion of residue P158 shifts the
conformation of DJ-1 in such a way as to allow for tighter packing of the monomer or the
dimer and this could in turn result in apparent decreased protein size.
Without proper regulation, misfolded proteins can accumulate and aggregate with
each other, and this can eventually lead to impaired cellular processes (291;323). Since
our data indicate that the L10P, L166P, and P158DEL mutations can alter protein folding,
it was of interest to determine the effects of these mutations on protein solubility. The
respective solubilities of WT, L10P, L166P, and P158DEL DJ-1 proteins were assessed
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by two different biochemical fractionation methods. When expressed in CHO cells under
normal culturing conditions, P158DEL DJ-1 and to a lesser extent L10P DJ-1
demonstrated reduced solubilities. Interestingly, when biochemical fractionation
experiments were performed following treatments with MG-132 or epoxomicin, L10P
and L166P DJ-1 proteins demonstrated dramatic accumulations of insoluble proteins
while WT DJ-1 was unaffected by these treatments. This indicated that L10P and L166P
DJ-1 protein variants, which are inclined to misfolding and being degraded, accumulate
as aggregates when degradation is impaired. The finding that more L10P accumulates in
the insoluble fractions compared to L166P in the presence of MG132 suggests that the
ability of the former variant to still form dimers may also promote this process.
Surprisingly, while P158DEL formed insoluble aggregates under native conditions,
proteasome inhibition did not enhance the accumulation of insoluble species. These
findings suggest that P158DEL DJ-1 can spontaneously accumulate as misfolded
aggregates that are largely regulated by proteasome-independent mechanisms.
Aggregation of DJ-1 mutant proteins also was studied at the microscopic level.
Under normal conditions, only a small percent of cells expressing L10P and P158DEL
DJ-1 depicted DJ-1 inclusions. Such a finding has not been reported for other pathogenic
DJ-1 mutants, suggesting that these mutants may be more prone to aggregation. MG-132
treatments induced the formation of L10P, L166P, and P158DEL DJ-1 intranuclear and
intracytoplasmic protein inclusions that were not detected in cells expressing WT DJ-1
protein under the same conditions. Most of the observed inclusions did not co-localize
with common aggresome markers, suggesting that they likely represent deposits of
aggregated DJ-1. The formation of these inclusions did not correlate with formation of
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insoluble DJ-1 observed biochemically. For example, biochemical analysis demonstrated
that P158DEL DJ-1 forms an intrinsic insoluble pool of protein and this is not
significantly altered by MG132 treatment. It is possible that MG132 treatment induced
this pool of P158DEL DJ-1 to coalesce into inclusions. Remarkably, inclusions were
most prominent in cells expressing L10P DJ-1 following MG132 challenge. Biochemical
analysis demonstrated that MG132 resulted in a dramatic accumulation of insoluble L10P
DJ-1 and it is possible that such a pool is required for inclusion formation. Similarly,
MG132 treatment resulted in the accumulation of insoluble L166P DJ-1 and inclusion
formation. Olzmann and colleagues showed that L166P DJ-1 formed perinuclear
aggresomes in cultured cells following treatments with MG-132; however it was
determined that this phenomenon only occurred in the presence of the E3 ubiquitinprotein ligase, parkin (325). Interestingly, no interactions between parkin and L10P or
P158DEL DJ-1 variants were discovered in the studies herein (data not shown), thus it is
likely that L10P and P158DEL DJ-1 inclusion formation is regulated by alternative
mechanisms.
In conclusion, these studies demonstrate that the pathogenic L10P and P158DEL
mutants result in the destabilization of DJ-1 and that proteasome degradation is at least
partially involved in this process. Additionally, the L10P and P158DEL mutations do not
prevent dimer formation, indicating that that the observed decreases in protein stability
may be caused by limited and localized perturbations in protein folding. These alterations
in protein structure are likely responsible for reduced protein solubilities and intracellular
protein inclusion formation. These properties of L10P and P158DEL mutants may
collectively contribute to DJ-1 loss-of-function by depleting the pool of functional
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protein. In addition, these novel findings indicate that different pathogenic DJ-1 mutants
can display diverse altered biochemical properties. Future studies to assess for specific
effects of pathogenic DJ-1 mutations on biological pathways in vivo and studies in
patients would give insights into the physiological role for DJ-1 protein especially as it
relates to the etiology of PD.
3.5

MATERIALS AND METHODS

Antibodies
DJ-5 is a mouse monoclonal antibody that is specific for human DJ-1 protein (296).
Affinity purified mouse anti-actin (clone C4) monoclonal antibody reacts with all forms
of vertebrate actin (Millipore, Billerica, MA). The affinity purified polyclonal antibody,
HA.11 (Covance, Emeryville, CA), reacts with proteins with the amino acid sequence,
YPYCVPVYA. Vimentin (C-20) is an affinity purified polyclonal antibody that reacts
with vimentin (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Anti-histone H3, CT,
pan (Millipore, Temecula, CA) is a polyclonal antibody that recognizes histone H3
protein. Affinity purified glyceraldehyde-3-phosphate dehydrogeanase (GAPDH) (clone
6C5) monoclonal antibody reacts with GAPDH from various species (Advanced
Immunochemical, Long Beach, CA).
Cloning of Human DJ-1 Constructs
Human full-length WT DJ-1 cDNA was cloned into the pZeoSV2 (Invitrogen,
Carlsbad, CA) mammalian expression vector at the HindIII and Xho I restriction sites.
Using the WT DJ-1 construct, the QuickChange® Site Directed Mutagenesis Kit
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(Stratagene, La Jolla, CA) was used in order to generate L10P, L166P, and P158DEL
mutant forms of DJ-1 in the pZeoSV2 vector. The sequences of the oligonucleotides used
for mutagenesis are listed in Table 1. The respective DJ-1 plasmid sequences were
verified by DNA sequencing as a service offered by the DNA Sequencing Facility of the
University of Pennsylvania.
A human N-terminal HA-tagged WT DJ-1 construct was generated by PCR, using
the human full-length WT pZeoSV2 construct as a template. The sequences for the
oligonucleotides are listed in Table 3-1. The tagged insert was cloned into the pCR 2.1
TOPO vector (Invitrogen) and subsequently cloned into the pZeoSV2 vector at the Hind
III and Xho I restriction sites. The sequence of the plasmid was verified by DNA
sequencing as described above.
Cell Culture
Chinese Hamster Ovary (CHO) cells were cultured in Dulbecco-modified Eagle
medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Cells were
incubated at 37ºC and 95% air/5% CO2 atmosphere.
Pulse-chase Protein Turnover Analysis
CHO cells were cultured in 100 mm dishes. Cells were transfected with pZeoSV2
full-length WT, L10P, L166P, or P158DEL human DJ-1 constructs using Lipofectamine
Reagent (Invitrogen), following the manufacturer’s protocol. At 24 hours post
transfection, cells were split into 35 mm dishes and cultured in complete DMEM for an
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additional 24 hours. At 48 hours post transfection, cells were methionine-deprived for 15
minutes by incubation in pre-warmed methionine-free DMEM (Invitrogen)/10% dialyzed
FBS (Hyclone) before adding 100μCi [35S]-methionine (Perkin-Elmer, Waltham, MA)
per ml of methionine free DMEM/10% dialyzed FBS for 30 min. Chase experiments
were conducted in triplicates with normal DMEM/FBS with or without 20μM MG-132
for 0, 1, 3, 6, and 10 hours. Cells were then rinsed with PBS and harvested in
cytoskeleton (CSK) buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 %
Triton X-100) containing 1 % SDS and boiled at 100 ºC for 5 minutes. CSK buffer was
added to the lysates in order to bring the final concentration of SDS to 0.25%. Lysates
were frozen on dry ice and kept frozen at -20 ºC until the last time point was harvested.
The radiolabelled protein extracts were pre-cleared with a rabbit serum pre-incubated
with protein A-agarose (Santa Cruz Biotechnology, Inc.) for 3 hours at 4ºC and
radiolabelled extracts were then immunoprecipitated overnight at 4ºC with antibody DJ5
pre-incubated with protein A/G PLUS-agarose (Santa Cruz Biotechnology, Inc). The
antibody-protein complexes were washed 3 times with 10 volumes of CSK buffer,
resuspended in 2 volumes of 2X SDS sample buffer and boiled at 100 ºC for 5 minutes.
The beads were removed by centrifugation and the samples were loaded onto 13 %
polyacrylamide gels. Following electrophoresis, gels were fixed with 50% methanol/5%
glycerol, dried and exposed to a PhosphorImager plate and the signal was quantified
using ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA).
Western Blot Analysis
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Protein samples were resolved by SDS-PAGE followed by electrophoretic transfer onto
nitrocellulose membranes. Membranes were blocked in Tris buffered saline (TBS) with
5% dry milk, and incubated overnight with primary antibodies diluted in TBS/ 5% dry
milk. Each incubation was followed by goat anti-mouse conjugated horseradish
peroxidase (HRP) (Amersham Biosciences, Piscataway, NJ) or goat anti-rabbit HRP
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA), and immunoreactivity was detected
using chemiluminescent reagent (NEN, Boston, MA) followed by exposure onto X-ray
film.
Size Exclusion Chromatography
Gel filtration chromatography was performed as previous described (366). CHO cells
transiently expressing human full-length WT, L10P, L166P, or P158DEL DJ-1 were
cultured in 100 mm dishes, grown to confluency, and harvested. To harvest cells, the
cells were rinsed and scraped in PBS. After recovery by centrifugation, cells were lysed
in PBS/0.1% Triton and the cell debris was sedimented at 13,000 x g for 5 min. The
extracts were filtered through a 0.22 µm filter and loaded onto the column. Fractions
were analyzed by immunoblotting with anti-human DJ-1 specific antibody DJ5.
Experiments were repeated at least 3 times and similar results were obtained.
Co-Immunoprecipitation and Heterodimer Analysis
CHO cells were cultured in 100 mm plates. Cells were transfected with Nterminal HA-tagged full-length WT human DJ-1 construct (HA-WThDJ/pZeoSV2) or cotransfected with HA-WThDJ/pZeoSV2 and pZeoSV2 full-length untagged WT, L10P,
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L166P, or P158DEL human DJ-1 constructs. After 24 hours, cells were rinsed and
scraped in PBS and lysed by vortexing into 500 uL of ice-cold 1X CSK buffer with
protease inhibitors. Cell debris was sedimented at 13,000 x g for 1 minute and
supernatants were removed to fresh tubes. 50 uL of each supernatant was saved as the
“Start” fraction. The remainders of the supernatants were incubated for 3 hours at 4 °C
with anti-HA tag antibody, HA.11 (Covance) preabsorbed to protein A-Agarose beads
(Santa Cruz Biotechonogy, Inc.). The beads were sedimented, repeatedly rinsed with icecold 1X CSK buffer, resuspended in 2X SDS sample buffer, heated to 100 oC and saved
as the “IP” fractions. The supernatants remaining after immunoprecipitation were saved
as the “Unbound” fractions. Sample buffer was added to the “Start” and “Unbound”
fractions and then they were heated to 100 oC for 5 minutes. The Start, IP, and Unbound
fractions were resolved by SDS-PAGE and immunoblotted with DJ5 antibody.
Biochemical Fractionation and Cell Compartment Fractionation
CHO cells were cultured in 100 mm dishes and transfected with pZeoSV2 full-length
WT, L10P, L166P, or P158DEL DJ-1 constructs using Lipofectamine transfection
reagent. At 24 hours post transfection, the cells were cultured for an additional 18 hours
in fresh DMEM with or without the addition of either 20μM MG-132 or 1μM
Epoxomicin. For biochemical fractionation, cells were scraped into PBS, sedimented,
and lysed into buffers of increasing solubilization strengths using previously described
methods (366). The respective biochemical fractions were analyzed by western blot with
the monoclonal antibodies DJ5 and anti-actin.
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For cell compartment fractionation, cells were scraped into ice-cold PBS and fractionated
into cellular compartments using the Qproteome Cell Compartment Kit (Qiagen,
Valencia, CA) following the manufacture’s protocol. Cell lysates were quantified using
the BCA assay and analyzed by western blot with the monoclonal antibodies DJ5 and
GAPDH and the polyclonal antibodies anti-histone H3 and vimentin (C-20).
Double-immunofluorescence Analyses
CHO cells were cultured in 35 mm dishes and transfected with pZeoSV2 fulllength WT, L10P, L166P, or P158DEL DJ-1 constructs using Lipofectamine transfection
reagent. At 48 hours post transfection, the cells were cultured for an additional 12 hours
in fresh DMEM with or without the addition of 20μM MG-132. Cells were rinsed in PBS
and fixed by incubation in ice-cold acetic-methanol (1 part acetic acid to 20 parts
methanol) at -20 °C for at least 30 minutes. Cells were rehydrated with water, rinsed with
PBS, and blocked in PBS/1% FBS/1% skin fish gelatin (Sigma)/1% milk/0.1% Triton for
30 minutes. Primary antibodies were diluted into blocking solution and cells were labeled
for 1-2 h at room temperature. Following PBS washed, coverslips were incubated with
anti-mouse IgG antibody secondary conjugated to Alexa 488 and anti-rabbit IgG
antibody conjugated to Alexa 594. Nuclei were counterstained with Hoechst
trihydrochloride trihydrate 33342 (Invitrogen), and coverslips were mounted using
Fluoromount-G (Southern Biotech, Birmingham, AL). Images were captured using an
Olympus BX51 fluorescence microscope mounted with a DP71 digital camera (Olympus,
Center Valley, PA). For quantification of cells with DJ-1 inclusions, images were
captured with a 20x objective and all cells in the field were counted.
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Table 3-1

3.6

Human DJ-1
Variant

Forward Oligonucleotide
sequence

Reverse Oligonucleotide
Sequence

L10P

5’-GCT CTG GTC ATC CCG
GCT AAA GGA GCA GAG3’

5’-CTC TGC TCC TTT
AGC CGG GAT GAC
CAG AGC-3’

L166P

5’-TTC GAG TTT GCG CCT
GCA ATT GTT GAA-3’

5’-TTC AAC AAT TGC
AGG CGC AAA CTC
GAA-3’

P158DEL

5’-CTT ACA AGC CGG GGG
GGG ACC AGC TTC GAG-3’

5’-CTC GAA GCT GGT
CCC CCC CCG GCT TGT
AAG-3’

HA-tagged WT

5’-AAG CTT GCC ACC ATG
TAC CCA TAC GAT GTT
CCA GAT TAC GCT ATG
GCT TCC AAA AGA GCT
CTG GTC ATC-3’

5’-CTC GAG CTA GTC
TTT AAG AAC AAG-3’
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4.1

ABSTRACT

PD is the most common neurodegenerative movement disorder. A pathological hallmark
of PD is the presence of intraneuronal inclusions comprised of fibrillized α-syn in
affected brain regions. Mutations in the gene, PARK7, which encodes DJ-1, can cause
autosomal recessive early-onset PD. Although DJ-1 has been shown to be involved in
diverse biological processes, several in vitro studies suggest that it can inhibit the
formation and protect against the effects of α-syn aggregation. We previously established
and characterized transgenic mice expressing pathogenic A53T human α-syn (M83 mice)
that develop extensive α-syn pathologies in the neuroaxis resulting in severe motor
impairments and eventual fatality. In the current study, we have crossbred M83 mice on
a DJ-1 null background (M83-DJnull mice) in efforts to determine the effects of the lack
of DJ-1 in these mice. Animals were assessed and compared for survival rate,
distribution of α-syn inclusions, biochemical properties of α-syn protein, demise and
function of nigral dopaminergic neurons, and extent of gliosis in the neuroaxis. M83 and
M83-DJnull mice displayed a similar onset of disease and pathological changes, and none
of the analyses to assess for changes in pathogenesis revealed any significant differences
between M83 and M83-DJnull mice. These findings suggest that DJ-1 may not function
to directly modulate α-syn nor does DJ-1 appear to play a role in protecting against the
deleterious effects of expressing pathogenic A53T α-syn in vivo. It is possible that α-syn
and DJ-1 mutations may lead to PD via independent mechanisms.

100

4.2

INTRODUCTION
In 1997, the seminal identification of a missense mutation (A53T) in α-syn in

several kindred with PD (357) lead to subsequent studies showing that α-syn is a major
component of several types of brain amyloidogenic pathological inclusions
(133;320;405;464). For example, it is now established that Lewy bodies, characteristic
neuronal inclusions of PD, are predominantly comprised of α-syn polymerized into 10-15
nm fibrils (133;320;464). The spectrum of neurodegenerative disorders with α-syn
pathological inclusions are termed synucleinopathies (122;133;320;405;464). α-Syn is a
140 amino acid protein that is predominantly expressed in the brain and which localizes
to presynaptic nerve terminals (76;133;320). The physiological role for α-syn is not fully
understood, but several functions including the abilities to act as an auxiliary molecular
chaperone and to play a role in maintaining synaptic nerve terminal integrity have been
suggested (33;59;76;464). Although there is substantial evidence supporting the toxic
nature of aberrant α-syn aggregation, mutations (missense or gene multiplication) in the
α-syn gene (SNCA) provide the most direct evidence for a pathogenic role of α-syn
(133;320;357;405;464).
PD is the most common neurodegenerative movement disorder (90;465). The
clinical features of PD include bradykinesia, postural instability, resting tremor, and
rigidity, which result from the progressive loss of dopaminergic neurons in the substantia
nigra pars compacta (86;112;127;164;334), as well as a range of nonmotor symptoms
(62;355). While for most patients the cause for PD is idiopathic, mutations in genes at
multiple loci, designated PARK1 through PARK 13, result in parkinsonian phenotypes
with distinct features (32;80;124;213). DJ-1 was initially associated with PD
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pathogenesis when homozygous recessive mutations in the PARK7 gene encoding DJ-1
protein were identified in patients with early-onset PD (46). Since this initial report,
various autosomal recessive mutations in DJ-1, including, missense, splice-site,
frameshift and large deletions have been discovered (2;14;46;144;146;157;270) in 1-2%
of PD patients with early to mid age of onset (144;154;263). DJ-1 mutations are thought
to cause PD due to a loss of functional DJ-1 protein, though the natural role for DJ-1 as it
relates to sporadic PD is not known (41;109;365;486). In addition, no autopsies have
been performed on individuals with DJ-1 mutations; therefore, the exact
neuropathological manifestations of disease in patients harboring DJ-1 mutations remains
to be determined.
DJ-1 encodes a 189 amino acid protein which is a member of the ThiJ/PfPI
superfamily based on its structure (170;248;313;469). It is expressed in both neurons and
astrocytes in the brain (19;21;218;325;387), but it is also expressed in many other organs
(121;324;489). DJ-1 has been shown to protect against a variety of insults including
oxidation, inflammation, mitochondrial inhibition, and proteasome dysfunction
(139;260;310;366;418;422;456;487;498). More specifically, in vitro studies have
suggested that DJ-1 may act to directly prevent α-syn aggregation (389;494) and several
groups have reported that DJ-1 can ameliorate the harmful effects of mutant α-syn in
vitro and in cell culture studies (27;389;493). Interestingly, elevated levels of oxidized
DJ-1 protein are present in the brains of patients with sporadic PD (65) and DJ-1
associates with inclusions in various other synucleinopathies (296;316). Thus, it is
plausible to hypothesize that DJ-1 may physiologically act to protect against the
formation or the harmful effects of aggregated α-syn.
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We previously reported a transgenic mouse of synucleinopathies that was
generated by expressing human A53T α-syn in the nervous system using the mouse prion
protein (PrP) promoter (131). These mice developed an age-dependent severe movement
disorder which is associated with abundant neuronal α-syn inclusions in the neuraxis and
axonal degeneration (131). Since DJ-1 has been postulated to have several protective
functions, including anti-α-syn aggregation properties, we sought to study the effects of
the lack of DJ-1 in these mice. We hypothesize that the loss of DJ-1 may exacerbate the
extent or promote the onset of disease in these mice, either by promoting α-syn
aggregation or the consequences of α-syn inclusions. In the current study, transgenic
mice homozygotically expressing human A53T α-syn (“M83 mice”) were crossed with
genetically altered null DJ-1 mice in order to generate homozygous A53T α-syn
transgenic mice on a DJ-1 null background (“M83-DJnull mice”). M83-DJnull mice were
analyzed and compared to M83 mice as it relates to survival rate, distribution of α-syn
pathologies, biochemical properties of the α-syn protein, and extent of gliosis in the
neuroaxis.

4.3

RESULTS

Generation of DJ-1 null mice
DJ-1 null mice were generated as described in detail in “Materials and Methods”
in order to create a loss-of-function DJ-1 mouse model. The disruption of DJ-1
expression was demonstrated with several DJ-1 antibodies by western blot analysis of
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total protein lysates that were extracted from the brain cortices of DJ-1 null, heterozygous
(Het), and WT mice (Fig. 4-1C). The protein signal for DJ-1 in DJ-1 Het mice was ~0.6
fold the intensity compared to WT mice and was completely absent in samples from DJ-1
null mouse tissues. Similar results were obtained using other tissues including
cerebellum, brainstem, spinal cord, liver and lung (data not shown). As reported by
others for other DJ-1 null mice, extensive histological analyses did not demonstrate any
evidence of degeneration in the nervous system (data not shown and see Fig. 3C)
(13;60;63;136;274).

M83-DJnull mice display a similar motor phenotype and age of onset as M83 mice.
In attempts to understand the role for DJ-1 in modulating α-syn pathology in vivo,
the previously established transgenic mouse line M83 expressing human A53T α-syn
(131) was cross-bred with the DJ-1 deficient mouse line described above in order to
generate mice homozygous for both the α-syn transgene and the DJ-1 null allele (“M83DJnull” mice). The double homozygous transgenic genotype was confirmed as described
in the “Materials and Methods” section. The lack of DJ-1 was confirmed by western blot
analysis that also demonstrated that the deficiency of DJ-1 did not alter the expression
levels of human α-syn (Fig. 4-1D). It is known that M83 mice exhibit a severe motor
impairment with mid to late age of onset and which eventually results in fatality (131).
To determine whether a DJ-1 deficiency would alter the disease motor phenotype and
onset of disease, a cohort of M83-DJnull mice and M83 mice were housed in parallel. It
was observed that the M83-DJnull mice presented symptoms of weight loss, neglect of
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grooming, decreased mobility, paralysis, and eventual fatality, symptoms similar to those
characterized for the M83 mice described
Figure 4-1

Generation of DJ-1 null mice.
A) Schematic of the DJ-1 gene (419)
showing the inserting of the β-geo
trap (gray box) in the intron between
exon 6 and 7 resulting in disruption of
the gene. The β-geo trap includes a
splice acceptor (SA), a selectable
marker β-Geo, which is a fusion of βgalactosidase and neomycin
phosphotransferase II, followed by a
stop codon and a polyadenylation
signal. B) Image showing the
analyses from 3 individual 6-month
old DJ-1 null (DJ null), DJ-1 het (DJ
het), and wild-type (WT) mice. Tail
DNA was extracted and analyzed by
PCR with primers specific for the neo
gene. An agarose gel stained with
ethidium bromide is shown. The
arrow indicates the predicted PCR
product for the neo cassette insert
used to disrupt DJ-1 expression. C)
Cerebral cortical tissues were
harvested and total protein lysates
were extracted. Equal amounts (12
ug) of protein extracts were loaded
onto 13% polyacrylamide gels and
analyzed by western blot analysis
with the polyclonal anti-DJ-1
antibodies, 691 and N-20 as well as a
monoclonal anti-actin antibody to
confirm equal protein loading. Three
samples were loaded, each from the
same mice depicted in B. D) The
brainstem and spinal cord tissues
were harvested from 2 individual DJ1 null (DJnull), M83-DJnull, M83,
and WT mice and HS protein lysates
were extracted. 4 ug of protein
extracts were loaded onto 13% polyacrylamide gels and analyzed by immunoblot with antibody 691 to assess DJ-1
expression. Blots were also analyzed with the human specific monoclonal anti-α-syn antibody, LB509, as well as a
monoclonal anti-actin antibody to assess protein loading.
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previously (131). The severity of disease symptoms was comparable between M83DJnull mice and M83 mice. Further, while the age range for the onset of disease in the
M83-DJnull mice was 4-16 months of age (Fig. 4-2), this was not significantly different
from the age of disease onset in M83 mice, which was 8-17 months of age. To confirm
this observation, statistical analyses comparing the survival rates between mice revealed
that the median age of disease onset for both mouse genotypes was 11 months of age.
Figure 4-2

The lack DJ-1 does not affect
the survival of M83-DJnull
mice. The graph depicts the
onset of motor phenotype in M83
mice (n=77) and M83-DJnull
mice (n=26).

The distribution and extent of α-syn pathologies is similar between M83-DJnull and
M83 mice.
Although M83-DJnull mice did not exhibit enhanced motor impairment or
decreased survival rate in comparison to M83 mice, it is possible that DJ-1 deficient
animals may display an altered distribution of α-syn inclusions, perhaps affecting areas of
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the nervous system that were not previously observed in M83 mice. Certain neuronal
populations, including the hippocampus, the olfactory bulb, dopaminergic neurons of the
substantia nigra, and Purkinje cells of the cerebellum are completely devoid of α-syn
inclusions in the M83 mouse (131). Thus, post mortem immunohistochemical and
immunofluorescence analyses were conducted on brain and spinal cord tissues from sick
M83-DJnull mice in order to assess the distribution of α-syn inclusions. These analyses
revealed that affected M83-DJnull mice demonstrate the same distribution of
somatodendritic α-syn neuronal inclusions and dystrophic α-syn neurites throughout the
neuraxis as seen in M83 mice. A high density of inclusions was observed in the spinal
cord, throughout the brainstem, the deep cerebellar nuclei, and some regions of the
thalamus, such as the medioventral, ventromedial and paracentral nuclei (Fig. 4-3A and
data not shown). In the cortex, α-syn inclusions were predominantly observed in the
motor cortex. Conversely, regions that were devoid of pathology in M83 mice, such as
the olfactory bulb, hippocampus, or Purkinje neurons were also spared of inclusions in
M83-DJnull mice (Fig. 4-3A and data not shown). In representative images showing the
similarities between the mouse genotypes, inclusions were immunoreactive with antibody
Syn 514 which detects pathological α-syn (Fig. 4-3A). Ubiquitin, which is known to
modify α-syn in the inclusions in M83 mice (131;376), also localized to most of the α-syn
inclusions in M83-DJnull animals (Fig. 4-3A). It was previously shown that α-syn
inclusions that are present in the diseased tissues of M83 mice are highly phosphorylated
at Ser129 in α-syn (463). Similarly, the majority of the α-syn inclusions in M83-DJnull
mice were immunoreactive for an antibody specific for this modification (Fig. 4-3A).
Notably, while α-syn inclusions were present in a few of the tyrosine hydroxylase (TH)-
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positive neurons of the locus coeruleus (Fig. 4-3B), none were present in the TH-positive
neurons of the substantia nigra in M83-DJnull animals (Fig. 4-3B), a phenomenon which
was also previously observed in M83 mice (131). Further, stereological analyses of the
substantia nigra in WT, M83, DJ-1 null and M83-DJnull animals did not reveal any
significant differences in the total number of dopaminergic neurons between mouse
genotypes when animals were analyzed at 6 and 12 months of age (Fig. 4-3C). However,
similar to M83 mice, a significant number of the α-syn inclusions in M83-DJnull mice
were positive for the amyloid binding dye Thioflavin-S (Fig. 4-3D)(131).
Figure 4-3
Neither the distribution of α-syn pathologies
nor the numbers of TH positive neurons in
substantia nigra are altered in M83-DJnull
mice compared to M83 mice. A)
Immunohistochemical analyses were performed
as described in “Materials and Methods”. M83 (1,
3, 5, and 7) and M83-DJnull tissues (2, 4, 6, and
8) were stained with the anti-ubiquitin antibody (1
and 2); anti-pSer129 antibody (3 and 4), or anti-αsyn antibody Syn 514 (5-8). The representative
images depict the pons (1-6) and CA2 region of
the hippocampus (7 and 8). B) Double
immunofluorescence analysis of the locus
coeruleus and substantia nigra from a 10 month
old sick M83-DJnull mouse. Tissues were double
labeled with anti-α-syn antibody Syn303 (green)
and anti-TH (red). The overlay is shown on the
right. C) Stereological analysis of TH positive
neurons in substantia nigra of WT, M83, DJ-1
null, and M83-DJnull mice at ages 6 and 12
months. The graph represents the mean value of
the total number of TH positive neurons for each
mouse strains as indicated. The error bars indicate
standard deviation (n=3). D) Spinal cord tissues
were double labeled with antibody Syn303 (red)
and Thioflavin S staining (green). The image
shows amyloidogenic α-syn inclusions in a 12
month old diseased M83-DJnull mouse. The bar =
100μm in A and B and 10μm in C.
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The α-syn in M83-DJnull mice does not display altered abundance or biochemical
properties compared to M83 mice.
Previous studies of M83 mice revealed that the formation of α-syn inclusions is
reflected by the accumulation of insoluble α-syn protein in the respective tissues analyzed
(131). While M83-DJnull mice did not reveal histological differences in comparison to
M83 mice, biochemical studies may reveal more subtle differences. Western blot
analyses were performed using extracts from brain cortical, cerebellar, and
brainstem/spinal cord (BS/SC) tissues which had been fractionated into buffers of
increasing solubilization strengths. Analyses between age-matched sick M83-DJnull and
M83 mice were compared. These analyses revealed that the abundance and biochemical
distribution of human α-syn was similar between the M83-DJnull and M83 mice in all of
the tissues analyzed. In the cerebral cortex, human α-syn was most abundantly extracted
into the HS, HS-TX and RIPA fractions for both mouse genotypes (Fig. 4-4A). In the
cerebellum of M83 and M83-DJnull mice, α-syn was distributed in a similar manner
(Fig.4-4B). However, α-syn exhibited slightly reduced solubility into SDS fractions in
cerebellar tissues of some of the mice analyzed (Fig. 4-4B). This observation was not due
to a DJ-1 deficiency, however, since it was variable from mouse to mouse, irrespective of
genotype (data not shown). In the BS/SC regions of affected M83 and M83-DJnull mice,
biochemical analysis revealed a similar accumulation of RIPA-insoluble/SDS-soluble
human α-syn (Fig. 4-4C). Additionally, while there were no differences in the abundance
or extractability of the α-syn present in the BS/SC tissues of the predicted ~17 kDa size,
when comparing between M83 and M83-DJnull mice, several insoluble, higher molecular
weight α-syn species were detected on some immunoblots (Fig. 4-4C). These species
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were previously shown to represent ubiquitinated forms of α-syn (376). However, this
phenomenon was not due to a DJ-1 deficiency since it was variable and independent of
DJ-1 expression (data not shown)(376).
M83-DJnull mice do not display increased levels of Ser 129 specific α-syn
phosphorylation.
In a previous report, diseased M83 mice exhibited increased levels of insoluble α-syn
protein which was highly phosphorylated specifically at amino acid residue Ser129 (463).
To determine whether a DJ-1 deficiency could alter the levels of the Ser129-specific
phosphorylation of α-syn in brain cortical, cerebellar, and BS/SC tissue extracts from
age-matched diseased M83 and M83-DJnull mice were compared by western blot
analysis with the antibody pSer129. α-Syn that was extracted from BS/SC tissues from
M83-DJnull mice was highly phosphorylated in the SDS-soluble fraction but barely
detectable in the HS, HS-TX, or RIPA fractions in all of the mice analyzed (Fig. 4-4C).
However, there were no differences between M83 and M83-DJnull mice when the levels
of phosphorylated α-syn were compared.

110

Figure 4-4
The paucity of DJ-1 does not affect the
levels or biochemical distribution of α-syn
nor does it affect Ser 129 specific α-syn
phosphorylation. Age-matched (10 month
old) diseased M83-DJnull (“1” and “2”) and
M83 (“3”) mice were analyzed for the
abundance and solubility of α-syn protein. The
levels of Ser 129 specific α-syn
phosphorylation were also compared between
mice. The brain cortex (A), cerebellum (B)
and BS/SC (C) were harvested and
sequentially extracted into HS extraction
solution, HS-Tx extraction solution, RIPA
extraction solution, and 2% SDS/8M urea
extraction solution (SDS). Equal amounts
(5ug) of each sample were loaded onto 15%
polyacrylamide gels and analyzed for α-syn
distribution by western blot analysis with the
monoclonal human specific α-syn antibody,
LB509 (in A-C). Ser 129 specific α-syn
phosphorylation in the BS/SC was assessed
with the monoclonal antibody, pSer129 (in C).
Additionally, blots were probed with antibody
691 to assess DJ-1 and an actin antibody to
confirm equal protein loading. The mobility of
molecular mass markers is indicated on the
left.
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M83-DJnull mice do not show increased gliosis.
It is well known that reactive gliosis can follow brain tissue damage and is
typically accompanied by inflammation (123). A recent study by Waak et al. showed that
the disruption of DJ-1 expression in astrocytes resulted in enhanced neurotoxcity which
was due to an elevated neuroinflammatory response (456). Diseased M83 mice exhibit
astrocytic gliosis in the brain regions where α-syn inclusions are the most abundant (131).
It is possible that a DJ-1 deficiency in M83-DJnull mice would result in an aberrant
inflammatory response in these animals. To test this hypothesis, M83 and M83-DJnull
mouse brain tissues were evaluated by immunohistochemistry analysis with the reactive
microglial antibody marker, IBA-1 as well as the astrocyte marker, GFAP. The
distributions of the microglia and astrocytes present in the mouse tissues were compared.
While these analyses revealed that reactive microglia were primarily localized to the
brainstem and spinal cord tissue regions, the distribution and abundance of microglia was
similar in M83 and M83-DJnull mouse tissues (Fig. 4-5A and data not shown).
Astrogliosis also was observed in areas of the neuroaxis such as the brainstem and spinal
cord where abundant α-syn pathological inclusions were present; however, the prevalence
was similar in M83 and M83-DJnull mice (Fig. 4-5A and data not shown). This
observation was further confirmed by biochemical fractionation/western blot analysis for
IBA-1 (Fig. 4-5B) and GFAP (Fig. 4-5C).
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Figure 4-5
Gliosis in M83-DJnull mice
does not differ from M83
mice.
A) Immunohistochemical
analyses were performed
using brain tissues harvested
from diseased M83 and M83DJnull mice. The distribution
of microglia was assessed
between mice using the
polyclonal antibody, IBA1,
which is specific for reactive
microglia. Analyses to
determine the presence of
astrocytes were conducted
using the polyclonal antibody,
GFAP. The representative
images show staining in the
pons. The scale bar = 100μm.
In B) and C), age-matched
diseased M83-DJnull (“1” and
“2”) and M83 (“3”) mice were
analyzed biochemically for
changes in gliosis. The
representative images show
the analyses from 10 month
old mice. Brainstem and
spinal cord tissues were
harvested, pooled together and
sequentially extracted as
described in “Materials and
Methods”. Equal amounts
(5ug) of each sample were
loaded onto 13%
polyacrylamide gels and
analyzed by western blot
analysis with antibody IBA1
in B) and antibody GFAP in
C). In B) and C), the mobility
of molecular mass markers is
indicated on the left.
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M83-DJnull mice do not have elevated levels of Peroxiredoxin 6.
During the course of previous proteomics analysis, we discovered that affected
M83 mice display increased levels of peroxiredoxin (Prx) 6 that is substantiated by
western blot analysis (Fig. 4-6A) and this may reflect an attempt to activate a protective
mechanism. In addition, DJ-1 is thought to be able to act as an atypical Prx-like
peroxidase (13) and to protect against oxidative insults
(13;53;181;196;253;366;455;493). It is possible that the disruption of DJ-1 expression
may induce further reactive stress in M83-DJnull mice. Therefore, the effect of the
paucity of DJ-1 on the levels of Prx6 induced by α-syn pathology was assessed.
However, no major differences between M83 and M83-DJnull mice were detected as it
related to the extent of Prx6 expression or biochemical distribution.
M83-DJnull mice do not exhibit changes in the levels of dopamine or its metabolites.
Since some studies suggest that DJ-1 and α-syn may modulate TH and L-3,4dihydroxyphenylalanine (L-DOPA) decarboxylase enzyme activities (185), it is possible
that M83-DJnull mice could display altered levels of dopamine (DA) and its metabolites.
To test this hypothesis, striatum tissues were dissected from WT, M83, DJ-1 null, and
M83-DJnull mice at 6 and 12 months of age. Tissues were analyzed by high performance
liquid chromatography-electrochemical detection (HPLC-ECD) to quantify and compare
the total levels of L-DOPA, DA, and 3,4-dihydoxyphenylacetic acid (DOPAC) between
mouse genotypes. However, there were no significant differences between animals for
either of the age groups analyzed (Fig. 4-7), indicating normal dopamine-related
biochemical activities in M83-DJnull mice.
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Figure 4-6
M83-DJnull mice do not
have elevated levels of Prx 6
relative to M83 mice. A)
The representative
immunoblots were performed
with HS-soluble extracts from
brainstem and spinal tissues
that were harvested from a WT
non-transgenic mouse, M83
mice that were sacrificed
before the manifestation of a
motor phenotype at 3 months,
6 months, and 10 months of
age, as well as a diseased M83
mouse. Equal amounts (10 ug)
of protein extracts were loaded
onto 15% polyacrylamide gels
and analyzed by western blot
analysis with antibody antiPrx6 to assess the levels of Prx
6 in the mice. Blots were also
probed with the human
specific α-syn antibody,
LB509 to verify the expression
of human α-syn protein as well
as a β-tubulin antibody to
assess protein loading. B)
Age-matched diseased M83-DJnull (“1” and “2”) and M83 (“3”) mice were analyzed for the levels of Prx 6. Brainstem
and spinal cord tissues were harvested, pooled together and sequentially extracted as described in “Material and
Methods”. Equal amounts (5ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by western
blot for Prx6 as well as actin. The representative images show the analyses from 10 month old mice. The mobility of
molecular mass markers is indicated on the left.

4.4

DISCUSSION
Some in vitro studies and cell culture paradigms indicate that DJ-1 may be able to

modulate the aggregation of α-syn and/or act to mitigate the toxicity of pathogenic forms
of α-syn (27;389;493;494). However, these properties of DJ-1 have not been directly
assessed in vivo. M83 transgenic mice are previously described animals that express
human A53T α-syn and developed a severe age-dependent motor phenotype
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Figure 4-7
Unaltered levels of DA in
the striatum of M83DJnull animals. Striatal
tissues were dissected from
WT, M83, DJ-1 null, and
M83-DJnull mice at ages 6
months and 12 months.
Tissues were analyzed by
HPLC to quantify DA in
(A), L-DOPA in (B), and
DOPAC in (C). The graphs
in A-C depict the mean of
the levels of the respective
analytes for each of the
indicated mouse strains at
the respective ages. D) The
ratio of DA/DOPAC was
calculated. In A-D, errors
bars indicate standard
deviation (n=3 for 6 month
animals and n=5 for 12
month animals).
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associated with the formation of α-syn pathological inclusions in the neuroaxis (131).
These inclusions were demonstrated to be composed of fibrillized aggregates of insoluble
α-syn protein with a high abundance in the brainstem and spinal cord while inclusions
were absent in some regions such as the olfactory bulb, hippocampus, and dopaminergic
neurons of the substantia nigra (131). In the current study, in efforts to ascertain whether
DJ-1 modulates α-syn aggregation and pathology in vivo, double homozygous M83DJnull transgenic mice were generated which express human A53T α-syn on a DJ-1 null
background. If DJ-1 normally acts to mitigate α-syn aggregation or has protective
functions against the deleterious effects of α-syn aggregation, it was hypothesized that the
DJ-1 deficient M83-DJnull mice would exhibit an exacerbated phenotype in comparison
to that observed in M83 mice. Statistical analyses comparing the survival rates revealed
that the disease onset was not earlier in M83-DJnull mice compared to M83 mice. The
median age of survival for both groups of animals was 11 months of age. This suggested
that DJ-1 may not play a major role in ameliorating the harmful effects of expressing
A53T mutant α-syn in vivo. However, to further assess the differences between these
mice, several analyses were conducted. Nevertheless, no major differences between M83
and M83-DJnull mice were observed in any of the analyses that were performed.
Immunohistochemical analyses comparing the distributions of α-syn pathologies
throughout the neuroaxis failed to detect any overt variations between M83 and M83DJnull mice. Both mouse groups consistently exhibited abundant pathologies in the same
tissue regions while the absence of inclusions in other areas was remarkably similar
between mice. These analyses also revealed that most of the inclusions in diseased M83DJnull animals were composed of ubiquitinated, fibrillized α-syn protein that was highly
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phosphorylated at amino acid residue Ser129 similar to inclusions in diseased M83 mice
(131;463) and in patients (117;150;232;404;463). The formation of inclusions in M83
and M83-DJnull mice was further validated by biochemical and western blot analyses to
assess the soluble extractability. However, the studies herein did not reveal any changes
relating to α-syn aggregation in M83-DJnull animals. In addition, these studies did not
reveal any differences in the levels of the phosphorylation of Ser129. Thus, these findings
suggest that DJ-1 does not directly alter α-syn in vivo as it relates to protein fibrillization,
phosphorylation, or aggregation. Neither does DJ-1 appear to directly modulate the
expression of mutant α-syn since similar levels of the mutant protein were observed
between mice in the brain regions analyzed.
While the present study suggests that DJ-1 does not act to directly regulate A53T
mutant α-syn in vivo, it is possible that DJ-1 can mitigate secondary deleterious effects of
α-syn aggregation in mice such as inflammation and oxidative stress. It was previously
established that M83 mice exhibited astrocytic gliosis associated with the formation of αsyn inclusions (131). Additionally, recent studies using a primary neuron and astrocyte
co-cultured model reveal that a DJ-1 deficiency is causal of an enhanced
neuroinflammatory response that results in increased neurotoxicity (456). To determine
whether DJ-1 modulates the gliosis associated with α-syn aggregation in vivo, diseased
M83 and M83-DJnull mice were analyzed by immunohistochemistry with astrocyte
specific and reactive microglia specific markers. However, these analyses did not reveal
any differences between mouse types relating to the distribution and/or extent of gliosis.
Additionally, the biochemical and immunoblot assessments of protein extracts from M83
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and M83-DJnull mouse tissues also did not identify any differences. Thus, since gliosis
was independent of DJ-1 expression, DJ-1 may not act to regulate gliosis in M83 mice.
Since DJ-1 and α-syn may regulate TH promoter activation and have an effect on
TH enzyme activity (189), it was relevant to assess for the levels of striatal DA in M83DJnull mice in comparison to WT, DJ-1 null, and M83 animals. However, no differences
were revealed for any of the genotypes when mice were analyzed for the levels of LDOPA, DA, or DOPAC. This supports previous findings in the literature which report
normal DA levels and its metabolites in DJ-1 null animals (136). Further, in the studies
herein, stereological analyses revealed no change in the number of nigral dopaminergic
neurons in both a young and old cohort of M83-DJnull mice. Our finding is also in
agreement with other reports which do not detect degeneration of these neurons in DJ-1
null mice (136).
In a variety of model systems, the expression of mutant A53T α-syn has been
shown to result in increased levels of oxidative stress (191;197;339).While DJ-1 has been
shown to be involved in diverse biological processes, several studies demonstrate its
ability to mitigate the toxic effects of aberrant oxidation
(13;53;181;200;253;366;455;493). In addition, in some studies DJ-1 was reported to be
able to act as an atypical Prx-like peroxidase (13). The current study demonstrated that
when compared to WT mice and healthy M83 mice, sick M83 animals exhibited
increased steady-state expression of Prx6. This phenomenon specifically occurred in the
BS/SC tissues of M83 mice where α-syn pathologies were most abundant.
Comparatively, no alterations in Prx6 were observed in the cortex in diseased M83
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animals (data not shown). This suggests that the increased levels of Prx6 observed in sick
M83 mouse BS/SC tissues may be a protective attempt against α-syn aggregation. It is
known that Prx6 levels are increased in PD and that this increase is associated with the
recruitment of Prx6 to Lewy body inclusions (360). Additionally, since Prx6 has been
shown to be up-regulated in response to oxidation (69), it could imply that α-syn
inclusion formation is accompanied by increased oxidative stress in sick M83 mice. To
determine whether these observed alterations in Prx6 were modulated by DJ-1 in vivo,
BS/SC tissues from sick M83 and M83-DJnull mice were analyzed by western blot
analysis and compared for immunoreactivity with the Prx6 antibody. However, these
analyses revealed that diseased M83 and M83-DJnull mice expressed Prx6 at similar
levels.
Herein, a loss-of-function DJ-1 mouse model was employed in attempts to
ascertain the role for DJ-1 in mitigating mutant α-syn in vivo. Many groups have utilized
DJ-1 deficient animals in efforts to define a physiological role for DJ-1 protein in vivo as
it relates to PD (13;60;136;204;274;354;480;483). However, while DJ-1 null animals
have been shown to exhibit mild behavioral changes, these were not associated with any
observed degeneration in the nervous system (13;60;63;136;480). Neither have DJ-1 null
mice exhibited increased signs of oxidative stress (63;480). A few studies have shown
that DJ-1 deficient animals are more vulnerable to paraquat (483), MPTP (204;274), and
rotenone toxicity (354), suggesting a role for DJ-1 in protecting against oxidative stress
and mitochondrial impairments.

120

In the present study, DJ-1 deficient animals were not more vulnerable to the toxic
effects of mutant A53T α-syn. These studies suggest that DJ-1 may not have a significant
role in mitigating the formation of α-syn inclusions and their deleterious effects in vivo.
Alternatively, there may be compensatory mechanisms in the mouse which act to mimic
the function of the lost DJ-1 protein. For example, recent studies by other groups suggest
a possible genetic interaction between DJ-1 and other PD related genes, PINK1 and
parkin (449;477). It is of interest to note that in the current study, no alterations in the
steady-state levels of parkin protein were observed in the brains of M83 and M83-DJnull
mice when they were analyzed by western blot (data not shown). Neither did PINK1
protein levels appear to be modulated by DJ-1 in the mice analyzed (data not shown).
Further, triple knockout mice that are deficient for DJ-1, parkin, and PINK1 do not have
decreased life spans nor do they exhibit phenotypes that are comparable to any of the
symptoms of PD (211). It is possible that yet unidentified candidate genes may be acting
to compensate for the loss of DJ-1 in vivo. Identifying such candidate genes would give
new insights into plausible biochemical mechanisms that underlie the pathogenesis of
PD.
4.5

MATERIALS AND METHODS

Antibodies
Anti-IBA1 is a rabbit polyclonal antibody raised against ionized calcium-binding adaptor
molecule 1 (Iba1), a marker for activated microglial cells (Wako Chemicals USA, Inc.,
Richmond, VA). Anti-glial fibrillary acidic protein (GFAP) is a rabbit polyclonal
antibody against glial fibrillary acidic protein, a specific marker for astrocytes (Promega
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Corporation, Madison, WI). LB509 is a mouse monoclonal antibody that specifically
reacts with human α-syn (18;132). Syn 303 and 514 are monoclonal antibodies raised
against oxidized forms of human α-syn and that preferentially recognize pathological
forms of the protein (130;462). pSer129 is a monoclonal antibody that specifically
recognizes α-syn that is phosphorylated at the Ser129 (463). Anti-ubiquitin (clone 1510)
is a mouse monoclonal antibody that reacts with conjugated and unconjugated forms of
ubiquitin (Millipore, Billerica, MA). Anti-actin (clone C4) is an affinity purified
monoclonal antibody that reacts with all vertebrate isoforms of actin (Millipore). Anti-TH
antibody (Millipore) is an affinity purified rabbit polyclonal antibody. An affinity
purified rabbit polyclonal antibody raised against a synthetic peptide corresponding to
amino acid residues 196-210 of human Prx6 was obtained from Sigma-Aldrich (Saint
Louis, MO). 691 is a rabbit polyclonal antibody raised against recombinant human DJ-1
protein but that reacts with DJ-1 from various species (296). DJ-1 (N-20) is an affinity
purified goat polyclonal antibody raised against a peptide corresponding to the Nterminus of human DJ-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Anti-βtubulin (clone TUB2.1) is a monoclonal antibody raised against β-Tubulin (Sigma). Goat
anti-mouse IgG Alexa Fluor 488 conjugated antibody and goat anti-rabbit or anti-mouse
IgG Alexa Fluor 594 conjugated antibodies were purchased from Molecular Probes
(Eugene, OR).
Generation of DJ-1 null mice
Murine embryonic stem (ES) cells (clone XE726) with a recombination resulting in the
disruption of the DJ-1 gene were obtained from BayGenomics (San Francisco, CA). This
cell line was generated by random exon trapping and it was determined by DNA
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sequencing that the recombination event occurred after exon 6 in the murine DJ-1 gene
(see Fig. 1A). These ES cells were injected into C57BL/6J blastocysts as a service of the
University of Pennsylvania Transgenic and Chimeric Mouse Facility and chimeric mice
were generated. The germ line transmission of the null-gene was determined by breeding
chimeras with C57BL/6J mice and PCR analyses of tail DNA with primers specific for the
neomycin gene. Mice homozygous for the null-allele were generated by crossing F1 mice,
and homozygous null mice were determined by PCR analyses of tail DNA and western
blot analysis of mouse tail protein samples (dissolved in 4%SDS, 8M urea) using an
antibody to DJ-1.
Generation of M83-DJnull mice
The previously established homozygous transgenic mice line M83 expressing A53T
human α-syn (131), was bred with the homozygous DJ-1 null mouse line described in the
previous section. The double heterozygous offspring were mated to generate double
homozygous transgenic mice. Mouse genotypes were confirmed by Southern blot
analysis of tail genomic DNA with a probe for human α-syn. Homozygous α-syn
transgenic lineages were identified by quantitative Southern blot analysis and verified by
backcrossing. Null DJ-1 homozygosity was determined by PCR against the neo gene and
western blot analysis of mouse tail protein samples as described in the previous section.
In some mice, immunoblotting of brain tissue extracts with 691 and LB509 antibodies
were used to confirm the loss of DJ-1 protein and the expression of human pathogenic αsyn protein respectively. Mice were sacrificed by CO2 euthanization as approved by the
University of Pennsylvania Institutional Animal Care and Use Committee.
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Immunohistochemical Analysis
Mice were sacrificed with CO2 euthanization and perfused with PBS/heparin, followed
by perfusion with either 70% ethanol/150mM NaCl or PBS buffered formalin. The brain
and spinal cord were then removed and fixed for 24 hours in the respective fixatives used
for perfusion. As previously described tissues were dehydrated at room temperature
through a series of ethanol solutions, followed by xylene and then were infiltrated with
paraffin at 60ºC (434). The tissues were then embedded into paraffin blocks which were
then cut into 6μm sections. Immunostaining of the sections was then performed using
previously described methods (102).
Double-Labeling Immunofluorescence Analysis
Paraffin-embedded tissue sections were deparaffinized and hydrated through a series of
graded ethanol solutions followed by 0.1M Tris, pH 7.6. The sections were incubated
simultaneously with the Syn 303 and anti-TH primary antibodies diluted in 5% dry
milk/0.1M Tris, pH 7.6. After extensive washing, sections were incubated with goat antimouse secondary conjugated to Alexa 488 and goat anti-rabbit secondary conjugated to
Alexa 594. After washing, the sections were coverslipped with VectaShield-DAPI
mounting medium (Vector Laboratories, Burlingame, CA) and visualized using an
Olympus BX51 microscope.
Unbiased Stereological Determination of Dopaminergic Neurons in the Substantia
Nigra
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The number of anti-TH immunoreactive neurons in the entire substantia nigra was
assessed for WT, M83, DJ-1 null, and M83-DJnull mice at ages 6 months and 12 months
using similar methods described by Kitada et al. (211) with a few exceptions. Brains were
fixed in 70% ethanol/150mM NaCl and sectioned at 10μm thickness. Every fifth section
was stained with anti-TH polyclonal antibody (Millipore). Three brains were analyzed for
each of the indicated mouse strains at each of the respective ages.
Thioflavin-S Staining
Paraffin-embedded tissue sections were incubated with antibody Syn303 followed by
anti-mouse conjugated Alexa Fluor 594 as described above. Sections were stained with
thioflavin-S by immersing in freshly made 0.0125% thioflavin-S/40%EtOH/60% PBS
and differentiated in 50% EtOH/50% PBS. The sections were coverslipped and visualized
as described above.
Mouse Protein Analysis
Cerebral cortical tissues were harvested from 6 month old DJ-1 null, DJ-1 Het, and WT
mice. Tissues were sonicated in 3 tissue volumes of 2% SDS/8M urea. Total protein
extracts were then quantified using the bicinchoninic acid (BCA) assay (Pierce
Biotechnology, Rockford, IL) and bovine serum albumin as the standard. Equal amounts
of protein extracts were resolved by SDS-PAGE and analyzed by western blot.
Sequential Biochemical Fractionation
The cortex, cerebellum, brainstem and spinal cord were dissected from mice. For each
mouse, the brainstem and spinal cord were pooled together and then all tissues were
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weighed and homogenized with a pellet pestle motor in 3 tissue volumes of high-salt
(HS) buffer (50 mM Tris [pH 7.5], 750 mM NaCl, 5 mM EDTA, with a protease inhibitor
cocktail at 1:1000 and PMSF at 1:500, and the phosphatase inhibitors, 20 uM NaF, 1 uM
NaVO4, and 1 uM okadaic acid) followed by sedimentation at 100,000 x g for 20
minutes. Supernatants were saved as the HS fraction. Pellets were homogenized in 3
tissues volumes of high salt-triton (HS-TX) buffer (HS buffer with 1% Triton X-100) and
sedimented at 100,000 x g for 20 minutes. The supernatants were saved as the HS-TX
fraction. The pellets were subjected to a sucrose myelin float by homogenizing in 3 pellet
volumes of sucrose buffer (HS buffer/1M sucrose) and after centrifugation, the myelinrich supernatants were discarded. Pellets were then homogenized in 2 tissue volumes of
radioimmunoprecipitation assay buffer (RIPA) buffer (50 mM Tris [pH 8.0], 150 mM
NaCl, 5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS with the
protease and phosphatase inhibitors), sedimented at 100,000 x g for 20 minutes, and the
supernatants were saved as the RIPA fraction. Pellets were then sonicated in 1 pellet
volume of 2% SDS/8M urea and were designated to be the SDS fractions. The fractions
were then quantified using the BCA assay, resolved by SDS-PAGE, and analyzed by
immunoblot as previously described above.
Catechol Quantification by HPLC with Electrochemical Detection (ECD)
Striatal catecholamine content was assessed in WT, M83, DJ-1 null, and M83-DJnull
mice. Mice were analyzed at 6 months and 12 months of age. In order to isolate the
striatum, the brains were submerged into ice-cold phosphate buffer and dissected into 1
mm-thick coronal sections using a vibratome (Series 1000, R.L. Slaughter, Essex, UK).
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Dissected tissues were weighed and homogenized by sonication in 10 volumes of 1 μM
3,4 dihydroxybenzylamine (DHBA) in 0.1M perchloric acid. Following centrifugation at
16,000 × g for 10min at 4oC, 20μl of the supernatants were injected onto an 1100 series
Agilent HPLC system controlled by Chemstation software (Agilent, Palo Alto, CA). The
mobile phase consisted of 72 mM citric acid, 28.4 mM sodium phosphate, 2% methanol,
pH 2.8. Catechols were resolved at a flow rate of 1 mL/min on a reverse-phase C18 Luna
column (150 X 4.6 mm, 5um; Phenomenex, Torrance, CA) and detected with a Coularray
detector (ESA Biosciences, Chemsford, MA) with the following working potentials (in
mV): -200, +50, +300 and +400. Chemstation software (version 1.04, ESA Biosciences)
was used for the quantification by comparing to the peak areas of known concentrations
of standards. Acid-precipitated protein pellets were extracted in 2% SDS / 50mM TrisCl, pH 7.4 and the protein concentrations were determined using the microBCA kit
(Peirce, Rockford, IL). Analyte levels were normalized to DHBA and protein
concentration.
4.6
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-Performed all co-immunoprecipitation/Western studies
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5.1

ASTRACT

Various mutations in the PARK2 gene which encodes the protein, parkin, are
causal of a disease entity termed autosomal recessive juvenile parkinsonism. Parkin can
function as an E3 ubiquitin protein ligase, mediating the ubiquitination of specific
targeted proteins and resulting in proteasomal degradation. Parkin is thought to lead to
parkinsonism as a consequence of a loss in its function. In this study, immunoblot
analyses of brain extracts from Balb/c, C57BL/6, C3H, and 129S mouse strains
demonstrated significant variations in immunoreactivity with anti-parkin monoclonal
antibodies (PRK8, PRK28, and PRK109). This resulted partly from differences in the
steady-state levels of parkin protein across mouse strains. There was also a complete loss
of immunoreactivity for PRK8 and PRK28 antibodies in C3H mice which was due to a
homologous nucleotide mutation resulting in an E398Q amino acid substitution. In
cultured cells, parkin harboring this mutation had a greater tendency to aggregate,
exhibited reduced interaction with the E2 ubiquitin conjugating enzymes, UbcH7 and
UbcH8, and demonstrated loss of function in promoting the proteasomal degradation of a
specific putative substrate, synphilin-1. In situ, C3H mice displayed age-dependent
increased levels of brain cortical synphilin-1 compared to C57BL/6, suggesting that
E398Q parkin in these mice is functionally impaired and that C3H mice may be a suitable
model of parkin loss-of-function similar to patients with missense mutations.
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5.2

INTRODUCTION
Parkinson disease (PD) is an insidious neurodegenerative disorder that is

characterized by the selective demise of specific neuronal populations, including
dopaminergic neurons of the substantia nigra, and is associated with an impairment of
motor functions. Most cases of PD are sporadic, but several disease-causing genes have
been identified (44). In 1998, it was shown that mutations in the parkin gene (also
known as PARK2) were responsible for a disease entity termed autosomal recessive
juvenile parkinsonism (AR-JP) (208). To date, a variety of nonsense, missense, exonic
deletion, splice site, duplication, and triplication mutations in PARK2 have been
identified in individuals with both early and late-onset PD (155;282;423;452). Since
several community based reports suggest that parkin mutations may contribute to up to
15% of the inherited cases of PD and are the major cause of early-onset PD
(44;144;266;352;475) , much work has been done to understand the role of parkin in the
pathogenesis of PD.
The parkin gene is large, spanning over 1.4 Mega bases with 12 exons and large
intronic regions (16;208;209). The gene encodes a ~52kDa protein that is 465 amino
acids in length (208). The protein has an amino terminal ubiquitin-like (Ubl) domain as
well as two RING finger domains which are separated by an IBR finger domain at the
carboxyl terminus (208;308). These structural features are common to E3 ubiquitinprotein ligases (E3 ligases)(424) and parkin can function in this capacity
(74;148;178;367;392;407). E3 ligases are a class of proteins that work in concert with
ubiquitin-conjugating enzymes (E2s) to mediate the transfer of ubiquitin to specific
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protein substrates. This ubiquitin transfer often targets substrates for proteolytic
degradation by the 26S proteasome (74;194). It is known that parkin can interact with the
E2 ubiquitin-conjugating enzymes, UbcH7 and UbcH8 (178;392;490). Additionally,
many groups have shown that under certain experimental paradigms, parkin can facilitate
the ubiquitination of a variety of substrates and can also aid in the subsequent degradation
of a subset of these substrates (68;72;83;173;177;216;306;370;393;409;439;490). Thus, it
is widely accepted that parkin functions as an E3 ligase; however, it is unclear how this
function may be related to PD (99;109;254).
Several of the pathogenic mutations in parkin have been shown to impair its E3
ligase activity. Pathogenic mutations, such as the T240R mutation, have been shown to
reduce the interactions between parkin and E2 ubiquitin-conjugating enzymes
(143;178;392;490). Additionally, this disrupted association of parkin with E2 enzymes
can result in reduced ubiquitination and degradation of parkin substrates
(72;178;392;407;490). It is also known that parkin can ubiquitinate itself which then
leads to its degradation by the proteasome (67;490). Pathogenic mutants which do not
demonstrate the ability to autoubiquitinate often show altered protein solubility (407).
This altered solubility may be related to decreased protein turnover that is specific to the
proteasome pathway (490).
It is hypothesized that parkin mutations may lead to parkinsonism through a loss
in parkin function since parkin has been shown to play a protective role in a number of
studies (71;178;201;447). Parkin deficient mice have been generated by several labs in
efforts to study the effects of parkin loss-of-function in vivo (135;186;212;350;379;454).
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Several inconsistencies have been reported regarding the effects of abolishing parkin in
mice. However, in general, parkin loss in mice is not associated with an increased
morbidity or loss of dopaminergic neurons (135;186;350;379;454;496). Nor has parkin
loss in mice been shown to have an effect on many of the putative parkin substrates
(217).
In this report, the western blot analyses of endogenous brain parkin from four
different mouse strains, C57BL/6, Balb/c, C3H, and 129S, are described. Dramatic
variations in the protein levels of endogenous parkin were observed between mouse
strains. Additionally, a novel endogenous homozygous missense mutation was
discovered in C3H mice which resulted in the parkin amino acid substitution, E398Q.
This mutation abolished the PRK8 and PRK28 parkin antibody epitopes in C3H mice
while immunoreactivity with the PRK109 antibody was retained. Because C3H mice may
potentially be used in future studies that involved parkin, the impact of the novel
endogenous parkin mutation on protein function was examined. Characterization of this
mutation indicates that C3H mouse parkin is functionally impaired, suggesting that the
C3H mouse strain may be a suitable in vivo model for endogenous loss-of-function
parkin studies.
5.3

RESULTS

Differential immunoreactivity for parkin protein in various mouse strains
During the course of analyzing parkin expression by immunoblotting in mice
from various backgrounds, dramatic differences were observed for immunoreactivity
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with 3 different monoclonal anti-parkin antibodies (Fig. 5-1). All three antibodies used
here (PRK8, PRK28 and PRK109) were previously shown to specifically recognize
human and mouse parkin and to recognize epitopes within the RING2 domain of parkin
(amino acids residues 399-465 of human parkin) (347). In brain cortex, PRK109 showed
the highest level of immunoreactivity in the 129S background, followed by the C3H
background and lowest, and about equivalent, levels in the Balb/c and C57BL/6 (BL6)
backgrounds. Immunoblotting with antibodies PRK8 and PRK28 also demonstrated
equivalent higher immunoreactivity in a 129S background compared to the Balb/c and
BL6 background. Surprisingly, the cortical brain extracts from C3H mice were devoid
of reactivity with both PRK8 and PRK28 antibodies. However, this result was not due to
a complete loss of parkin expression in C3H mice as the PRK109 antibody recognized
parkin in C3H tissue extracts. These results suggest that PRK8, PRK28, and PRK109
antibodies recognize different epitopes and that somehow, in C3H mice, the epitope that
is specifically recognized by the PRK8 and PRK28 antibodies is altered.
Figure 5-1

Western blot analysis showing differential levels of
immunoreactivity with different parkin antibodies
in various mouse strains. Cerebral cortical tissues
were harvested from Balb/c, C57BL/6 (BL6), C3H, and
129S mice and total protein lysates were extracted.
Equal amounts (18 ug) of total protein extracts were
loaded on 13% polyacrylamide gels and analyzed by
western blot analysis with the anti-parkin monoclonal
antibodies, PRK8, PRK28, and PRK109 as well as an
actin antibody to confirm equal protein loading. The
representative blot above shows extracts from 10 week
old mice. Two samples were loaded, each from separate
mice of the indicated strains. All experiments were replicated and similar results were obtained for a total of n=4 mice
from each strain.
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Similar levels of the parkin mRNA transcript are observed in different mice
backgrounds.
To begin to understand the reasons for the differences in immunoreactivity with
parkin antibodies in the Balb/c, BL6, C3H, and 129S mice backgrounds, the levels of
parkin mRNA in these mice was determined. Two-step quantitative real-time reversetranscription polymerase chain reaction (qRT-PCR) analyses were performed using total
RNA extracted from cortical tissues of Balb/c, BL6, C3H, and 129S mice. Analyses were
performed in duplicate using 3 independent RNA samples for each of the different mouse
strains. All mouse strains expressed comparable levels of the parkin mRNA transcript
(Fig. 5-2A and B), indicating that the differences observed in parkin protein
immunoreactivity levels are not due to differences in the amount of mRNA.
Figure 5-2
Similar levels of the parkin mRNA
between different mice stains. Total
RNA was extracted from cerebral cortical
tissues that were harvested from Balb/c,
BL6, C3H, and 129S mice. Parkin and actin
mRNA transcripts were quantified using
two-step qRT-PCR. Experiments were
performed in duplicate and 3 separate
samples were analyzed for each mouse
strain. A) The parkin and actin qRT-PCR
products are shown. The image represents
the products from one of the mice analyzed
for the indicated strain. B) The ratio of the
Parkin to Actin CT value was calculated for
each sample. The graph depicts the average
of the ratios between replicate samples for
each mouse strain. The error bars indicate
standard deviation (n=6).
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Parkin antibody epitope mapping studies
To further explain the differences in immunoreactivity observed in various mouse
strains with different parkin antibodies, the epitopes recognized by these antibodies were
mapped in greater detail. For these epitope mapping studies, full-length and various Nand C-terminal truncated forms of human parkin were expressed in bacteria as Nterminally GST-tagged recombinant proteins (Fig. 5-3). Western blotting with an antiGST antibody demonstrated similar expression for all proteins. The PRK8 antibody
recognized GST-parkin(1-408), but not GST-parkin(1-399), indicating that the epitope
for this antibody includes residues 400-408. PRK8 reacted with both GST-parkin(381465) and GST-parkin(399-465), but reactivity for GST-parkin(399-465) was much
weaker. These data indicate that the epitope of antibody PRK8 require residues 400-408,
but extends further upstream of this sequence. Antibody PRK28 demonstrated similar
immunoreactive properties to antibody PRK8, with an additional weak reactivity with
GST-parkin(1-399). Therefore, the epitope for PRK28 also requires amino acid residues
400-408 and extends further upstream than PRK8. Antibody PRK109 reacted with GSTparkin(1-420), but not GST-parkin(1-408) indicating that the epitope for this antibody
includes residues 409-420.
An endogenous mutation in the C3H parkin gene is responsible for the loss of PRK
8 and PRK 28 immunoreactivity.
Since genetic alterations can result in differences in the parkin protein that could
be responsible for some of the differences in immunoreactivity observed in the different
mouse strain backgrounds, we proceeded to determine the parkin cDNA sequence
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Figure 5-3
Parkin antibodies epitope mapping studies. A. Schematic of parkin protein. The numbers indicate the amino acid
residues that correspond to the respective protein domains. Ubl is the ubiquitin-like domain, Mid is the linker domain,
R1 is the first RING finger domain,
IBR is the in-between-ring-finger
domain, and R2 is the second RING
finger domain. B. Full-length
human parkin cDNA corresponding
to amino acids 1-465 and various
truncated cDNA fragments of
parkin were cloned in the bacterial
expression vector pDEST15, that
expresses N-terminal GST-tagged
recombinant proteins. The
recombinant proteins were
expressed in BL21 E. coli cells. The
cells were harvested and equal
amounts of total protein lysates
were analyzed by western blot with
a GST antibody in order to confirm
similar expression of the respective
proteins. Additionally, equal
amounts of the protein extracts
were assessed for immunoreactivity
with the PRK8, PRK28, and
PRK109 antibodies. The
experiments were performed in
duplicate. Representative blots are
shown for each construct. The identical blot for PRK28 is shown at different exposure times in order to reveal the faint
immunoreactivity of the 1-399 construct that is not readily detectable at the shorter exposure time. The mobility of
molecular mass markers is indicated on the left.

(nucleotides 963-1388) around the region comprising the antibody epitopes for each
mouse strain. This analysis revealed that the cDNA sequences for Balb/c, BL6 and 129S
mice was identical to the previously published sequence for Balb/c (210). However, the
cDNA sequence for the C3H strain revealed 2 homologous nucleotide alterations (c. 1140
C>T and c. 1192G>C) (Fig. 5-4 and data not shown). The nucleotide change at
position 1140 is a silent mutation that does not change the amino acid. The 1192G>C
substitution results in the missense mutation E398Q. This mutation is equivalent to a
E399Q mution in human parkin, since mouse parkin has one less residue (Gly 139) than
human parkin (210). DNA sequencing of genomic tail DNA confirmed that the C3H

137

parkin mutation occurred at the DNA level and was not due to post-transcriptional events
(Figure 5-4S1).
Figure 5-4
Discovery of a novel
endogenous parkin
mutation in C3H mice.
RT-PCR was performed
using total RNA that was
extracted from cerebral
cortical tissues of BL6,
Balb/c, C3H, and 129S
mice. The amplified PCR
products spanned bases 8951395 of the mouse parkin
cDNA sequence. The PCR
products were sequenced
and analyzed for mutations.
The image shows the
respective portion
(nucleotide bases 11771200) of sequencing
electropherogram for the
various mouse strains. The
corresponding amino acid
sequences are written above
the respective DNA codons.
A novel endogenous
G1192C parkin cDNA
mutation was identified in
C3H mice. This mutation
translates into a missense
E398Q mutation. The 1192
cDNA residue is underlined
in order to highlight the
location of the novel
G1192C mutation in the
mouse parkin cDNA
sequence.

Since the E399Q mutation is within the epitopes for both PRK8 and PRK28, the
effects of this mutation on the reactivity of these antibodies was determined. The E399Q
mutation was introduced into the bacterial vector expressing GST-parkin(380-465) and
the protein was expressed concurrently with the similar WT protein. Immunoblotting
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with an anti-GST antibody demonstrated equivalent expression of both proteins (Fig. 55A). Immunoreactivity with PRK109 was not affected by the E399Q mutation, however
this mutation abolished the reactivity with both PRK8 and PRK28 (Fig 5-5A).
To confirm these findings in mammalian cells, a construct expressing full-length
untagged human WT parkin (parkin/pcDNA3.1) was used to overexpress human parkin
in mouse neuroblastoma Neuro-2A (N2A) cells. In addition, similar vectors expressing
T240R and E399Q mutant parkin were used. While antibody PRK109 recognized both
WT and parkin mutants, antibodies, PRK8 and PRK28 did not react with E399Q parkin
(Fig. 5-5B). These data indicate that the E399Q mutation disrupts the epitopes of the
PRK8 and PRK28 antibodies and that the equivalent mutation (E398Q) in C3H mice
explains the lack of immunoreactivity with these antibodies.
The E399Q human parkin mutant shows reduced solubility without associated
inclusion formation.
Several of the reported PD-linked parkin mutations, some in close proximity to
the E399Q mutation, lead to altered solubility when they are expressed in mammalian
cells (148;407;460). To investigate whether the E399Q parkin amino acid substitution
alters these biochemical properties of parkin, solubility assays were performed.
HEK293T cells were transiently transfected with untagged full-length WT, E399Q, or
T240R mutant human parkin constructs. Cell lysates were sequentially extracted in
buffers of increasing solubilization strengths. Extracts were then analyzed by western blot
with the PRK109 antibody. In comparison to the other fractions, WT Parkin protein was
mostly extracted into the soluble TX fractions and to a lesser extent into the SDS
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insoluble fractions (Fig. 5-6A and B). A significant fraction of both E399Q and
pathogenic T240R human parkin mutants was extracted in the insoluble SDS-fractions
(Fig. 5-6A and B).
Figure 5-4S1

DNA sequencing of mouse parkin from genomic tail DNA. Genomic DNA was extracted from the tails of 10 week
old BL6 and C3H mice using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI) following
the manufacture’s protocol. Polymerase chain reactions were conducted on the purified DNA in order to amplify
nucleotides 1167-1273 of the mouse parkin sequence. The primer sequences for the reaction were as follows. Forward:
5’-CTA CAG GGT GGA CAA AAG AGC CGC -3’ and Reverse: 5’- CAA TTG GCA CGT TGC AGC GAG GAC-3’.
The reaction products were confirmed by topoisomerase reaction into pCRTopo2.1 vector (Invitrogen Corporation) and
DNA sequencing.
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Figure 5-5

Abolishment of the PRK8 and
PRK28 antibody epitopes due to
the E399Q human parkin
mutation. A) pDEST15/parkin
380-465 and pDEST15/parkin 380465 E399Q constructs were used to
express the respective proteins in
BL21 E. coli. Total protein lysates
were extracted and equal amounts
of protein (600 ng) were resolved
on 13% polyacrylamide gels and
analyzed by western blot with
GST, PRK8, PRK28, and PRK109
antibodies. B) Full-length untagged
wild-type and mutant (T240R and
E399Q) human parkin cDNA
cloned in the mammalian
expression vector pcDNA3.1 were
used to express these proteins in
mouse N2A neuroblastoma cells.
Following transfection with the
respective constructs, equal
amounts (4 ug) of total protein
lysates were resolved on 13%
polyacrylamide gels and assessed
by western blot for recognition of
the indicated parkin antibodies.
Additionally, the blots were probed with an actin antibody to confirm equal protein loading. The mobility of molecular
mass markers is indicated on the left.

To determine whether this altered extractability of E399Q mutant parkin is
associated with the formation of protein inclusions, immunofluorescence studies were
conducted. HEK293T cells transiently expressing untagged full-length WT, E399Q, or
T240R human parkin were assessed for parkin localization with the PRK109 antibody.
Following these analyses, while parkin was found to exhibit similar homogeneous
cytoplasmic staining for all of the parkin variants, inclusions were not detected in any of
the cells analyzed (Fig. 5-6C).
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Figure 5-6

The E399Q human
parkin mutant shows
reduced solubility in
mammalian cells
without associated
inclusion formation.
HEK293T cells were
transfected in duplicate
with untagged full-length
WT, E399Q, or T240R
human parkin/pcDNA
3.1 constructs. A) and B)
At 48 hours post
transfection, cells were
harvested and
sequentially extracted
into PBS/0.1% Triton
(TX) buffer, RIPA
buffer, and 2%
SDS/17mM Tris (SDS)
buffer. Equal amounts
(16ug) of each sample
were loaded onto 10%
polyacrylamide gels and
analyzed by western blot
for parkin distribution
with the PRK109
antibody. Blots were also
probed with an actin
antibody to assess equal
protein loading. The
mobility of molecular
mass markers is indicated
on the left. The western
blot images were
quantified as described in
“Materials and Methods”.
The total percentage of
parkin extracted into SDS
fractions was calculated
for each sample. Error
bars indicate standard deviation (n=4). C) Immunofluorescence analysis of HEK293T cells expressing WT or mutant parkin
immunostained with PRK109 (red) and counterstained with Hoerscht (blue). The merged images depict the absence of inclusions in
cells expressing WT, E399Q, or T240R parkin. Scale bar =10um.

The E399Q parkin mutant is functionally impaired.
Parkin functions as an E3 ubiquitin-protein ligase, acting to promote the
ubiquitination and subsequent degradation of its substrates (178;367;490). Synphilin-1
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has been identified as one of the putative substrates for parkin (72;257). Several of the
pathogenic mutations in parkin, including the T240R mutation, have been shown to
impair the ability for parkin to promote the degradation of synphilin-1 (72;407). In order
to ascertain whether the E399Q mutation hinders parkin function, steady-state levels of
synphilin-1 were analyzed in the presence of WT, T240R, or E399Q parkin. The levels of
synphilin-1 were compared between parkin variants. In addition, some transfected cells
were treated with the proteasome inhibitor, clasto-lactacystin β-lactone (Omuralide), to
assess that the degradation of synphilin-1 promoted by parkin was due to the proteasome.
HEK293T cells were co-transfected with myc-tagged synphilin-1 and either pcDNA3.1
mock vector or the respective pcDNA3.1 untagged parkin constructs. Cells were
transfected with a 4:1 cDNA ratio of parkin to synphilin-1 as under these conditions, it
has been previously shown that parkin promotes the degradation of synphilin-1 (257).
Total cell lysates were analyzed by immunoblot with anti-c-Myc and PRK109 antibodies.
Expression of WT parkin led to a significant decrease in synphilin-1 steady-state levels in
comparison to the levels for synphilin-1 when it had been co-expressed with mock vector
(Fig. 5-7A and B). However, neither the T240R nor the E399Q parkin had any effect on
the steady-state levels of synphilin-1. Additionally, as it has been previously shown,
parkin-mediated degradation of synphilin-1 occurs via the proteasome pathway (257),
since it was completely blocked in the presence of a specific proteasome inhibitor.
To further determine the effects of WT, T240R, and E399Q parkin on the
stability of synphilin-1, HEK293T cells were co-transfected with myc-tagged synphilin-1
and either pcDNA3.1 mock vector or the respective pcDNA3.1 untagged human parkin
constructs as described above. Synphilin-1 turnover was assessed by pulse-chase analyses
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Figure 5-7
E399Q mutant parkin is
functionally impaired.
HEK293T cells were cotransfected either with mock
pcDNA3.1 vector “(-)” or
full length WT, T240R, or
E399Q human parkin
pcDNA 3.1 constructs as
well as the pcDNA3.1 myctagged full-length
synphilin-1 construct. The
co-transfection experiments
were performed using a
parkin to synphilin-1 cDNA
ratio of 4:1. At 24 hours
post transfection, (A and B)
cells were incubated for 16
hours with fresh DMEM or
with DMEM containing
5uM Omuralide. Cells were
then harvested and total
protein lysates were
extracted. Extracts were
resolved by 10 %
polyacrylamide gels and
immunoblotted with the
monoclonal antibodies antic-Myc clone 9E10 to assess
synphilin-1 levels, PRK109
antibody to confirm parkin
expression, and anti-actin
antibody to ensure equal
protein loading. All
experiments were
performed in triplicate and
repeated at least 3 times.
The mobility of molecular
mass markers is indicated
on the left. The levels of
synphilin-1 were quantified
as described in “Materials
and Methods” and the graph
in B depicts the percentage
of synphilin-1 protein
standardized to that in the
mock vector samples. The
error bars indicate standard
deviation between replicate
samples (n=4). C) Cells
were pulsed with 35Smethionine for 1 hour and
chased for 0, 1, 3, or 6
hours. The inset shows
representative pulse-chase
experiments. Experiments
were conducted in triplicates. The results are plotted as percentage of protein over time standardized to the 0 hrs time
point. The error bars show standard deviation (n=3).
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with 35 S-methionine and the effects of the respective parkin variants on synphilin-1
turnover were compared. Synphilin-1 exhibited a half-life of ~6 hours in the absence of
parkin (Fig. 5-7C). WT parkin enhanced the turn-over of synphilin-1, reducing the halflife to ~1 hour. However, neither T240R nor E399Q parkin had an effect on synphilin-1
degradation, suggesting that both mutants are functionally inactive.
Synphilin-1 was initially identified as a substrate for parkin in studies
investigating interacting proteins (72). It is possible that the E399Q mutation disrupts the
direct interaction between mutant parkin and synphilin-1 that would prevent parkinmediated degradation. To determine whether there is a loss in the direct interaction
between E399Q mutant parkin and synphilin-1, co-transfection and coimmunoprecipitation experiments were conducted. HEK293T cells were co-transfected
with myc-tagged synphilin-1 and untagged human WT, E399Q, or T240R mutant parkin
constructs. At 48 hours post transfection, soluble cells lysates were immunoprecipated
with an anti-c-Myc antibody followed by immunoblot with the PRK109 antibody. All
parkin variants, including the E399Q mutant, were co-immunoprecipitated with
synphilin-1 (Fig. 5-8). Thus, the E399Q Parkin mutation does not disrupt the interaction
between parkin and synphilin-1.
It has been previously shown that parkin specifically interacts with the E2
ubiquitin conjugating enzymes, UbcH7 and UbcH8, in order to exert its function as an E3
ligase (178;392;490). One plausible explanation for the impaired function exhibited by
the E399Q parkin mutant could be disrupted binding with E2 enzymes. To test this
hypothesis, co-transfection and co-immunoprecipitation experiments were conducted.
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Figure 5-8
E399Q mutant parkin can
directly interact with
synphilin-1. HEK293T cells
were transiently co-transfected
with myc-tagged synphilin-1
and pcDNA3.1 mock vector
(“none”) or with untagged fulllength WT, T240R, or E399Q
human parkin pcDNA3.1
constructs. Cells were
harvested and soluble protein
lysates were extracted
(“Input”). The cell lysat es
were then immunoprecipitated
using anti-c-Myc polyclonal
antibody (“IP”). Equal
amounts of the input, IP, and
unbound supernatant
(Unbound) fractions were
resolved by SDS-PAGE and
analyzed by western blot
(“WB”) with anti-c-Myc monoclonal antibody 9E10 or with anti-parkin antibody PRK109. Experiments were repeated
at least 3 times. The mobility of molecular mass markers is indicated on the left.

HEK293T cells were co-transfected with HA-tagged UbcH7 or UbcH8 constructs and
either mock pcDNA3.1 or untagged pcDNA3.1 full-length WT, T240R, or E399Q human
parkin constructs. At 48 hours post transfection, cell lysates were immunoprecipitated
with a polyclonal anti-HA antibody, HA.11, followed by immunoblot with the
monoclonal antibodies PRK109 and anti-HA (clone 12CA5). These analyses revealed
that while UbcH7 recruited similar levels of both WT and T240R parkin, the binding of
E399Q parkin with UbcH7 was dramatically reduced (Fig. 5-9). Interestingly, in
comparison to binding with UbcH7, parkin was recruited less effectively by UbcH8 and
the levels of T240R and E399Q mutant parkin recruited by UbcH8 were modestly
reduced in comparison to WT parkin. Together, these results indicate a loss of function of
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the E399Q mutant may be due, at least in part, to reduced interactions with E2 ubiquitin
conjugating enzymes.
Figure 5-9
The E399Q
parkin mutant
shows reduced
binding to UbcH7
and UbcH8.
HEK293T cells
were cotransfected with
pRK5-HA-UbcH7
or pRK5-HAUbcH8 and either
pcDNA3.1 mock
vector (“mock”) or
with untagged fulllength WT,
T240R, or E399Q
human parkin
pcDNA3.1
constructs. Cells
were harvested
and soluble protein
lysates were extracted (“Input”). The cell lysates were then immunoprecipitated using the anti-HA polyclonal antibody,
HA.11 (“IP”). Input and IP fractions were resolved by SDS-PAGE and analyzed by immunoblot with the monoclonal
antibodies PRK109 and anti-HA (clone 12CA5). The PRK109 blots are shown at 5 second and 20 second exposure
times to highlight the differences in signal intensity reflected by the binding of parkin with UbcH7 versus that with
UbcH8.

Synphilin-1 levels are increased in C3H mice.
Since E399Q mutant parkin was incapable of down-regulating synphilin-1 expression in
cultured cells (Fig. 5-7), it is plausible to hypothesize that the parkin in C3H mice,
harboring the homologous E398Q mutation, may show increased levels of the synphilin-1
substrate in situ. To test this hypothesis, total protein extracts from cerebral cortical
tissues of 10 week old BL6 and C3H mice were analyzed by western blot with the
affinity purified synphilin-1 antibody, UPN79. No differences in synphilin-1 were
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detected between mice at this age (Fig. 5-10A and B). However, it is possible that
synphilin-1 may accumulate in C3H mice in an age dependent manner. To determine
this, cerebral cortical protein extracts from 8 month old BL6 and C3H mice were
immunoblotted with antibody UPN79. Remarkably, extracts from 8 month old C3H mice
revealed 2.0 ± 0.18 fold higher synphilin-1 levels than BL6 mice of the same age (Fig 510C and D).
To confirm that these changes were not due to differences at the transcriptional
level, qRT-PCR analyses were performed using total RNA extracted from cortical tissues
of the 8 month old BL6 and C3H mice used for synphilin-1 protein analysis described
above. Both mouse strains expressed comparable levels of the synphilin-1 mRNA
transcript (Fig. 5-10D and E), indicating that the differences observed in synphilin-1
protein immunoreactivity are not due to differences in the amount of mRNA. These
findings are consistent with the notion that the E398Q mutation impairs the ability of
parkin to mediate the degradation of synphilin-1, leading to an age-dependent
accumulation of synphilin-1 in C3H mice.
5.4

DISCUSSION

Western blot analyses of brain extracts from Balb/c, C57BL/6, C3H, and 129S mice
revealed dramatic variations in immunoreactivity with 3 monoclonal parkin antibodies
(PRK8, PRK28, and PRK109). Notably, immunoreactivity for PRK8 and PRK28 was
absent in C3H mice. This was especially unexpected since it had been previously
reported that the epitopes for the PRK8, PRK28, and PRK109 antibodies were similarly
located around the second RING domain of parkin (347). In efforts to gain insights into
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Figure 5-10

Synphilin-1 protein levels are increased in C3H mice. Cerebral cortical tissues were harvested from BL6 and C3H
mice. Protein lysates were extracted from animals at ages 10 weeks (A and B) and 8 months (C and D). Equal amounts
(18 ug) of high-salt protein extracts were loaded onto 10% polyacrylamide gels and analyzed by western blot analysis
with the affinity purified polyclonal antibody, UPN79 to assess synphilin-1, as well as an actin antibody to confirm
equal protein loading. Four samples were loaded, each from separate mice of the indicated strains. The graphs in B and
D show the average ratios of the levels of UPN79 to actin normalized to the values in BL6 animals at the respective
aforementioned ages. E) Total RNA was extracted from cerebral cortical tissues that were harvested from the same
BL6 and C3H mice analyzed in C. Synphilin-1 and actin mRNA transcripts were quantified using two-step qRT-PCR.
Experiments were performed in duplicate and 3 separate samples were analyzed for each mouse strain. The synphilin-1
and actin qRT-PCR products are shown. The image shows the products from one of the mice analyzed for the indicated
strains. F) The ratio of the synphilin-1 to actin CT value was calculated for each sample. The graph depicts the average
of the ratios between replicate samples for each mouse strain. The error bars indicate standard deviation (n=6).

how epitope differences could account for some of these changes in mouse parkin
immunoreactivity, thorough epitope mapping studies were conducted. The analyses of a
variety of recombinant N-terminal and C-terminal truncated parkin proteins allowed for
the PRK8, PRK28 and PRK109 antibody epitopes to be more discretely mapped. The
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PRK8 antibody epitope requires residues 400-408 of human parkin but also extends
upstream of these residues. The PRK28 epitope also requires residues 400-408 but
extends slightly further upstream of the PRK8 epitope. Lastly, the PRK109 epitope is
further downstream and includes residues 409-420 of human parkin protein.
Genetic analysis revealed a homologous nucleotide substitution (c. 1192G>C) in
C3H mice that results in an E398Q missense amino acid change. This alteration is
responsible for the disruption of the PRK8 and PRK28 epitopes in C3H mice. These
findings and the epitope mapping are particularly important due to the prevalent use of
these parkin antibodies in several studies (52;115;156;243;244;347).
Immunoblotting with antibody PRK109 demonstrated variations in the levels of
parkin in different mouse strains with the highest level being observed in 129S mice
followed by C3H and lowest, and about equivalent levels, in the Balb/c and BL6 mice.
Similar results were obtained when comparing parkin levels in 129S, Balb/c and BL6
mice with antibodies PRK8 and PRK28. Genetic studies revealed no alterations that
would affect the PRK109 epitope in 129S, C3H, Balb/c and BL6 mice. Nor were any
genetic mutations identified that would affect the PRK8 or PRK28 epitopes in 129S,
Balb/c and BL6 mice. Additionally, the levels of brain parkin mRNA were found to be
similar between strains, indicating post-transcriptional effects. These findings are likely a
reflection of differences in parkin protein levels that may result from differences in
translation efficiencies or turnover rates in the different mouse strains. Interestingly, no
differences in the steady-state levels of other PD relevant proteins including α-syn, DJ-1,
or tau were observed between mouse strains (data not shown). Neither were there
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differences in the levels of the E3 ligase, ARIH1 (data not shown), which shares close
functional homology to parkin (275). Thus, the differences that were observed in parkin
between mice strains appear to be specific and not due to the consequence of more
generalized effects.
There has been no report of a naturally occurring human E399Q parkin
polymorphism or pathogenic mutation, however there are several reported pathogenic
mutations that are in close proximity to the this residue [R396G (475), A398T(282;452),
R402C (26;270), R402H (416), R402W(359)], suggesting that it may affect protein
structure or function. In addition, this glutamic acid residue at the 398 is conserved in
other species including rat, pig, and macaque (208;210); NCBI protein database
accession numbers NP_064478, NP_001038068, and ACL68652). Directly supporting
this hypothesis, it was shown in this study that the E399Q mutant parkin exhibited
reduced solubility when it was overexpressed in mammalian cells. However, this did not
lead to the formation of aggregated protein that could be observed at the microscopic
level. This suggests that the E399Q parkin mutation may result in protein misfolding
without the accumulation into large aggregates. Changes in parkin solubility have been
associated with a variety of stimuli including oxidative stress, heat shock, as well as a
battery of other types of stress and may have a consequence on parkin function
(243;459;470). For instance, changes which induce a shift in parkin solubility could
thereby deplete soluble pools of parkin and may result in the impairment of parkin’s
function toward substrates.
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It was further shown in this report that the E399Q mutant parkin is deficient in the
ability to mediate the degradation of the parkin substrate, synphilin-1, similar to the
T240R parkin pathological mutant. Neither the steady-state levels nor the turn-over rate
of synphilin-1 were affected by co-expression of the E399Q or T240R parkin mutants in
HEK293T cells, while expression of WT parkin dramatically reduced the levels of
synphilin-1 in these studies. These data supported previous findings which showed a
marked decrease in synphilin-1 steady-state levels with the co-expression of WT parkin
at a parkin to synphilin-1 cDNA ratio of 4:1, findings which were not observed under the
same conditions for the T240R parkin mutant (257). It is of interest to note that high
molecular weight forms of polyubiquitylated synphilin were not detected in any of the
parkin co-expression experiments performed in the studies herein (Fig. 7). This could be
because typical ubiquitination “smears” are below detectable levels under the
experimental conditions used and/or these observations may be related to the finding by
Lim et al. which suggests that parkin can mediate different types of ubiquitin linkage
(257). Nevertheless, the data herein demonstrates impaired function of E399Q and
T240R parkin mutants towards down-regulating synphilin protein levels in comparison to
WT parkin protein. This was not due to the inability for these mutants to interact with
synphilin since WT, E399Q, and T240R parkin all showed similar interactions with
synphilin by co-immunoprecipitation studies, consistent with previous findings (72).
It is interesting that the novel E399Q parkin mutation lies between the IBR and
RING2 domains of the parkin protein. This feature is also common to the previously
characterized T415N pathogenic parkin mutant. The T415N parkin mutation interfered
with the proper recruitment of E2 enzymes to parkin (490) and resulted in impairments in
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parkin-mediated degradation (407). However, this was not associated with a loss in
substrate binding activity (72;407). Similarly, in the current study, in comparison to the
other parkin variants analyzed, the E399Q parkin mutant showed dramatically reduced
binding with the E2 enzyme, UbcH7. This aberration likely partially contributes to the
deficiencies exhibited by the E399Q parkin mutant related to degradation of the
synphilin-1 substrate.
The novel E399Q parkin mutant showed reduced solubility and functional
impairments when it was analyzed in mammalian cells indicating that the homologous
E398Q mutation in C3H mice may result in mice that are deficient or impaired in parkin
activity. To support this hypothesis, there was a 2 fold increase in the cortical levels of
synphilin-1 in 8 month old C3H mouse brains in comparison to BL6 mice. This
difference was not observed in mice at 10 weeks of age which suggests that other E3
ligases or other modes of degradation play a more prominent role in the turnover of
synphilin-1 at this age. While C3H mice do not show any overt behavioral characteristics
that may be attributed to a functional parkin deficiency, the attempts to identify in vivo
effects of parkin’s loss-of-function in mice have proven to be very difficult. Genetically
generated parkin null mice fail to display any major differences in most of the behavioral,
morphological, and biochemical analyses that have been previously conducted
(349;350;431;453). Subtle differences in parkin null mice have been identified in a few
studies, but many inconsistencies have also been reported (116;135;186;335;379;496).
Interestingly, no differences in synphilin-1 levels were detected in brain tissues of parkin
null animals in comparison to WT animals in previous studies (217). However, this does
not discredit the finding of the increased steady-state levels of synphilin-1 observed in
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C3H mice in the current study. It is possible that this discrepancy could be due to a
number of factors including antibody specificity, tissue extraction method, or tissuespecific differences in parkin regulation of synphilin-1. Further, since it is likely that
synphilin-1 may also be regulated by parkin independent mechanisms, it is unknown how
this may be affected in a model system that is completely devoid of parkin versus a
system where parkin is available, albeit impaired. Analysis of other putative parkin
substrates such as Pael-R or p38/JTV-1 (217) could also indirectly help to confirm a loss
of parkin function in C3H mice. However, while specific antibodies are not readily
available, future studies to assess for alterations in these putative substrates would be
informative.
In summary, these studies demonstrate that parkin protein levels differ in various
mouse background strains. Additionally, the C3H mouse harbors a previously unreported
mutation (E398Q) in parkin that abolishes immunoreactivity with antibodies PRK8 and
PRK28. Characterization of this novel mutation revealed that it promotes the misfolding
of parkin, impairs its ability to interact with E2 conjugating enzymes, and disrupts its
function towards the synphilin-1 substrate. These findings indicate that C3H mice are
carriers of a missense parkin mutation and that they may be a suitable model of parkin
loss-of-function similar to human patients that have missense mutations. In addition, the
difference in the level of parkin expression demonstrated here in various widely-used
mouse strains is an important confound that should be taken into account in mouse
studies.
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5.5

EXPERIMENTAL PROCEDURES

Mouse strains
C57BL/6, C3H, BALB/c, and 129S mice at 10-12 weeks and 8 months of age were used
for studies. All mice were purchased from Charles River Laboratories Inc (Wilmington,
MA). Mice were sacrificed by CO2 euthanization as approved by the University of
Pennsylvania Institutional Animal Care and Use Committee.
Antibodies
PRK8, PRK28, and PRK109 are mouse monoclonal antibodies raised against human
parkin but that react with parkin from various species, including murine (347). Mouse
anti-(GST) monoclonal antibody clone A00865.01 was obtained from GenScript
(Piscataway, NJ). Affinity purified mouse anti-actin (clone C4) monoclonal antibody
reacts with all forms of vertebrate actin (Millipore, Billerica, MA). Two c-Myc
antibodies were used in these studies: purified anti-c-Myc monoclonal antibody clone
9E10 (M4439, Sigma-Aldrich, Saint Louis, MO) and an affinity purified anti-c-Myc
polyclonal antibody (Sigma-Aldrich, Saint Louis, MO). Two HA antibodies were used in
these studies: anti-HA monoclonal antibody clone 12CA5 (Roche Diagnostics,
Indianapolis, IN) and affinity purified polyclonal antibody, HA.11 (Covance, Emeryville,
CA). UPN79 is an affinity purified polyclonal antibody raised against human full-length
recombinant synphilin-1 (312).
Relative quantification of the mouse parkin mRNA transcript
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Cerebral cortical tissues were harvested from 10 week old Balb/c, BL6, C3H, and 129S
mice and divided in half. Half of the tissue was frozen on dry ice for subsequent protein
analysis and total RNA was extracted from the remaining half using TRIzol reagent
(Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s protocol. Three
tissue samples were prepared for each mouse strain. The RNA products were reverse
transcribed to cDNA using Taqman RT-PCR reagents (Applied Biosystems Inc, Foster
City, CA) with oligo dT primers that were supplied in the kit. The RT reactions were
conducted according to the manufacturer’s protocol. Real-time PCR analyses were
performed on the cDNA products using 2X SYBR Green Master Mix reagent (Applied
Biosystems) and Applied Biosystems 7000 Real-Time PCR System (Applied
Biosystems). Reactions were performed in duplicate for each cDNA sample in a 96 well
plate. Primers were designed to amplify a 98 base pair product of mouse parkin cDNA
that corresponds to nucleotides 396-494. The sequences for the parkin primers were as
follows. Forward: 5’-AGCAGCCAGAGGTCCAGTTA-3’ and Reverse: 5’CACTGAACTCGGAGCTTTCC-3’. Additionally, a mouse β-actin loading control was
amplified. Mouse β-actin primers were designed to amplify a 99 base pair product
corresponding to cDNA nucleotides 698-797. The sequences of the β-actin primers were
as follows. Forward: 5’-CTTCCTCCCTGGAGAAGAGC-3’ and Reverse: 5’AAGGAAGGCTGGAAAAGAGC-3’. The thermo cycling conditions for the
amplification were as follows: 1 cycle for 2 minutes at 50ºC, 1 cycle for 10 minutes at
95ºC, followed by 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC, followed by 1
cycle for 15 seconds at 95ºC, 1 cycle for 20 seconds at 60ºC, and 1 cycle for 15 seconds
at 95ºC. The CT values for each sample were obtained. Parkin values were normalized to
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β-actin by taking the ratio of parkin to β-actin for each sample. The normalized results
were averaged for replicate samples and graphed. Error bars represent standard deviation
where n=6. After the reaction, equal volumes of the PCR products, one for each sample
type, were loaded onto 7-8% non-denaturing polyacrylamide/Tris Borate EDTA (TBE)
gels and were resolved by electrophoresis. The gels were then stained with ethidium
bromide at 1ug/mL for 20 minutes and the DNA bands were visualized with a UV light
and photographed. Additionally, the reaction products were confirmed by DNA
sequencing.
RT-PCR analysis and DNA sequencing of the mouse parkin cDNAs
Mouse total RNA was extracted and reverse transcribed from cortical tissue as described
above. Polymerase chain reactions were conducted on the cDNA products using
AccuPrimeTM SuperMix II (Invitrogen) in order to amplify nucleotides 895-1395 of the
mouse Parkin cDNA sequence. The primer sequences for the reaction were as follows.
Forward: 5’-GAGCTCCATCACTTCAGGATCCTTGGA-3’ and Reverse: 5’CTACACGTCAAACCAGTG ATC TCC CAT-3’. The PCR products were digested
with ExoSAP-IT ® reagent (USB Corporation, Cleveland, OH) and sequenced by the
DNA sequencing facility of the University of Pennsylvania.
Mouse protein analysis
Cerebral cortical tissues were harvested from mice as described above. The tissue was
sonicated in 3 tissue volumes of either high salt (HS) buffer (50mM Tris [pH 7.5], 750
mM NaCl, 5mM EDTA, with a protease inhibitor cocktail at 1:1000 and PMSF at 1:500)
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or 2% SDS/8M urea. Tissue extracts were then quantified using the bicinchoninic acid
(BCA) assay (Pierce Biotechnology, Rockford, IL) and bovine serum albumin as the
standard. Equal amounts of protein extracts were resolved by SDS-PAGE. The samples
were analyzed by western blot with PRK8, PRK28, PRK109 and UPN79 antibodies.
Additionally, membranes were blotted with anti-actin antibody to assess equal loading.
At least 4 independent tissue samples were analyzed for each mouse strain at each
respective age.
Parkin antibodies epitope mapping
Using full length human parkin cDNA as a template, primers were designed to generate
various truncated parkin constructs by PCR. See Table 5-1 for the oligonucleotide
sequences used for PCRs. AccuPrime SuperMix II (Invitrogen) was used for the
reactions. PCR products were cloned by topoisomerase reaction into the shuttling vector
pCR8/GW/TOPO (Invitrogen) and confirmed by DNA sequencing. These cDNA
fragments were introduced into the Gateway pDEST15 vector by recombinase reaction
using LR Clonase II enzyme (Invitrogen). BL21 cells were then transformed with
positive pDEST15 clones. Transformed cultures were subsequently induced with 500uM
Isopropyl Beta-D-1-thiogalatopyranoside (IPTG) for 2 hours at 37ºC in a shaking
incubator. After induction of protein expression, the cells were lysed by sonication in 3
pellet volumes of 2% SDS/8M urea. Protein extracts were then quantified using the BCA
assay and analyzed by immunoblot with anti-GST, PRK8, PRK28, and PRK109
antibodies.
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Table 5-1 Oligonucleotide sequences used to generate N-and C- terminal truncated human parkin
mutants for PRK8, PRK28 and PRK109 epitope mapping studies.
Nucleotides
amplified in PCR

Corresponding
Amino Acid
Sequence

Forward Oligonucleotide
sequence

Reverse Oligonucleotide
sequence

1-1398

1-465

5’-ATG ATA GTG TTT GTC
AGG TTC AAC TCC-3’

5’- CTA CAC GTC GAA CCA
GTG GTC CCC CAT -3’

1-1260

1-420

5’-ATG ATA GTG TTT GTC
AGG TTC AAC TCC-3’

5’-CTA GCG GGG ACA GGG
CTT GGT GGT TTT CTT-3’

1-1224

1-408

5’-ATG ATA GTG TTT GTC
AGG TTC AAC TCC-3’

5’-CTA TTT GGA GGC TGC
TTC CCA ACG AGC CTG-3’

1-1197

1-399

5’-ATG ATA GTG TTT GTC
AGG TTC AAC TCC-3’

5’-CTA CTC GGC GGC TCT TTC
ATC GAC TCT GT-3’

661-1398

221-465

5’-GAA ACA CCA GTA GCT
TTG CAC CTG AT-3’

5’- CTA CAC GTC GAA CCA
GTG GTC CCC CAT -3’

1141-1398

381-465

5’-TTT GAA GCC TCA GGA
ACA ACT ACT CAG-3’

5’- CTA CAC GTC GAA CCA
GTG GTC CCC CAT -3’

1195-1398

399-465

5’-GAG CAG GCT CGT TGG
GAA GCA GCC-3’

5’- CTA CAC GTC GAA CCA
GTG GTC CCC CAT -3’

Generation of E399Q human parkin construct for bacterial expression
For expression in bacteria, using the Gateway pDEST15 human parkin 381-465 construct
as a template (described above), the QuickChange Site Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) was used in order to generate the E399Q mutant form of
human parkin protein. The oligonucleotide sequence for the mutagenesis reaction was as
follows: forward-5’- GAAAGAGCCGCCCAGCAGGCTCGTTGG-3’ and reverse-5’CCAACGAGCCTGCTG GGCGGCTCT TTC-3’. The sequence of the construct was
confirmed by DNA sequencing. The plasmid was subsequently expressed in BL21 cells,
harvested, and analyzed as described in the previous section.
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Generation of human parkin constructs for expression in mammalian cells
The full-length untagged WT human parkin cDNA was cloned into the XhoI and Apa I
restriction sites on the pcDNA3.1(+) mammalian expression vector (Invitrogen). This
WT parkin construct was used as a template to perform site directed mutagenesis in order
to generate the full-length E399Q mutant. The same oligonucleotides were used as in the
E399Q mutagenesis reaction as described in the previous section. Additionally, the WT
parkin/pcDNA 3.1 construct was used as a template in a site directed mutagenesis
reaction to generate the human parkin T240R pathogenic mutant. The oligonucleotide
sequences for the T240R mutagenesis reaction were as follows: forward-5’ATCACTTGC ATTAGGTGCACAGACGTC-3’ and reverse-5’GACGTCTGTGCACCTAATGCAAGTGAT-3’. The sequence for both the E399Q and
T240R parkin mutants were verified by DNA sequencing.
Cell culture
Neuro-2A mouse neuroblastoma (N2A) cells and human embryonic kidney (HEK)-293T
cells were cultured in Dulbecco-modified Eagle medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St.Louis, MO), 100
U/mL penicillin and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA). Cells were
incubated at 37ºC and 95% air/5% CO2 atmosphere.
Biochemical fractionation of human parkin variants
HEK293T cells were cultured in 10 cm dishes. In duplicate, cells were transfected with
either the pcDNA3.1 full-length WT, E399Q, or T240R human parkin constructs using
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Lipofectamine Reagent (Invitrogen), following the manufacterer’s protocol. At 48 hours
post transfection, cells were rinsed and scraped in 1X PBS and sedimented at 13,000 g.
Cells were vortexed vigorously in 2 pellets volumes of ice-cold PBS/0.1% Triton buffer
containing protease inhibitors. The cell debris were sedimented at 13,000 g for 2 minutes
and the supernatants were stored on ice. The PBS/0.1% Triton extraction was repeated
and following sedimentation, the supernatants from both extractions were pooled together
as the TX fraction. The remaining pellet was rinsed with the PBS/0.1% Triton buffer and
the rinse was discarded. The cell pellet was then resuspended into 2 pellet volumes of icecold RIPA buffer with protease inhibitors, vortexed vigorously, stored on ice for 5-10
minutes, and then vortexed again. The cell debris were sedimented at 13,000 g for 2 min
and the supernatant was collected as the RIPA fraction. The remaining pellet was rinsed
with RIPA buffer and the rinse was discarded. Lastly, the pellet was solubilized in 1
pellet volume of 2% SDS/8M urea which was collected as the SDS fraction. All extracts
were quantified by BCA assay and analyzed by western blot analysis with the PRK109
and actin antibodies. Western blot images were scanned using a CanoScan Lide30
scanner (Canon U.S.A., Inc., Lake Success, NY). The levels of PRK109 signal were
quantified for each sample using ImageQuant 5.0 analysis software (GE Healthcare,
Piscataway, NJ).
Immunofluorescence and Confocal Analyses of parkin
HEK293T cells were cultured in 35 mm dishes. Cells were transfected in duplicate either
with the pcDNA3.1 full-length WT, E399Q, or T240R human parkin constructs using
Lipofectamine Reagent (Invitrogen), following the manufacterer’s protocol. At 24 hours
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post transfection, cells were rinsed in PBS and fixed by incubation in ice-cold aceticmethanol (1:20) at -20 °C for 30 minutes. Cells were rehydrated with water, rinsed with
PBS, and blocked in PBS/2% FBS/0.1% Triton. Cells were then incubated with PRK109
antibody diluted into PBS/2% FBS at a concentration of 1:2000 overnight at 4°C, washed
3 times with PBS at 10 minutes each, and then incubated at room temperature (~23 ºC)
with a goat anti-mouse secondary antibody conjugated to Alexa Fluor ® 594 (Invitrogen)
diluted into PBS/2% FBS for 1 hour. Cells were rinsed 3 times with PBS and then stained
with Hoerscht 33342 trihydrochloride trihydrate ( 0.5ug/mL) (Invitrogen) for 5 minutes at
room temperature (~23 ºC). Cells were rinsed with water and then coverslipped with
CytosealTM 60 mounting media (Richard-Allen Scientific, Kalamazoo, MI). The images
were visualized with a Zeiss LSM-510 Meta confocal microscope (Carl Zeiss
MicroImaging Inc, Thorwood, NY, USA).
Effects of parkin on synphilin-1 steady-state levels
A mammalian expression construct expressing C-terminal myc-tagged full-length human
synphilin-1 (synphilin-c-myc/pcDNA 3.1) was kindly provided by Dr. Virginia Lee. In
triplicate, HEK293T cells were co-transfected with synphilin-c-myc/pcDNA 3.1 and
either pcDNA3.1 mock vector, or pcDNA3.1 human full-length WT parkin, E399Q
mutant parkin, or T240R mutant parkin constructs. Cells were co-transfected with parkin
to synphilin-1 cDNA ratio of 4:1 using the calcium phosphate transfection protocol
described by Gallagher et al. (120). At 21 hours post transfection, fresh complete media
was added to the cells that were cultured for an additional 16 hours with or without 5uM
clasto-lactacystin-β-lactone (Omuralide)(EMD Chemicals Inc, Gibbstown, NJ). Cells
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were then rinsed in PBS and lysed by sonication in 2% SDS/8M urea. Cell extracts were
quantified by BCA assay and analyzed by western blot with monoclonal antibodies antic-myc clone 9E10, PRK109, and anti-actin. The 9E10 signal was quantified as described
in previous sections.
Pulse-chase synphilin-1 turnover analysis
In triplicate, HEK293T cells were cultured in 35mm dishes. Cells were co-transfected
with synphilin-c-myc/pcDNA 3.1 and either pcDNA3.1 mock vector, or pcDNA3.1
human WT parkin, E399Q mutant parkin, or T240R mutant parkin constructs. Cells were
co-transfected with a parkin to synphilin-1 cDNA ratio of 4:1 using the calcium
phosphate transfection protocol described above. At 24 hours post transection, cells were
methionine-deprived for 20 minutes by incubation in pre-warmed methionine-free
DMEM (Invitrogen, Carlsbad, CA)/10% dialyzed FBS before adding 100μCi [35S]methionine (Invitrogen, Carlsbad, CA) per ml of methionine free DMEM/10% dialyzed
FBS for 1 hour. Chase experiments were conducted with normal DMEM/FBS for 0, 1,
3, and 6 hours. Cells were then rinsed with PBS and harvested in ice-cold cytoskeleton
(CSK) buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100,
protease inhibitors). The radiolabelled protein extracts were pre-cleared with a rabbit
serum pre-incubated with protein A-agarose (Santa Cruz Biotechnologies, Santa Cruz,
CA) for 3 hours at 4ºC and radiolabelled extracts were then immunoprecipitated
overnight at 4ºC with anti c-Myc polyclonal antibody (Sigma) pre-incubated with protein
A-agarose (Santa Cruz Biotechnology, Inc). The antibody-protein complexes were
washed 3 times with 10 volumes of CSK buffer, resuspended in 2 volumes of 2X SDS
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sample buffer and boiled at 100 ºC for 5 minutes. The beads were removed by
centrifugation and the samples were loaded onto 13 % polyacrylamide gels. Following
electrophoresis, gels were fixed with 50% methanol/5% glycerol, dried and exposed to a
PhosphorImager plate and the signal was quantified using ImageQuant 5.0 analysis
software.
Co-immunoprecipitation/Western studies of parkin and synphilin-1
In triplicate, using the calcium phosphate transfection method, HEK293T cells were
transfected in 35mm dishes with either synphilin-c-myc/pcDNA 3.1 alone or cotransfected with synphilin-c-myc/pcDNA 3.1 as well as either the pcDNA3.1 untagged
full-length human WT, E399Q, or T240R parkin constructs. At 21 hours post
transfection, fresh complete media was added to the cells that were cultured for an
additional 24 hours. Cells were then rinsed, scraped, and harvested in PBS by
centrifugation at 13,000 g for 2 minutes. The cell pellets were lysed in 500 uL of ice-cold
CSK buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100) and
cell debris was sedimented at 13,000 x g for 2 minutes. 30 uL of the supernatant was
incubated at 100ºC for 5 minutes with SDS sample buffer as the “Input” fraction. The
remaining supernatant was incubated overnight at 4ºC with anti-c-Myc polyclonal
antibody (Sigma-Aldrich) that had been pre-incubated with protein A-agarose beads
(Santa Cruz Biotechnologies, Santa Cruz, CA). The antibody-protein complexes were
then washed 3 times with 10 volumes of CSK buffer, resuspended in 20uL of 2X SDS
sample buffer, and incubated at 100ºC for 5 minutes as the immunoprecipitate (“IP”)
fractions. 30uL of the unbound supernatants were also incubated at 100ºC for 5 minutes
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with SDS sample buffer as the “Unbound” fractions. The Start, IP, and Unbound
fractions were resolved by SDS-PAGE and immunoblotted with PRK109 antibody.
Co-immunoprecipitation/Western studies of parkin with UbcH7 and UbcH8The mammalian expression vectors expressing N-terminal HA-tagged full-length human
UbcH7 or UbcH8 (pRK5-HA-UbcH7 and pRK5-HA-UbcH8, respectively) were kindly
donated by Dr. Ted Dawson. In triplicate, using the calcium phosphate transfection
method, HEK293T cells were co-transfected in 35mm dishes with either pRK5-HAUbcH7 or pRK5-HA-UbcH8 and pcDNA 3.1 mock vector or pcDNA3.1 untagged fulllength WT, E399Q, or T240R human parkin constructs. Cells were cultured, harvested,
and lysed as described in the previous section. 50uL of the lysate was incubated at 100°C
for 5 minutes with SDS sample buffer as the “Input” fraction. The remaining lysate was
incubated for 3 hours at 4°C with HA.11 polyclonal antibody (Covance) that had been
preabsorbed to protein A-agarose beads (Santa Cruz Biotechnologies). The antibodyprotein complexes were then washed 3 times with 10 volumes of CSK buffer,
resuspended in 20uL of 2X SDS sample buffer, and incubated at 100ºC for 5 minutes as
the “IP” fractions. The Input and IP fractions were resolved by SDS-PAGE and
immunoblotted with the monoclonal antibodies PRK109 and anti-HA (Roche).
Quantification of mouse synphilin-1 protein
Western blot images were obtained (described above) and scanned using a CanoScan
Lide30 scanner. The levels of UPN79 and actin were quantified for each mouse using
ImageQuant 5.0 analysis software. The levels of UPN79 were normalized between mice
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by calculating the ratio between the UPN79 value to that for actin. The normalized results
for the mice of the same genetic background were averaged together and graphed.
Relative quantification of the mouse synphilin-1 mRNA transcript
Cerebral cortical tissues were harvested from 8 month old BL6 and C3H mice. Half of
the tissue was frozen on dry ice for protein analysis and total RNA was extracted from
the remaining half using TRIzol reagent (Invitrogen) as described in detail in previous
sections. Three tissue samples were prepared for each mouse strain. Reverse
transcription reactions and real-time PCR analyses were performed as described above.
Primers were designed to amplify a 107 base pair product of mouse synphilin-1 cDNA
that corresponds to nucleotides 988-1095. The sequences for the synphilin-1 primers
were as follows. Forward: 5’-ATATCGCTCTTGCCACACCTA-3’ and Reverse: 5’CAGGCATTCTGCATGGCCCTT-3’. Additionally, a mouse β-actin loading control was
amplified as described above. The CT values for each sample were obtained. Synphilin-1
values were normalized to β-actin by taking the ratio of synphilin-1 to β-actin for each
sample.
5.6
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CHAPTER SIX
Discussion

In efforts to gain insights into the biochemical pathways involved in idiopathic
PD, much attention has been devoted towards understanding the roles for a number of the
gene products implicated in familial forms of the disease. This thesis aimed to investigate
the biochemical and cellular properties of mutant DJ-1, α-syn and parkin proteins using
cell culture and mouse models. Based on the findings described herein (chapters 2-5),
several conclusions can be drawn regarding the relevance of these studies as it relates to
the field at large.
6.1

DJ-1 acts to mitigate oxidative stress but can also protect against a

variety of other toxic insults.
In chapter 2, stable overexpression of WT and E163K human DJ-1variants in
N2A cells revealed that in response to noxious stimuli, DJ-1 is generally a protective
protein. DJ-1 acted to protect against proteolytic stress induced by inhibitors of the 26S
proteasome. It also protected against toxicity caused by mitochondrial complex I and III
inhibitors. Remarkably, while WT DJ-1 efficiently ameliorated the harmful effects of
oxidation, E163K DJ-1 failed to protect against oxidative stress and rendered cells to be
selectively vulnerable to oxidative insults. This suggests that the E163K DJ-1 mutation
acts as a dominant-negative, specifically during conditions of oxidative stress. It also
implies that specific DJ-1 residues affect individual functions of the protein and may
implicate DJ-1 in a variety of biochemical pathways.
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It remains to be elucidated how DJ-1 mechanistically protects against cell toxicity
and thus it is unknown why E163K DJ-1 renders cells to be selectively vulnerable to
oxidative insults. It is thought that oxidation of DJ-1 residue C106 to cysteine sulfinic
acid acts to regulate the protective properties of DJ-1 protein
(43;53;185;301;328;455;494). Blackinton and colleagues discovered that hydrogen
bonding of C106 with DJ-1 residue E18 modulates C106 oxidation propensity (43).
Based on knowledge gained from crystallization studies, residue E163 is not thought to
be in close proximity to C106 (233;471). It is worth mentioning that additional DJ-1
residues other than C106 can be modified by oxidation both in vitro and in vivo
(65;207;389). Perhaps the E163K substitution creates electrostatic abnormalities that
could account for the oxidative deficiencies exhibited by mutant protein in the studies
herein. It is known that the E163K DJ-1 substitution disrupts a salt bridge that normally
occurs between residues E163 and R145 in DJ-1 and that this alteration thereby weakens
a network of hydrogen bonds that span the DJ-1 dimer interface (233). Future studies to
assess for changes that occur to specific residues of E163K DJ-1 protein under oxidative
conditions would be insightful.
It was somewhat surprising to find that E163K DJ-1 behaved as a dominantnegative when expressed in mouse N2A cells during oxidative stress. One plausible
explanation for this finding is that E163K DJ-1 dimerizes with and inactivates
endogenous murine DJ-1 protein, thereby rendering cells expressing E163K DJ-1 to be
selectively vulnerable to oxidative insults. In the studies herein, we were unable to coimmunoprecipitate E163K human DJ-1 together with endogenous murine DJ-1,
suggesting that co-dimerization of the two DJ-1 isoforms does not occur. However, our
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co-immunoprecipitation studies were not completely exhaustive since alternative
approaches utilizing additional types of tagged DJ-1 constructs and/or additional
antibodies may have yielded different results. Thus, it would be premature to definitively
conclude that E163K human DJ-1 does not somehow inactivate endogenous murine DJ-1
under oxidative conditions.
There can also be other explanations for the dominant-negative effect exhibited
by E163K DJ-1 in N2A cells. It is thought that while oxidation of DJ-1 residue C106 to
sulfinic acid activates the protective function of DJ-1 protein, further oxidation of C106
to sulfonic acid under extreme oxidizing condition inactivates the protein
(43;53;301;494). Though it has never been investigated, one would expect that
inactivated or damaged forms of DJ-1 would need to be cleared from the cell by one of
the cardinal protein degradation pathways. Perhaps E163K DJ-1 is particularly vulnerable
to inactivation following oxidation and thus in a model system in which the inactivated
E163K DJ-1 mutant is overexpressed during oxidative insult, this could result in a
combinatorial strain on cellular antioxidant mechanisms as well as protein degradation
machineries. The proposed combination of events could be the cause for the dominantnegative effect exhibited by E163K DJ-1 during oxidative stress. It would be interesting
to determine the effects of oxidative stress on the turn-over rate of E163K mutant DJ-1 in
efforts to address the question of whether oxidation plays a role in modulating
degradation of the E163K mutant. Additionally, studies to assess for the pathogenicity of
inactivated DJ-1 protein on cells during stress would be enlightening.
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Since we showed that E163K DJ-1 can effectively protect against mitochondrial
stress in N2A cells, it was unexpected to find that in response to oxidative stress, E163K
DJ-1 demonstrated reduced redistribution towards mitochondria. Mitochondrial
localization sequences have not yet been identified for DJ-1 neither is it fully understood
what mechanistic role DJ-1 plays to maintain mitochondrial homeostasis. However, since
E163K DJ-1 retained protective properties in the presence of mitochondrial toxins but
failed to redistribute to mitochondria in response to oxidative stress specifically, it
suggests that DJ-1 may have a variety of mitochondrial functions and that these functions
may be regulated by different mechanisms. Canet-Aviles and colleagues argued that
mitochondrial localization of DJ-1 is driven by C106 oxidation (53). If this is true, it is
possible that residue C106 in E163K DJ-1 has aberrant redox properties. Thus, it would
be interesting to determine the role of C106 in the regulation of E163K DJ-1
mitochondrial localization.
Though we and others have shown that DJ-1 protects against oxidative stress
(27;137;181;196;204;252;253;418;479;482), Gorner and colleagues argue that DJ-1 is
not a direct antioxidant but instead indirectly influences cell viability by modulating
redox signaling pathways (139). Since we showed that the cytoprotective properties of
the E163K DJ-1 mutant were impaired during oxidative stress, it would be interesting to
determine the impact of this on signaling pathways. It is worth noting that we were
unable to detect differences in any of the signaling molecules analyzed in the studies
herein including phosphorylated and nonphosphorylated Akt and phosphorylated and
nonphosphorylated ERK1 and 2 (data not shown). However, the discrepancies between
our findings and those reported in literature (129;142;252;484), may be due to differences
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between cell-types used for studies. Thus, it would be interesting to assess for the effects
of E163K DJ-1 on signaling pathways during oxidative stress by conducting studies using
cell lines better fitted for protein signaling analyses.
6.2

Misfolded DJ-1 mutants can be degraded by the proteasome pathway but

alternative catabolic mechanisms are likely.
In chapter 3, it was shown that in comparison to WT DJ-1 protein, pathogenic DJ-1
mutants, L10P, L166P, and P158DEL, were dramatically destabilized when expressed in
CHO cells. Interestingly, the analyzed mutant proteins were only partially stabilized by
MG-132, albeit to variable degrees. It was also discovered that all of the DJ-1 mutants
exhibited aberrant folding patterns. Additionally, insoluble forms of mutant L10P and
L166P DJ-1 proteins could be stabilized following treatments with either MG-132 or
epoxomicin, and P158DEL DJ-1 demonstrated reduced solubility even in the absence of
these treatments. Further, L10P, L166P, and P158DEL DJ-1 proteins were associated into
atypical intranuclear and cytoplasmic protein inclusions in CHO cells following exposure
to MG-132. Conversely, the biochemical properties of WT DJ-1 protein were completely
unaffected by proteasome inhibition in the analyses herein. Taken together, these
findings suggest that L10P, L166P, and P158DEL DJ-1 mutations contribute to disease as
a function of decreased protein stability and indicate that the 26S proteasome can regulate
specific variants of DJ-1 protein.
It is interesting to note that turnover of WT DJ-1 protein was unaltered by inhibition
of the proteasome. Additionally, the highly unstable pathogenic DJ-1 mutants analyzed
could only be stabilized in part by MG-132. While neither L10P nor P158DEL DJ-1
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proteins have been characterized prior to the studies herein, L166P DJ-1 has been shown
by others to be stabilized in cells treated with various proteasome inhibitors
(138;139;298;307;324). Interestingly, however, among all of these studies, it was only
Gorner and colleagues who chose to report that MG-132 and epoxomicin were not
sufficient to completely stabilize L166P DJ-1 in mammalians cells (138;139). Perhaps
others chose to overlook this observation, though it is also possible that proteasome
regulation of mutant DJ-1 proteins could be cell-type specific. Notwithstanding, our
findings support a role for degradation of both WT and mutants forms of DJ-1 by
proteasome-independent mechanisms.
To date, it is not fully elucidated what alternative proteolytic pathways may act to
regulate DJ-1 protein. A recent study by Giaime and colleagues revealed that DJ-1 could
be cleaved by caspase-6 enzyme (129). It was also determined in the study by Giaime et
al. that the L166P mutation enhanced DJ-1 susceptibility to caspase-6 cleavage. Further,
since DJ-1 cleavage by other caspases was not discovered in the study, it was implied that
proteolysis of DJ-1 by caspase-6 is specific. Ironically however, though it was
demonstrated that caspase-6 cleavage of DJ-1 could occur in vitro, the proteasome
inhibitor, lactacystin, and the calpain inhibitor, ALLN, acted to stabilize L166P DJ-1
much more potently than caspase-6 inhibitors (129). Thus, this suggests that regulation of
DJ-1 likely occurs via diverse catabolic pathways and it will be interesting to determine
what factors act to target DJ-1 for degradation by these distinct mechanisms.
Since pathogenic DJ-1 mutants are partially destabilized by the proteasome, it is of
interest to ascertain which E3 ligases may act to mediate this effect. Interestingly, Moore
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et al. showed that WT DJ-1 associated with the E3 ligase, parkin, during oxidative
conditions (304). Additionally, when co-expressed together in mammalian cells, various
pathogenic DJ-1 mutants, including L166P, were able to interact with parkin (304).
However, in the study by Moore et al., parkin failed to enhance the degradation of DJ-1
but instead acted to stabilize WT and L166P DJ-1 variants (304). Olzmann and
colleagues also reported that parkin failed to mediate the degradation of L166P DJ-1,
though interaction between the two proteins was also detected in that study (325). We
were unable to detect any interactions between parkin and WT, L10P or P158DEL DJ-1
variants in the studies herein (data not shown) and thus, it is unlikely that these DJ-1
variants are regulated by parkin-mediated mechanisms.
Novel DJ-1 interacting proteins including TNF receptor-associated protein (TTRAP)
and Bcl-2-associated athanogene 1 (BAG1) may be involved in modulating DJ-1
(91;498). TTRAP selectively interacted with L166P DJ-1 in mammalian cells and this
association was potently enhanced in the presence of MG-132 (498). BAG1 was also
discovered to interact with both WT and L166P DJ-1 proteins and was reported to
increase the dimer/monomer ratio for both variants (91), although the latter finding may
be somewhat controversial since L166P DJ-1 fails to dimerize in our studies or in other
reports. It remains to be determined whether TTRAP or BAG1 proteins can modulate the
turn-over rates of WT DJ-1 or pathogenic DJ-1 mutants. Thus, studies to investigate the
effects of TTRAP and BAG1 on DJ-1 turnover would clarify the regulatory effects of
these proteins on DJ-1.
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It is possible that BAG1 and/or TTRAP may act to regulate the solubility of
pathogenic DJ-1 mutants. Deeg and colleagues reported that L166P DJ-1 accumulated
abnormally in cell nuclei under normal culturing conditions and that this aberration could
be down-regulated by BAG1 protein (91). Interestingly, Zucchelli et al. showed that upon
treating neuroblastoma cells with MG-132, TTRAP protein formed large juxtanuclear
aggresomes, though it wasn’t reported whether DJ-1 localized to these inclusions (498).
In the studies herein, L10P, L166P, and P158DEL DJ-1 variants formed intranuclear and
cytoplasmic inclusions following treatments with MG-132. The majority of these
inclusions were not classical aggresomes and this finding was somewhat surprising. To
date, there have been no other reports describing the type of atypical DJ-1 positive
inclusions that were observed in the studies herein. Previously, Olzmann and colleagues
had reported that L166P and parkin colocalized into perinuclear aggresomes following
proteasome impairments (325); however, the observations described in this thesis do not
fit that profile. Thus, more thorough investigations into the mechanisms of DJ-1 inclusion
formation are needed.
It has been shown that L166P DJ-1 can exhibit a gain-of-function toxicity effect when
expressed in mammalian cells (91;389;418;487;498). Zucchelli and colleagues showed
that while TTRAP protected against MG-132-induced apoptosis in neuroblastoma cells,
L166P DJ-1 significantly inhibited the protective activity of TTRAP by modulating
signaling of pro-apoptotic mediators (498). Expression of L166P DJ-1 rendered
transiently expressing mammalian cells to be selectively vulnerable to endoplasmic
reticulum stress (487) and H2O2 induced cell death (389;418). L166P DJ-1 was also
shown to reduce cell viability when expressed in cells under normal culturing conditions
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(91), although this finding has never been reported by others. Since L10P, L166P, and
P158DEL DJ-1 variants form atypical protein inclusions following proteasome
impairments, it is hypothesized that all three DJ-1 mutants may be toxic to cells, though
this question has never been addressed. Further, autopsy tissues are currently unavailable
for PD patients harboring L10P, L166P or P158DEL DJ-1 mutations. Thus, it will be
interesting to determine whether any of the three mutant DJ-1 proteins can act to enhance
protein aggregation in vivo.
6.3

Genetically altered mice may not fully recapitulate the molecule pathways

affected by genes associated with PD.
Pathogenic DJ-1 mutations are thought to cause PD as a consequence of the loss of
DJ-1 protective function (47). In efforts to model a DJ-1 loss-of-function in vivo, DJ-1
deficient mice were generated as described in chapter four. However, mice lacking DJ-1
did not demonstrate any of the cardinal signs of parkinsonism, neither were there any
signs of nervous system degeneration in these animals. This was not completely
surprising since similar findings have been reported by other groups (13;60;63;136;274).
Nevertheless, many have shown DJ-1 null mice to be susceptible to a variety of toxic
insults (204;354;483) and this suggests that DJ-1 acts in a protective capacity in vivo.
It was reported that DJ-1 could modulate the aggregation of α-syn and/or act to
alleviate the toxic effects of pathogenic forms of α-syn in vitro (27;389;493;494);
however, prior to the findings described herein, it had never been reported whether
similar functions for DJ-1 could be recapitulated in vivo. As detailed in chapter four,
generation of homozygous double-transgenic M83-DJnull mice enabled us to address this
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question for the first time. M83-DJnull mice were analyzed and compared to previously
characterized M83 mice (131) as it related to survival rate, distribution of α-syn
pathologies, biochemical properties of the α-syn protein, and the secondary effects of
expressing mutant α-syn. Since no significant differences were discovered between
mouse genotypes, it was concluded that DJ-1 may not directly modulate α-syn, nor
protect against the harmful effects that result from α-syn aggregation in vivo.
The findings reported in this thesis suggest that attempting to gain insights into
familial forms of PD using mouse models may prove to be difficult. While in humans,
DJ-1 deficiency may result in early-onset PD (47;152;200), we and others have shown
that mice lacking DJ-1 are relatively normal (13;60;63;136;211;274). Similarly, although
patients harboring the A53T α-syn mutation develop PD marked by nigrostriatal
dopamine neurodegeneration and associated nigral LB pathologies (134), it is clear that
transgenic mice expressing human A53T α-syn exhibit a phenotype that is distinct from
human disease (51;131;247;279;444). Further, in chapter 5, we describe our discovery
of a novel endogenous E398Q parkin mutation in C3H mice which appears to inactivate
parkin in these animals. A variety of parkin mutations are causative of juvenile to earlyonset forms of PD which are thought to result from parkin loss-of-function
(26;154;155;270;282;359;416;478). Our analyses in chapter 5 reveal that C3H mice may
be suitable parkin loss-of-function models; however, unlike patients harboring parkin
missense mutations, C3H mice do not demonstrate any of the classical symptoms of PD.
Future thorough anatomical, biochemical, and behavioral characterizations of the
nigrostriatal dopaminergic system in C3H animals may be insightful.
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Stories told from the studies of genetically altered mice suggest that it may be
presumptuous to assume that any single genetic mutation alone can be causative of PD.
Instead, one could argue that patients harboring PD-linked mutations may just be more
susceptible to environmental stimuli and/or other noxious insults that may synergistically
lead to nigral neurodegeneration and the onset of behavioral impairments. If this is true,
it is possible that if insulted with the proper stimuli, genetically altered mice may be able
reproduce some of the classical symptoms of PD. To support this idea, it has been shown
that parkin deficient mice are particularly susceptible to nigral degeneration caused by
neuroinflammatory stimuli (116). Similarly, in comparison to normal mice, DJ-1
deficient animals are more vulnerable to paraquat exposure (483) as well as exposure to
mitochondrial inhibitors (204;354). Paraquat exposure also exacerbates disease in
transgenic mice expressing human A53T α-syn (321). Nonetheless, it is not fully
elucidated what mechanisms contribute to the vulnerabilities displayed by the genetically
altered animals used in these studies. Future studies to identify factors that can enhance
the effects of modulating parkin, DJ-1, or α-syn in vivo will give insights into the roles of
these proteins in the pathogenesis of both inherited and sporadic forms of PD.
6.4

Oxidative stress, mitochondrial dysfunction and protein degradation

impairments may all impinge on PD pathogenesis.
This thesis presented a range of studies involving the effects of mutations on DJ-1,
parkin, and α-syn proteins in efforts to gain insights into the molecular mechanisms that
may be causal of PD. Based on the findings presented herein, it is fair to conclude that
PD is a complex disorder that may develop subsequent to a combination of events that
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synergistically result in the disease. Our findings from the studies of the E163K DJ-1
mutant suggest that oxidative stress may be a pathogenic factor in PD and also support a
role for DJ-1 in acting to mitigate this insult. It is known that oxidative damage of DJ-1 is
linked to sporadic PD (65;374). Further, we have shown that DJ-1 can effectively protect
against oxidative toxicity. Thus it is proposed that development of therapeutic strategies
that would act to upregulate DJ-1 and thereby ameliorate any harmful oxidation that may
occur in vivo would likely serve to protect against the development of PD in humans.
It is also suggested from our studies that interactions of DJ-1 with mitochondria may
be required for the protective effects of DJ-1 against oxidative insults. Though there is
much to be learned regarding this idea, it is possible that impairments in DJ-1 activity
may somehow link oxidative stress to mitochondrial dysfunction in PD. It’s known that
mitochondrial complex I is vulnerable to oxidative damage (64;435). We have shown that
DJ-1 can assuage H2O2 toxicity and can also protect against inhibitors of mitochondrial
complexes. Whether these protective mechanisms exhibited by DJ-1 are somehow related
remains to be determined. Future studies to assess for the mitochondrial role of DJ-1
especially as it relates to how oxidation may modulate this would be beneficial in
determining how mitochondrial impairments may contribute to the onset of PD.
It is also apparent from our studies of DJ-1, parkin, and α-syn mutations that protein
degradation impairments may be involved in PD pathogenesis. We showed that L10P,
L166P and P158DEL DJ-1 mutants were capable of promoting the formation of
intracellular inclusion bodies in a proteasome dependent manner. Though it remains to be
elucidated, if similar effects occur in patients, it is possible that certain DJ-1 mutations
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may contribute to disease as a consequence of proteasome impairments and/or
impairments in other protein degradation machineries. Our studies also revealed that
parkin mutations, such as T240R and E399Q, may disrupt parkin E3 ligase function. In
patients harboring parkin mutations, accumulation of parkin substrates such as synphilin1 may work to induce proteolytic stress and this may act to instigate subsequent disease.
The latter idea is supported in the literature (212;265;461). Further, in agreement with
previous studies (131;247;444), we showed that pathogenic mutant A53T α-syn protein
tended to aggregate in mice, forming intracellular inclusions that were reminiscent of LB
pathologies, similar to those observed in patients with disease. We did not investigate the
effects of α-syn inclusion formation on activities of the proteasome or other known
cellular proteases. Studies by other groups have attempted to address this question;
however many of the reported findings are in disagreement (280;319;410). We showed
that many of the α-syn inclusions in mice were positive for ubiquitin, and this finding
may support a role for the ubiquitin-proteasome pathway in clearing misfolded forms of
pathogenic α-syn protein in vivo. Taken together, we provide evidence to suggest that
therapeutic strategies that aim to directly modulate and/or mitigate the effects of impaired
protein degradation in humans may help to prevent neurodegeneration observed in PD.
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